ScienceIP SampleTextSearchReport

Science IP Order: 3550000
Client Reference: 3456-789
Benzoyl Peroxide and Tea Tree Oil in Acne

Compositions
Prepared for Dr. Jane Doe
Imaginary Pharmaceuticals
January 9, 2013
Science IP
2540 Olentangy River Road
Columbus, Ohio 43202
Telephone: 866-360-0814
Fax: 614-447-5443
ScienceIP@cas.org
CONFIDENTIAL
Table of Contents
Click (or Ctrl-click) page number to jump to a section

Original Search Request 3
Science IPs Understanding of the Request 3
Science IP Search Results 4
Research Summary 4
Discussion of Search Strategy 4
Detailed Results 5
Patent References 5
Non-Patent References 139
Science IP Search Documentation 149
Search Strategy 149
Sources Used 156
Primary Searcher: Sharilyn Woods

Disclaimer
Copyright2013. American Chemical Society (ACS). All Rights Reserved.
Except for distribution to Customers immediate client, any distribution of this report in any form without prior
written permission from ACS is prohibited.
The information contained herein has been obtained from sources believed to be reliable. Science IP,
Chemical Abstracts Service (CAS), and American Chemical Society (ACS) disclaim all warranties as to
accuracy, completeness or adequacy of such information; and shall have no liability for errors, omissions or
inadequacies in the information contained herein or the interpretation thereof.
Science IP does not provide legal advice. For legal advice, please review with your legal counsel.
Page 2 of 158
Science IP Order: 3550000 Client Reference: 3456-789
Original Search Request

Conduct a search of the literature and patents for references to acne compositions containing benzoyl
peroxide and tea tree oil. Remove the duplicates.
Science IPs Understanding of the Request
Search the literature and patents for references containing benzoyl peroxide and tea tree oil in acne
compositions. Remove the duplicates
Page 3 of 158
Science IP Search Results

Research Summary
A search was conducted in the Chemical Abstracts database for benzoyl peroxide by CAS Registry
Number and by names collected from the Chemical Abstracts Registry and combined with references to
tea tree oil or melaleuca. These references were then combined with terms for acne or anti-acne, and 28
references were retrieved.
A search was conducted in the Derwent World Patents Index for benzoyl peroxide by Derwent Registry
Number and by names and combined with the results for tea tree oil by Derwent Registry Number and by
names. These references were then combined with terms for acne or anti-acne, and 33 references were
retrieved.
A search was conducted in the fulltext patent databases (US, EP, FR, GB, DE, WO, AU, CA, CN and JP),
and three different approaches were used to help target the results. Benzoyl peroxide was searched
within 250 words of tea tree oil within 250 words of the acne terms. Benzoyl peroxide was searched
within 250 words of tree oil and then combined with terms for acne or anti-acne. The third approach was
for all of the concepts to be limited to the title, abstract or claims. The three approaches retrieved 311
references.
Other bibliographic patent databases were searched for benzoyl peroxide and tea tree oil and acne
terms, and 49 references were retrieved.
STNIndex which is an index to more than 120 databases on STN was searched to identify which
databases might contain references on our search topic. Nine additional databases were identified and
searched, and 41 references were retrieved.
The duplicates were removed, and 199 patent references and 42 non-patent literature references were
retrieved. These references can be found below in the Detailed Results section with the bibliographic
citation, abstracts and either hit indexing or keywords in context displayed.
Please let me know if you have any questions.
Discussion of Search Strategy
The scope of each database searched is shown in the Sources Used section at the end of the report.
If additional information about the databases is desired, please contact the searcher.
Answers resulting from text search strategies are general and it is likely that some answers will not be of
interest.
Return to Table of Contents
Page 4 of 158
Detailed Results
Hypertext links have been added to selected patent numbers. Links for US documents open the
corresponding Google Patents web page. Links for AU, CA, DE, EP, FR, GB, and WO documents
open the corresponding page at the Espacenet web site. A patent family link has been added to
USPATFULL and USPAT2 citations. Patents for other patent authorities (and non-patent records)
are available, via CAS Fulltext Options, by clicking the Full-text link above the patent titles.
Patent References
For this sample report, only the 26 references from HCAPLUS, the first 7 references from USPATFULL,
the first 4 references from PCTFull, and the reference from IFIPAT are displayed below.
L56 ANSWER 1 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN

ACCESSION NUMBER: 2012:1402229 HCAPLUS Full-text
DOCUMENT NUMBER: 157:530072
TITLE: Treatment of inflammatory and infectious skin
disorders
INVENTOR(S): Taylor, Emma
PATENT ASSIGNEE(S): University of California, USA
SOURCE: PCT Int. Appl., 48pp.
LANGUAGE: English
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE

--------------- ---- -------- -------------------- --------
WO 2012129499 A1 20120927 WO 2012-US30335 20120323
PRIORITY APPLN. INFO.: US 2011-466510P P 20110323
AB Disclosed herein is a compn. comprising of resveratrol and/or derivs. thereof
and/or functionally related compds. and benzoyl peroxide and/or derivs. thereof
and/or functionally related compds. for the treatment of acne and other
inflammatory or infectious skin disorders. Also disclosed are methods of
treating acne and other inflammatory and infectious skin disorders using the
compns. described herein. Efficacy of a combination benzoyl peroxide and
resvetraol against of Pityrosporum acnes acnes was shown.
IPCI A61K0009-06 [I,A]; A61K0009-20 [I,A]; A61K0031-03 [I,A]; A61K0031-075
[I,A]; A61K0031-085 [I,A]; A61P0031-00 [I,A]; A61P0017-10 [I,A]
IPCR A61K0009-06 [I,A]; A61K0009-20 [I,A]; A61K0031-03 [I,A]; A61K0031-075
[I,A]; A61K0031-085 [I,A]; A61P0017-10 [I,A]; A61P0031-00 [I,A]
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST inflammatory infectious skin disorder treatment benzoyl peroxide
resvetraol
IT Essential oils
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Melaleuca; treatment of inflammatory and infectious skin
disorders)
IT Acne
(vulgaris; treatment of inflammatory and infectious skin disorders)
IT 52-01-7, Spironolactone 68-26-8, Retinol 69-72-7, Salicylic acid,
biological studies 79-14-1, Glycolic acid, biological studies
94-36-0, Benzoyl peroxide, biological studies
112-38-9, Undecylenic acid 114-07-8, Erythromycin 123-99-9, Azelaic
acid, biological studies 127-56-0, Sulfacetamide sodium 130-26-7,
Clioquinol 302-79-4, Tretinoin 501-36-0, Resveratrol 501-36-0D,
Resveratrol, derivs. 537-42-8 537-42-8, Pterostilbene 777-11-7,
Page 5 of 158
Haloprogin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1404-04-2,
Neomycin 1404-26-8, Polymyxin B 1405-87-4, Bacitracin 1406-18-4,
Vitamin E 2398-96-1, Tolnaftate 4759-48-2, Isotretinoin 7704-34-9,
Sulfur, biological studies 12650-69-0, Mupirocin 18323-44-9,
Clindamycin 22199-08-2, Silver sulfadiazine 22255-22-7 22916-47-8,
Miconazole 23593-75-1, Clotrimazole 27208-80-6, trans-Piceid
29342-05-0, Ciclopirox 38963-95-0, Resveratroloside 42438-89-1
53515-95-0 62218-08-0, -Viniferin 62218-13-7,
-Viniferin 65277-42-1, Ketoconazole 65472-88-0, Naftifine
86386-73-4, Fluconazole 91161-71-6, Terbinafine 99592-32-2,
Sertaconazole 101828-21-1, Butenafine 106685-40-9, Adapalene
118292-40-3, Tazarotene) 145356-39-4 148766-36-3, cis-Piceid
150258-83-6 204076-78-8 224452-66-8, Retapamulin 1093198-85-6
(treatment of inflammatory and infectious skin disorders)
Page 6 of 158
TITLE: Oil compositions for treatment of dermatological
disorders
INVENTOR(S): Edelson, Jonathan; Kotyla, Timothy; Theobald, Klaus
PATENT ASSIGNEE(S): Anterios, Inc., USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2012103037 A1 20120802 WO 2012-US22278 20120123
US 20120328549 A1 20121227 US 2012-356634 20120123
AB The present invention provides oil compns. and assocd. methods and reagents,
useful for the treatment and/or prevention of dermatol. conditions. The compns.
comprise an oil agent including oils contg. a medium-chain triglyceride, a
surfactant, a paraben, and a least one inactive agent. The oil agents inhibit
activity of sweat and/or sebaceous glands, show antiperspirant and/or deodorant
activity and can be used to treat or prevent certain clin. conditions assocd.
with sweat, such as, for example, hyperhidrosis, chromhidrosis and bromhidrosis.
The oil compns. provided are formulated for and achieve transdermal delivery,
for example by topical administration. For example, antiperspirant effects of
topical Labrafac Lipopihle WL 1349 was demonstrated in subjects with excessive
sweating and may be used effectively in treating hyperhidrosis.
IPCI A61P0017-10 [I,A]; A61K0031-20 [I,A]
IPCR A61P0017-10 [I,A]; A61K0031-20 [I,A]
Section cross-reference(s): 1, 62
IT Essential oils
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(Melaleuca alternifolia; oil compns. for treatment and/or
prevention of dermatol. conditions)
IT Dermatological agents
(anti-acne agents; oil compns. for treatment and/or
prevention of dermatol. conditions)
IT Acne
Alopecia
Antibacterial agents
Antibiotics
Antiperspirants
Burn
Dermatological agents
Eczema
Human
Hyperhidrosis
Jatropha curcas
Lupus erythematosus
Oral drug delivery systems
Personal deodorants
Pharmaceutical creams
Pharmaceutical gels
Pharmaceutical injections
Pharmaceutical ointments
Pharmaceutical powders
Prophylaxis
Psoriasis
Page 7 of 158
Raynaud disease
Rosacea
Sebaceous gland
Seborrhea
Skin, neoplasm
Skin disease
Skin hyperpigmentation
Skin infection
Sunscreens
Surfactants
Sweat gland
Topical drug delivery systems
Transdermal drug delivery systems
(oil compns. for treatment and/or prevention of dermatol. conditions)
IT 60-54-8, Tetracycline 68-26-8, Retinol 94-36-0,
Benzoyl peroxide, biological studies 110-40-7, Diethyl
sebacate 114-07-8, Erythromycin 123-95-5, Butyl stearate 143-28-2,
Oleyl alcohol 302-79-4, Tretinoin 1327-41-9, Aluminum chlorohydrate
3380-34-5, Triclosan 4759-48-2, Isotretinoin 7429-90-5D, Aluminum,
compd. with zirconium 7440-67-7D, Zirconium, compd. with aluminum
7446-70-0, Aluminum chloride, biological studies 7784-25-0, Ammonium
alum 9005-65-6, Polysorbate 80 9006-65-9, Dimethicone 10284-64-7,
Aluminum dichlorohydrate 18323-44-9, Clindamycin 18472-51-0,
Chlorhexidine gluconate 34513-50-3, Octyldodecanol 53026-85-0,
Aluminum Chlorohydrex 106685-40-9, Adapalene 107231-12-9, Botulinum
toxin 118292-40-3, Tazarotene 134375-99-8, Aluminum Zirconium
Trichlorohydrex Gly 134910-86-4, Aluminum Zirconium Tetrachlorohydrex
Gly 173763-15-0, Aluminum sesquichlorohydrate 773082-14-7, Aluminum
dichlorohydrex
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(oil compns. for treatment and/or prevention of dermatol. conditions)
Page 8 of 158
TITLE: High lubrication shaving aid comprising surfactants
and organic polyhalogenic post-foaming agents
INVENTOR(S): Kulesza, John E.
PATENT ASSIGNEE(S): USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2012057782 A1 20120503 WO 2010-US54705 20101029
PRIORITY APPLN. INFO.: WO 2010-US54705 20101029
AB A shaving aid compn. is provided comprising a hydrophilic surfactant, such as
triethanolamine stearate, at 5-20% by wt., an org. polyhalogenic agent at 3-10%
by wt. that both promotes post application foaming, increases lubricity, and
reduces skin irritation. The shaving aid is optionally used to deliver one or
more therapeutics to the skin of a subject and is therefore operable to prevent
or treat a skin condition, such as acne. Shaving compns. comprising
triethanolamine stearate surfactant and CF-61 and CF-76 post-foaming agents were
exemplified. Inclusion of 5% benzoyl peroxide reduced acne vulgaris and
pseudofolliculitis barbaein humans.
[I,A]; A61Q0019-00 [I,A]
[I,A]; A61Q0019-00 [I,A]
CC 62-4 (Essential Oils and Cosmetics)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(Melaleuca alternifolia; high lubrication shaving compns.
comprising surfactants, org. polyhalogenic post-foaming agents and
therapeutic agents for preventing or treating skin condition)
(anti-acne agents; high lubrication shaving compns.
comprising surfactants, org. polyhalogenic post-foaming agents and
therapeutic agents for preventing or treating skin condition)
IT Acne
(vulgaris; high lubrication shaving compns. comprising surfactants,
org. polyhalogenic post-foaming agents and therapeutic agents for
preventing or treating skin condition)
IT 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol,
biological studies 69-72-7, Salicylic acid, biological studies
102-71-6, Triethanolamine, biological studies 108-46-3, Resorcinol,
biological studies 3380-34-5, Triclosan 4568-28-9, Triethanolamine
stearate 9002-88-4, Polyethylene 9003-39-8, Povidone 11103-57-4,
Vitamin A 25322-68-3, PEG 36653-82-4, Cetyl alcohol 37321-65-6,
Propylene glycol stearate 59409-41-5
(high lubrication shaving compns. comprising surfactants, org.
polyhalogenic post-foaming agents and therapeutic agents for preventing
or treating skin condition)
Page 9 of 158
TITLE: Treatment of acne by stem cell conditioned media
INVENTOR(S): Riordan, Neil H.; Riordan, Tiemey M.
PATENT ASSIGNEE(S): Aidan Research and Consulting, Llc., USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2012047733 A2 20120412 WO 2011-US54094 20110929
WO 2012047733 A3 20120621
US 20120195969 A1 20120802 US 2011-249145 20110929
AB The present invention relates to methods and topical compns. for treatment of
acne or acneform conditions, particularly, but not limited to acne vulgaris,
with products generated from culture of stem or progenitor cells. For example,
mesenchymal stem cells, obtained from placenta using collagenase and phosphate-
buffered saline (PBS), were suspended in -MEM culture media supplemented with
fetal bovine serum (FBS) and antibiotic, and the culture medium was changed
every 2-3 days. Upon confluence, cells were trypsinized, washed, and cultured
in Roswell Park Memorial Institute (RPMI) media without phenol red or FBS for 24
h. The conditioned media was collected and sterile filtered to exclude cells
and cellular debris. The media was then mixed at a 1:1 vol. ratio with a
moisturizing cream and used for topical treatment of a female with history of
severe acne. After 3 days 18 of the inflammatory lesions and 1 of the
noninflammatory lesions had resolved. At the end of 10 days only 2
noninflammatory lesions remained on the patient's face.
[I,A]; A61K0031-07 [I,A]; A61P0017-00 [I,A]
[I,A]; A61K0038-19 [I,A]; A61P0017-00 [I,A]
Section cross-reference(s): 1, 9, 62
ST stem cell conditioned culture media topical acne
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3CB2; topical compns. comprising conditioned media of cultured stem
cells for treatment of acne)
IT ATP-binding cassette transporters
(ABCG2, biomarker; topical compns. comprising conditioned media of
cultured stem cells for treatment of acne)
IT Proteins
(ASMA, biomarker; topical compns. comprising conditioned media of
IT Proteins
(BLB; topical compns. comprising conditioned media of cultured stem
IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bois; topical compn. derived from conditioned media of cultured stem
IT CD antigens
(CD133; topical compns. comprising conditioned media of cultured stem
Page 10 of 158
IT CD antigens
(CD29, biomarker; topical compns. comprising conditioned media of
IT CD antigens
IT CD antigens
IT CD antigens
IT CD antigens
IT CXC chemokine receptors
(CXCR4, biomarker; topical compns. comprising conditioned media of
IT Proteins
(Cripto, biomarker; topical compns. comprising conditioned media of
IT Alcohols
(C1-12; topical compns. comprising conditioned media of cultured stem
IT Alcohols
(C16-18, cetostearyl alc.; topical compns. comprising conditioned media
of cultured stem cells for treatment of acne)
IT Enzyme inhibitors
(DNA methyltransferase inhibitors; topical compns. comprising
conditioned media of cultured stem cells for treatment of acne
)
IT Hematopoietin receptors
(FLT3 receptors, ligand; topical compns. comprising conditioned media
IT Histocompatibility antigens
(HLA, class I, biomarker; topical compns. comprising conditioned media
IT Intercellular adhesion molecules
(ICAM-1, biomarker; topical compns. comprising conditioned media of
IT Proteins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(Kirre; topical compns. comprising conditioned media of cultured stem
Page 11 of 158
(Kuki nut; topical compn. derived from conditioned media of cultured
stem cells for treatment of acne)
IT Antigens
(Ly-6A, biomarker; topical compns. comprising conditioned media of
IT Proteins
(MEPE, biomarker; topical compns. comprising conditioned media of
IT Essential oils
(Marhoram; topical compn. derived from conditioned media of cultured
IT Essential oils
(Melaleuca; topical compn. derived from conditioned media of
IT Proteins
(Muashi-1; topical compns. comprising conditioned media of cultured
IT Transcription factors
(NANOG, biomarker; topical compns. comprising conditioned media of
IT Octamer transcription factors
(Oct-3, biomarker; topical compns. comprising conditioned media of
IT Proteins
(PODXL (podocalyxin-like protein), biomarker; topical compns.
comprising conditioned media of cultured stem cells for treatment of
acne)
IT Paired box transcription factors
(Pax6; topical compns. comprising conditioned media of cultured stem
IT Proteins
(RC-2; topical compns. comprising conditioned media of cultured stem
IT Proteins
(SH-3, biomarker; topical compns. comprising conditioned media of
IT Proteins
(SH-4, biomarker; topical compns. comprising conditioned media of
IT Transcription factor SOX
(SOX2, biomarker; topical compns. comprising conditioned media of
IT Antigens
(SSEA-3 (stage-specific embryonic antigen 3), biomarker; topical
compns. comprising conditioned media of cultured stem cells for
treatment of acne)
Page 12 of 158
IT Antigens
(SSEA-4 (stage-specific embryonic antigen 4), biomarker; topical
compns. comprising conditioned media of cultured stem cells for
treatment of acne)
IT Antigens
(STRO-1, biomarker; topical compns. comprising conditioned media of
IT Proteins
(Tra-1-60, biomarker; topical compns. comprising conditioned media of
IT Proteins
(Tra-1-81, biomarker; topical compns. comprising conditioned media of
IT Umbilical cord
(Warton's jelly; topical compns. comprising conditioned media of
IT Wnt proteins
(Uses)
(Wnt-3A; topical compns. comprising conditioned media of cultured stem
IT Keloid
(acne; topical compns. comprising conditioned media of
IT Wnt proteins
(agonists; topical compns. comprising conditioned media of cultured
(allspice; topical compn. derived from conditioned media of cultured
(almond; topical compn. derived from conditioned media of cultured stem
IT Proteins
(Uses)
(angiopoietin-like 2; topical compns. comprising conditioned media of
IT Proteins
(Uses)
(angiopoietin-like 3; topical compns. comprising conditioned media of
(animal; topical compn. derived from conditioned media of cultured stem
IT Essential oils
(anise; topical compn. derived from conditioned media of cultured stem
(anti-acne agents; topical compns. comprising conditioned
Page 13 of 158
media of cultured stem cells for treatment of acne)
(apricot kernel; topical compn. derived from conditioned media of
IT Solvents
(aprotic; topical compns. comprising conditioned media of cultured stem
(argan; topical compn. derived from conditioned media of cultured stem
(avocado; topical compn. derived from conditioned media of cultured
IT Essential oils
(basil, Ocimum basilicum; topical compn. derived from conditioned media
IT Essential oils
(bergamot; topical compn. derived from conditioned media of cultured
(berry; topical compn. derived from conditioned media of cultured stem
IT Activated leukocyte cell adhesion molecules
CD34 antigens
CD44 antigens
Endoglins
Melanoma cell adhesion molecules
Vascular cell adhesion molecule 1
Vimentins
c-Kit proteins
(biomarker; topical compns. comprising conditioned media of cultured
IT Essential oils
(camphor; topical compn. derived from conditioned media of cultured
IT Essential oils
(cassia; topical compn. derived from conditioned media of cultured stem
IT Essential oils
(cedarwood; topical compn. derived from conditioned media of cultured
IT Essential oils
(celery seed; topical compn. derived from conditioned media of cultured
IT Essential oils
(chamomile; topical compn. derived from conditioned media of cultured
Page 14 of 158
(chili; topical compn. derived from conditioned media of cultured stem
IT Essential oils
(cinnamon; topical compn. derived from conditioned media of cultured
IT Essential oils
(clary sage; topical compn. derived from conditioned media of cultured
IT Stem cell
(cloned; topical compns. comprising conditioned media of cultured stem
IT Essential oils
(clove; topical compn. derived from conditioned media of cultured stem
IT Retinoids
(combination with; topical compn. derived from conditioned media of
IT Acne
(comedo; topical compns. comprising conditioned media of
IT Culture media
(conditioned; topical compns. comprising conditioned media of cultured
IT Essential oils
(cumin; topical compn. derived from conditioned media of cultured stem
IT Skin
(dermis; topical compn. derived from conditioned media of cultured stem
IT Stem cell
(embryonic; topical compns. comprising conditioned media of cultured
IT Skin
(epidermis; topical compn. derived from conditioned media of cultured
IT Essential oils
(eucalyptus; topical compn. derived from conditioned media of cultured
IT Tooth
(exfoliated, stem cells derived from; topical compns. comprising
)
IT Blood serum
(fetal bovine serum (FBS); topical compn. derived from conditioned
(fish; topical compn. derived from conditioned media of cultured stem
IT Hair
(follicle, stem cells of; topical compns. comprising conditioned media
IT Essential oils
Page 15 of 158
(geranium; topical compn. derived from conditioned media of cultured
IT Essential oils
(ginger; topical compn. derived from conditioned media of cultured stem
IT Amino acid transporters
(glutamate-aspartate transporter; topical compns. comprising
)
(gourd; topical compn. derived from conditioned media of cultured stem
(grape seed; topical compn. derived from conditioned media of cultured
IT Essential oils
(grapefruit; topical compn. derived from conditioned media of cultured
(hazelnut; topical compn. derived from conditioned media of cultured
(hemp seed; topical compn. derived from conditioned media of cultured
IT Lanolin
(hydrogenated; topical compns. comprising conditioned media of cultured
IT Essential oils
(hyssop; topical compn. derived from conditioned media of cultured stem
IT Controlled-release drug delivery systems
(immediate-release; topical compn. derived from conditioned media of
IT Essential oils
(jasmine; topical compn. derived from conditioned media of cultured
IT Essential oils
(juniper; topical compn. derived from conditioned media of cultured
IT Essential oils
(laurel leaf; topical compn. derived from conditioned media of cultured
IT Essential oils
(lavender; topical compn. derived from conditioned media of cultured
IT Essential oils
Page 16 of 158
(lemon; topical compn. derived from conditioned media of cultured stem
IT Essential oils
(lemongrass; topical compn. derived from conditioned media of cultured
IT Essential oils
(lime; topical compn. derived from conditioned media of cultured stem
IT Alcohols
(linear, esters, ceraphyls; topical compn. derived from conditioned
(macadamia nut; topical compn. derived from conditioned media of
IT Essential oils
(manuka; topical compn. derived from conditioned media of cultured stem
IT Triglycerides
(medium-chain; topical compns. comprising conditioned media of cultured
IT Stem cell
(mesenchymal stem cell; topical compns. comprising conditioned media of
(mustard; topical compn. derived from conditioned media of cultured
IT Perfumes
(myrrh; topical compn. derived from conditioned media of cultured stem
IT Stem cell
(neural; topical compns. comprising conditioned media of cultured stem
IT Essential oils
(nutmeg; topical compn. derived from conditioned media of cultured stem
IT Biomarkers
(of stem cells; topical compns. comprising conditioned media of
IT Resins
(olibanum; topical compn. derived from conditioned media of cultured
IT Essential oils
(orange, sweet; topical compn. derived from conditioned media of
IT Essential oils
(oregano; topical compn. derived from conditioned media of cultured
IT Solvents
Page 17 of 158
(org.; topical compns. comprising conditioned media of cultured stem
IT Transcription factors
(p27rex-1, biomarker; topical compns. comprising conditioned media of
IT Essential oils
(patchouli; topical compn. derived from conditioned media of cultured
IT Essential oils
(peppermint; topical compn. derived from conditioned media of cultured
IT Physiological saline solutions
(phosphate-buffered; topical compns. comprising conditioned media of
IT Sebaceous gland
(pilosebaceous; topical compn. derived from conditioned media of
IT Essential oils
(pine leaf; topical compn. derived from conditioned media of cultured
(pine seed; topical compn. derived from conditioned media of cultured
(poppyseed; topical compn. derived from conditioned media of cultured
IT Glycoproteins
(prominin 1; topical compns. comprising conditioned media of cultured
IT Solvents
(protic; topical compns. comprising conditioned media of cultured stem
(pumpkin seed; topical compn. derived from conditioned media of
IT Endometrium
(regenerative cells of; topical compns. comprising conditioned media of
(rice bran; topical compn. derived from conditioned media of cultured
IT Essential oils
(rose; topical compn. derived from conditioned media of cultured stem
IT Essential oils
(rosemary; topical compn. derived from conditioned media of cultured
IT Essential oils
Page 18 of 158
(rosewood; topical compn. derived from conditioned media of cultured
IT Essential oils
(sage, Salvia officinalis; topical compn. derived from conditioned
IT Essential oils
(sandalwood; topical compn. derived from conditioned media of cultured
IT Essential oils
(sassafras; topical compn. derived from conditioned media of cultured
(sesame; topical compn. derived from conditioned media of cultured stem
IT Hedgehog protein
(Uses)
(sonic; topical compns. comprising conditioned media of cultured stem
IT Essential oils
(sour orange neroli; topical compn. derived from conditioned media of
IT Essential oils
(sour orange; topical compn. derived from conditioned media of cultured
IT Essential oils
(spearmint; topical compn. derived from conditioned media of cultured
IT Embryo, animal
(stem cell; topical compns. comprising conditioned media of cultured
IT Adipose tissue
Endothelium
Heart
Intestine
Kidney
Liver
Osteoblast
Osteoclast
Parthenogenesis
(stem cells derived from; topical compns. comprising conditioned media
IT Cord blood
Placenta
(stem cells of; topical compns. comprising conditioned media of
(teaseed; topical compn. derived from conditioned media of cultured
IT Essential oils
(thyme, Thymus vulgaris; topical compn. derived from conditioned media
Page 19 of 158
IT Combination chemotherapy
Controlled-release drug delivery systems
Cosmetic liquids
Cosmetic packs
Pharmaceutical carriers
Pharmaceutical emulsions
Pharmaceutical excipients
Pharmaceutical gels
Pharmaceutical patches
(topical compn. derived from conditioned media of cultured stem cells
for treatment of acne)
IT Canola oil
Coconut oil
Corn oil
Cottonseed oil
Essential oils
Essential oils
Hydrocarbon oils
Hydrocarbon oils
Isoalkanes
Jojoba oil
Linseed oil
Oils
Olive oil
Palm kernel oil
Palm oil
Paraffin oils
Peanut oil
Petrolatum
Polysiloxanes
Rape oil
Safflower oil
Soaps
Soybean oil
Sunflower oil
IT Acne
Animal tissue culture
Anti-inflammatory agents
Chelating agents
Fever and Hyperthermia
Hematopoietic precursor cell
Histone deacetylase inhibitors
Human
Hypoxia
Inflammation
Nonpolar solvents
Polar solvents
Scar
Stem cell
Surfactants
Thickening agents
(topical compns. comprising conditioned media of cultured stem cells
IT Nestins
Page 20 of 158
IT Bone morphogenetic protein 2
(Uses)
IT Fibronectins
(Uses)
IT Growth factors, animal
(Uses)
IT Hepatocyte growth factor
(Uses)
IT Interleukin 11
(Uses)
IT Interleukin 5
(Uses)
IT Interleukin 6
(Uses)
IT Leukemia inhibitory factor
(Uses)
IT Transforming growth factor
(Uses)
IT Alcohols
IT Glycols
IT Polyoxyalkylenes
Page 21 of 158
IT Alcohols
(trihydric; topical compns. comprising conditioned media of cultured
(truffle; topical compn. derived from conditioned media of cultured
IT Bombesin receptors
(type BB2, biomarker; topical compns. comprising conditioned media of
IT Collagens
(type I, biomarker; topical compns. comprising conditioned media of
IT Essential oils
(valerian; topical compn. derived from conditioned media of cultured
(vegetable; topical compn. derived from conditioned media of cultured
IT Acne
(vulgaris; topical compns. comprising conditioned media of cultured
(walnut kernel oil; topical compn. derived from conditioned media of
IT Vitamins
(water-insol.; topical compn. derived from conditioned media of
(wheat germ; topical compn. derived from conditioned media of cultured
IT Essential oils
(wintergreen; topical compn. derived from conditioned media of cultured
IT Essential oils
(ylang-ylang; topical compn. derived from conditioned media of cultured
IT Integrins
(1, biomarker; topical compns. comprising conditioned media of
IT 9001-78-9, Alkaline phosphatase 9027-73-0, CD73 9028-86-8, Aldehyde
dehydrogenase 9054-63-1, CD13 antigen 120178-12-3, Telomerase reverse
transcriptase
(biomarker; topical compns. comprising conditioned media of cultured
IT 69-72-7, Salicylic acid, biological studies 94-36-0,
Benzoyl peroxide, biological studies
Page 22 of 158
(combination with; topical compn. derived from conditioned media of
IT 9037-42-7, DNA methyltransferase
(inhibitor; topical compns. comprising conditioned media of cultured
IT 9076-57-7, Histone deacetylase, inhibitor
(inhibitors; topical compns. comprising conditioned media of cultured
IT 50-21-5D, Lactic acid, C12-15 alkyl esters 50-70-4, Sorbitol, biological
studies 60-29-7, Diethyl ether, biological studies 60-33-3, Linoleic
acid, biological studies 64-18-6, Formic acid, biological studies
64-19-7, Acetic acid, biological studies 67-64-1, Acetone, biological
studies 67-66-3, Chloroform, biological studies 67-68-5, Dimethyl
sulfoxide, biological studies 68-12-2, Dimethylformamide, biological
studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol,
biological studies 71-43-2, Benzene, biological studies 75-05-8,
Acetonitrile, biological studies 75-09-2, Dichloromethane, biological
studies 102-76-1, Triacetin 108-88-3, Toluene, biological studies
109-99-9, Tetrahydrofuran, biological studies 110-27-0, Isopropyl
myristate 110-54-3, Hexane, biological studies 111-02-4, Squalene
112-10-7, Isopropyl stearate 112-80-1, Oleic acid, biological studies
118-60-5, Octyl salicylate 122-62-3, Dioctyl sebacate 123-91-1,
1,4-Dioxane, biological studies 123-95-5, Butyl stearate 134-09-8,
Menthyl anthranilate 141-78-6, Ethyl acetate, biological studies
143-28-2, Oleyl alcohol 540-10-3, Cetyl palmitate 1323-03-1, Myristyl
lactate 3687-46-5, Decyl oleate 6283-92-7, Lauryl lactate 6938-94-9,
Diisopropyl adipate 8013-52-3, Industrial methylated spirit
16958-85-3, Octyl palmitate 25265-75-2, Butylene glycol 27458-93-1,
Isostearyl alcohol 27841-06-1 29710-31-4, Cetyl octanoate
31807-55-3, Isododecane 35274-05-6, Cetyl lactate 42233-08-9, Tridecyl
behenate 58958-60-4, Isostearyl neopentanoate 90052-75-8, Octyldodecyl
stearoyl stearate 97338-28-8
IT 9001-12-1, Collagenase 9014-42-0, Thrombopoietin 9061-61-4, Nerve
growth factor 11096-26-7, Erythropoietin 62683-29-8,
Colony-stimulating factor 67763-96-6, IGF-1 83869-56-1,
Granulocyte-macrophage colony-stimulating factor 106096-93-9, BFGF
143011-72-7, Granulocyte colony-stimulating factor 1199555-26-4,
-MEM
(Uses)
IT 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol,
biological studies 59-52-9, Dimercaprol 60-00-4,
Ethylenediaminetetraacetic acid, biological studies 64-17-5, Ethanol,
biological studies 67-56-1, Methanol, biological studies 67-63-0,
Isopropyl alcohol, biological studies 107-15-3, Ethylenediamine,
biological studies 637-12-7, Aluminum stearate 7664-38-2D, Phosphoric
acid, di- and trialkyl esters 25322-68-3, Polyethylene glycol
Page 23 of 158
TITLE: Pharmaceutical or cosmetic compositions comprising
benzoyl peroxide
INVENTOR(S): Levin, Daniel; Harms, Arthur
PATENT ASSIGNEE(S): Norac Pharma, USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2012037000 A1 20120322 WO 2011-US51153 20110912
US 20120064135 A1 20120315 US 2011-210855 20110816
US 2010-389456P P 20101004
US 2011-210855 A 20110816
AB The present invention relates to the prepn. of compns. comprising benzoyl
peroxide, with or without other addnl. active ingredients. The process involves
introducing benzoyl peroxide, along with any other active ingredients present,
into a fatty substance that contains and protects the ingredients that would
otherwise be unstable when in contact with one another. The compn. is designed
to allow all ingredients to become available for skin contact or skin absorption
when the fatty substance softens and/or melts as the compn. is applied to the
skin. The benzoyl peroxide may be pre-micronized to a particle distribution
size of about d90 of 0.1 to 150 , preferably d90 of 10 to 15 . Further,
pharmaceutical or cosmetic ingredients may be contained within the fatty
substances, with or without, benzoyl peroxide therein or may be present outside
of the fatty substance but elsewhere within formulated pharmaceutical or
cosmetic products using the active ingredients protected by the fatty substance.
These compns. are useful in aq.-based formulations to treat diseases by topical,
transdermal and/or s.c. administration. Thus, a formulation contained tretinoin
0.1, benzoyl peroxide 15.0, water 49.25, xanthan gum 0.3, Polyoxyl 40 stearate
5.0, stearic acid 17.0, stearyl alc. 3.0, iso-Pr myristate 10.0, BHT 0.1, and
sorbic acid 0.2 g.
IPCI A01N0031-00 [I,A]; A61K0031-075 [I,A]
IPCR A01N0031-00 [I,A]; A61K0031-075 [I,A]
ST pharmaceutical cosmetic benzoyl peroxide
IT Resins
USES (Uses)
(Manila elemi; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Essential oils
USES (Uses)
(Melaleuca; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(animal; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
IT Skin disease
(bacterial; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Materials
Page 24 of 158
(fatty; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
IT Shear
(high; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(hydrogenated; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Carboxylic acids
USES (Uses)
(hydroxy; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(kokum; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(mango kernel; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Fluidization
(microfluidization; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Acne
Animal virus
Antibiotics
Antitumor agents
Antiviral agents
Beeswax
Butter
Ceiba pentandra
Cosmetics and Personal care products
Drug delivery systems
Emulsifying agents
Fungi
Fungicides
Grease (food-derived)
Mammary gland, neoplasm
Melanoma
Melting point
Neoplasm
Particle size distribution
Rosacea
Skin
Stability
Tinea pedis
Vitiligo
Wart
Witch hazel
(pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
IT Alkanes
Page 25 of 158
Carnauba wax
Castor oil
Coal tar
Cocoa butter
Coconut oil
Corticosteroids
Cottonseed oil
Estrogens
Fats and Glyceridic oils
Glucocorticoids
Glycerides
Hydrocarbon oils
Jojoba oil
Lanolin
Lard
Olive oil
Palm oil
Paraffin oils
Petroleum
Polyesters
Polyoxyalkylenes
Progestogens
Retinoids
Steroids
Tallow
Triglycerides
Vitamins
USES (Uses)
peroxide)
IT Resins
USES (Uses)
(podophyllum; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Polyethers
USES (Uses)
(polyester-, block, diblock; pharmaceutical or cosmetic compns.
comprising benzoyl peroxide)
IT Polyesters
USES (Uses)
(polyether-, block, diblock; pharmaceutical or cosmetic compns.
IT Pharmaceutical injections
(s.c. injections; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(shea butter; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Nail disease
Tinea (skin disease)
(tinea unguium; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
Page 26 of 158
USES (Uses)
(vegetable; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(wheat germ; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Antibiotics
(-lactam; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT 9004-95-9, Ethoxylated cetyl alcohol
USES (Uses)
(Brij C 10, Brij 52; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT 9002-92-0, Ethoxylated lauryl alcohol
USES (Uses)
(Brij L 23; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT 50-18-0 50-23-7 50-24-8 50-78-2 50-81-7, L-Ascorbic acid,
biological studies 51-21-8 56-25-7 57-10-3, Hexadecanoic acid,
biological studies 57-10-3D, Hexadecanoic acid, esters 57-11-4,
Octadecanoic acid, biological studies 57-11-4D, Octadecanoic acid,
esters 57-62-5 59-05-2 60-54-8 67-45-8 68-26-8, Retinol
69-72-7, biological studies 70-10-0 76-25-5 77-52-1 79-14-1,
biological studies 94-36-0, biological studies 97-00-7
106-79-6 108-46-3, 1,3-Benzenediol, biological studies 111-01-3
111-46-6, biological studies 112-37-8, Undecanoic acid 112-53-8,
1-Dodecanol 112-86-7 112-95-8, Eicosane 114-07-8, Erythromycin
123-76-2 124-18-5, Decane 124-94-7 126-07-8 130-26-7 143-07-7,
Dodecanoic acid, biological studies 154-21-2 302-79-4, Retinoic acid
334-48-5, Decanoic acid 338-98-7 356-12-7 378-44-9 472-15-1
508-02-1 536-59-4 538-24-9 544-63-8, Tetradecanoic acid, biological
studies 564-25-0 593-45-3, Octadecane 626-86-8 629-94-7,
Heneicosane 777-11-7 859-18-7 1143-38-0 1314-13-2, Zinc oxide
(ZnO), biological studies 1397-89-3, Amphotericin B 1400-61-9,
Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-26-8,
Polymyxin B 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4,
Vitamin E 2022-85-7 2098-66-0 2135-17-3 2152-44-5 2398-96-1
3055-97-8 3093-35-4 3116-76-5 4419-39-0 4759-48-2 5593-20-4
5633-20-5 6713-27-5 7681-93-8 7704-34-9, Sulfur, biological studies
7733-02-0 7761-88-8, Nitric acid silver(1+) salt (1:1), biological
studies 9004-98-2, Brij 98 9005-00-9, Brij S10 10118-90-8
10540-29-1 11056-06-7, Bleomycin 11103-57-4, Vitamin A 11111-12-9,
Cephalosporin 12001-76-2, Vitamin B 12650-69-0 15387-18-5
18323-44-9 21462-39-5 22832-87-7 22916-47-8 23214-92-8
23593-75-1 24169-02-6 24729-96-2 25036-49-1 25322-68-3
27196-00-5, Tetradecanol 27523-40-6 28069-65-0 29342-05-0
30303-65-2, Docosanol 33069-62-4 39809-25-1 55079-83-9 56049-79-7
56093-45-9, Selenium sulfide 56420-45-2 59277-89-3 60628-96-8
61318-91-0 64872-76-0 65277-42-1 65899-73-2 67392-87-4
67915-31-5 78613-35-1 80474-14-2 84625-61-6 85213-14-5, Adipic
acid-dipropylene glycol-phthalic anhydride-trimethylolpropane alternating
copolymer 86386-73-4 90566-53-3 91161-71-6 99011-02-6
101530-10-3 101828-21-1 104227-87-4 104987-11-3 105102-22-5
106685-40-9 107868-30-4 112809-51-5 114977-28-5 118292-40-3
120511-73-1 124832-26-4 130726-68-0 137071-32-0 137234-62-9
153559-49-0 171228-49-2 184475-35-2 918504-65-1 1006879-72-6
Page 27 of 158
USES (Uses)
peroxide)
Page 28 of 158
TITLE: Antiaging and wrinkle treatment methods using
nanoemulsion compositions
INVENTOR(S): Baker, James R., Jr.; Ciotti, Susan M.
PATENT ASSIGNEE(S): NanoBio Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 40pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20120064136 A1 20120315 US 2011-229080 20110909
AB The present invention relates to methods for treating, preventing, minimizing,
and/or diminishing signs of aging in the skin comprising administering to the
subject in need thereof a nanoemulsion compn. The nanoemulsion comprises at
least one drug or non-drug active agent, an active agent having antiaging and/or
anti-wrinkle properties, an active cosmetic substance, an antiviral agent, an
anti-acne active agent, or any combination thereof. For example, skin
permeation of two different active ingredients, benzoyl peroxide or adapalene
from nanoemulsion were evaluated in vitro in a skin model. There was an
increase in the delivery of the second active incorporated in the nanoemulsion
to the epidermis and dermis, as compared to a com. prepn.
INCL 424401000; 424400000; 424059000; 424062000; 514569000; 514714000;
514159000; 977788000; 977906000; 977926000
[I,A]; A61K0031-60 [I,A]; A61Q0017-04 [I,A]; A61Q0019-08 [I,A];
A61Q0019-00 [I,A]; A61Q0019-02 [I,A]; A61P0017-00 [I,A]; A61P0017-10
[I,A]; A61P0031-12 [I,A]; A61P0017-02 [I,A]; A61K0009-107 [I,A];
B82Y0005-00 [N,A]
[I,A]; A61K0031-327 [I,A]; A61K0031-60 [I,A]; A61P0017-00 [I,A];
A61P0017-02 [I,A]; A61P0017-10 [I,A]; A61P0031-12 [I,A]; A61Q0017-04
[I,A]; A61Q0019-00 [I,A]; A61Q0019-02 [I,A]; A61Q0019-08 [I,A];
B82Y0005-00 [N,A]
NCL 424/401.000; 424/059.000; 424/062.000; 424/400.000; 514/159.000;
514/569.000; 514/714.000; 977/788.000; 977/906.000; 977/926.000
IT Essential oils
RL: COS (Cosmetic use); NANO (Nanomaterial); BIOL (Biological study); USES
(Uses)
(Melaleuca alternifolia; antiaging and wrinkle treatment
methods using nanoemulsion compns.)
IT Essential oils
(Uses)
(Melaleuca; antiaging and wrinkle treatment methods using
nanoemulsion compns.)
(anti-acne agents; antiaging and wrinkle treatment methods
using nanoemulsion compns.)
IT Acne
Aftershaves
Antiaging cosmetics
Antioxidants
Antiviral agents
Barrier cosmetics
Page 29 of 158
Bath preparations
Bile
Chelating agents
Cosmetic aerosols
Cosmetic creams
Cosmetic emulsions
Cosmetic foams
Cosmetic gels
Cosmetic liquids
Cosmetic lotions
Cosmetic nanoemulsions
Cosmetic ointments
Cosmetic powders
Cosmetic sprays
Deodorants
Foundations (cosmetics)
Human
Humectants
Hydration, physiological
Melasma
Nonpolar solvents
Pharmaceutical capsules
Pharmaceutical microcapsules
Polar solvents
Scar
Sebaceous gland
Shampoos
Skin cleansers
Skin conditioners
Skin emollients
Skin-lightening cosmetics
Sunscreens
Suntanning products
Surfactants
Viscosity
Wrinkle-preventing cosmetics
(antiaging and wrinkle treatment methods using nanoemulsion compns.)
IT 50-00-0D, Formaldehyde, polymers with alkoxylated alkylphenol 50-21-5,
Lactic acid, biological studies 50-21-5D, Lactic acid, C12-15 alkyl
esters 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid,
biological studies 52-51-7, Bronopol 55-56-1, Chlorohexidine
56-40-6, Glycine, biological studies 56-40-6D, Glycine, alkyldimethyl
derivs. 56-81-5, Glycerol, biological studies 56-81-5D, Glycerol,
monoesters 56-81-5D, Glycerol, monoesters with lanolin fatty acids
57-09-0, Hexadecyltrimethylammonium bromide 57-55-6, Propylene glycol,
biological studies 57-88-5, Cholesterol, biological studies 59-02-9,
-Tocopherol 59-50-7, Chlorocresol 59-52-9, Dimercaprol
60-00-4, Edetic acid, biological studies 60-29-7, Diethyl ether,
biological studies 60-33-3, Linoleic acid, biological studies 62-76-0,
Sodium oxalate 64-17-5, Ethanol, biological studies 64-18-6, Formic
acid, biological studies 64-19-7, Acetic acid, biological studies
65-85-0, Benzoic acid, biological studies 67-56-1, Methanol, biological
studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1,
Acetone, biological studies 67-66-3, Chloroform, biological studies
67-68-5, Dimethyl sulfoxide, biological studies 68-12-2,
Dimethylformamide, biological studies 68-26-8, Retinol 68-26-8D,
Vitamin A, derivs. 69-72-7, Salicylic acid, biological studies
Page 30 of 158
69-93-2, Uric acid, biological studies 70-18-8, Glutathione, biological
studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol,
biological studies 71-43-2, Benzene, biological studies 73-31-4,
Melatonin 75-05-8, Acetonitrile, biological studies 75-09-2,
Dichloromethane, biological studies 76-22-2, Camphor 77-86-1, Tris
buffer 77-92-9, Citric acid, biological studies 78-70-6, Linalool
79-09-4, Propionic acid, biological studies 81-23-2, Dehydrocholic acid
81-25-4, Cholic acid 83-44-3, Deoxycholic acid 83-46-5,
-Sitosterol 87-69-4, L-(+)-Tartaric acid, biological studies
89-78-1, Menthol 89-83-8, Thymol 94-36-0, Benzoyl
peroxide, biological studies 97-78-9, N-Lauroylsarcosine
100-51-6, Benzyl alcohol, biological studies 100-95-8 102-71-6,
Triethanolamine, biological studies 102-76-1, Triacetin 103-47-9, CHES
106-22-9, Citronellol 106-23-0, Citronellal 106-24-1, Geraniol
106-25-2, Nerol 107-15-3, Ethylenediamine, biological studies
108-88-3, Toluene, biological studies 108-95-2, Phenol, biological
studies 109-99-9, Tetrahydrofuran, biological studies 110-27-0,
Isopropyl myristate 110-44-1, Sorbic acid 110-54-3, Hexane, biological
studies 110-85-0, Piperazine, biological studies 111-02-4, Squalene
111-42-2, Diethanolamine, biological studies 112-10-7, Isopropyl
stearate 112-80-1, Oleic acid, biological studies 115-69-5,
2-Amino-2-methyl-1,3-propanediol 116-31-4, Retinal 118-60-5
121-44-8, Triethylamine, biological studies 121-54-0,
2-[2-[p-Diisobutylphenoxy]ethoxy]ethyl dimethylbenzylammonium chloride
122-18-9, Benzyldimethylhexadecylammonium chloride 122-62-3, Dioctyl
sebacate 122-99-6, Phenoxyethanol 123-03-5, Cetylpyridinium chloride
123-46-6, Girard-T reagent 123-91-1, 1,4-Dioxane, biological studies
123-95-5, Butyl stearate 124-03-8, Ethylhexadecyldimethylammonium
bromide 124-68-5, 2-Amino-2-methyl-1-propanol 126-92-1, Sodium octyl
sulfate 127-08-2, Potassium acetate 127-09-3, Sodium acetate
128-13-2, Ursodeoxycholic acid 128-37-0, Butylated hydroxytoluene,
biological studies 134-03-2, Sodium ascorbate 134-09-8, Menthyl
anthranilate 137-16-6, N-Lauroylsarcosine sodium salt 137-66-6,
Ascorbyl palmitate 138-86-3, Limonene 139-07-1, Dodecyl dimethyl
benzylammonium chloride 139-08-2, Benzyldimethyltetradecylammonium
chloride 139-88-8, Niaproof 4 141-43-5, Monoethanolamine, biological
studies 141-53-7, Sodium formate 141-78-6, Ethyl acetate, biological
studies 142-50-7, Nerolidol 142-72-3, Magnesium acetate 142-91-6,
Isopropyl palmitate 143-28-2, Oleyl alcohol 143-62-4, Digitoxigenin
144-02-5, Sodium 5,5-diethylbarbiturate 144-55-8, Sodium carbonate
(NaHCO3), biological studies 145-42-6, Sodium taurocholate 150-25-4,
BICINE 151-21-3, Sodium lauryl sulfate, biological studies 275-51-4,
Azulene 288-32-4, Imidazole, biological studies 298-14-6, Potassium
bicarbonate 302-95-4, Sodium deoxycholate 303-98-0, Coenzyme Q10
304-59-6, Potassium sodium tartrate 361-09-1, Sodium cholate 471-34-1,
Calcium carbonate, biological studies 474-25-9, Chenodeoxycholic acid
489-84-9, Guaiazulene 497-19-8, Sodium carbonate, biological studies
501-36-0, Resveratrol 502-61-4, Farnesene 512-85-6, Ascaridole
515-69-5, Bisabolol 525-79-1, Kinetin 529-05-5, Chamazulene
536-59-4, Perillyl alcohol 540-10-3, Cetyl palmitate 540-69-2,
Ammonium formate 540-84-1, Isooctane 541-02-6,
Decamethylcyclopentasiloxane 541-05-9, Hexamethylcyclotrisiloxane
546-80-5, Thujone 553-08-2, Thonzonium bromide 556-33-2 556-50-3
556-67-2, Octamethylcyclotetrasiloxane 577-11-7, Triton GR-5M
584-08-7, Potassium carbonate 590-29-4, Potassium formate 631-61-8,
Ammonium acetate 638-11-9, Isopropyl n-butyrate 866-83-1 866-84-2
868-18-8 877-24-7 1066-33-7, Ammonium bicarbonate 1119-94-4,
Dodecyltrimethylammonium bromide 1119-97-7,
Trimethyl(tetradecyl)ammonium bromide 1132-61-2, MOPS 1135-40-6, CAPS
1185-53-1, Trizma hydrochloride 1200-22-2, Lipoic acid 1303-96-4,
Page 31 of 158
Sodium tetraborate decahydrate 1310-73-2, Sodium hydroxide, biological
studies 1323-03-1, Myristyl lactate 1323-38-2, Glyceryl
monoricinoleate 1323-42-8 1323-83-7, Glyceryl distearate 1330-85-4
1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate
1338-43-8, Sorbitan monooleate 1406-18-4, Vitamin E 1643-20-5,
N,N-Dimethyldodecylamine N-oxide 2044-56-6, Lithium dodecyl sulfate
2281-11-0 2311-46-8, Isopropyl n-hexanoate 2311-59-3, Isopropyl
n-decanoate 2386-53-0, Sodium 1-dodecanesulfonate 2386-54-1, Sodium
1-butanesulfonate 2420-29-3, Hexaethylene glycol monooctadecyl ether
2646-38-0, Chenodeoxycholic acid sodium salt 2832-45-3, Sodium
hexanesulfonate 3012-65-5, Ammonium citrate dibasic 3055-94-5,
Triethylene glycol monododecyl ether 3055-95-6, Pentaethylene glycol
monododecyl ether 3055-96-7, Hexaethylene glycol monododecyl ether
3055-97-8, Heptaethylene glycol monododecyl ether 3055-98-9,
Octaethylene glycol monododecyl ether 3055-99-0, Nonaethylene glycol
monododecyl ether 3164-29-2 3245-38-3, Deoxycholic acid methyl ester
3687-46-5, Decyl oleate 3700-67-2, Dimethyldioctadecylammonium bromide
4263-52-9, Sodium 2-bromoethanesulfonate 4292-10-8 4478-97-1,
Pentaethylene glycol monohexadecyl ether 4484-59-7, Triethylene glycol
monohexadecyl ether 4602-84-0, Farnesol 4669-23-2, Triethylene glycol
monodecyl ether 4719-04-4 4759-48-2, Isotretinoin 5157-04-0,
Hexaethylene glycol monotetradecyl ether 5168-91-2, Hexaethylene glycol
monohexadecyl ether 5204-74-0, Triethylammonium acetate 5274-68-0,
Tetraethylene glycol monododecyl ether 5300-03-8, Alitretinoin
5324-84-5, 1-Octanesulfonic acid sodium salt 5392-40-5, Citral
5538-94-3, Dioctyl dimethylammonium chloride 5625-37-6, PIPES
5698-39-5, Octaethylene glycol monohexadecyl ether 5703-94-6,
Tetraethylene glycol monodecyl ether 5785-44-4 6009-70-7, Ammonium
oxalate monohydrate 6009-98-9, Taurochenodeoxycholic acid sodium salt
6080-58-6 6106-24-7, biological studies 6108-17-4, Lithium acetate
dihydrate 6131-90-4, Sodium acetate trihydrate 6131-98-2, Sodium
bitartrate monohydrate 6132-02-1, Sodium carbonate decahydrate
6132-04-3 6153-56-6, Oxalic acid dihydrate 6229-23-8 6283-92-7,
Lauryl lactate 6381-59-5 6381-92-6, Ethylenediaminetetraacetic acid
disodium salt dihydrate 6487-48-5, Potassium oxalate monohydrate
6829-55-6D, Tocotrienol, derivs. 6850-27-7, Trimethylammonium acetate
6850-28-8, TRIS-acetate 6938-94-9, Diisopropyl adipate 6976-37-0,
Bis-TRIS 7173-51-5, 1-Decanaminium-N-decyl-N,N-dimethyl-chloride
(Uses)
(antiaging and wrinkle treatment methods using nanoemulsion compns.)
Page 32 of 158
TITLE: Pharmaceutical or cosmetic compositions comprising
benzoyl peroxide
INVENTOR(S): Levin, Daniel; Harms, Arthur
PATENT ASSIGNEE(S): Norac Pharma, USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20120064135 A1 20120315 US 2011-210855 20110816
WO 2012037000 A1 20120322 WO 2011-US51153 20110912
US 2010-389456P P 20101004
US 2011-210855 A 20110816
AB The present invention relates to the prepn. of compns. comprising benzoyl
peroxide, with or without other addnl. active ingredients. The process involves
introducing benzoyl peroxide, along with any other active ingredients present,
into a fatty substance that contains and protects the ingredients that would
otherwise be unstable when in contact with one another. The compn. is designed
to allow all ingredients to become available for skin contact or skin absorption
when the fatty substance softens and/or melts as the compn. is applied to the
skin. The benzoyl peroxide may be pre-micronized to a particle distribution
size of about d90 of 0.1 to 150 , preferably d90 of 10 to 15 . Further,
pharmaceutical or cosmetic ingredients may be contained within the fatty
substances, with or without, benzoyl peroxide therein or may be present outside
of the fatty substance but elsewhere within formulated pharmaceutical or
cosmetic products using the active ingredients protected by the fatty substance.
These compns. are useful in aq.-based formulations to treat diseases by topical,
transdermal and/or s.c. administration. Thus, a formulation contained tretinoin
0.1, benzoyl peroxide 15.0, water 49.25, xanthan gum 0.3, Polyoxyl 40 stearate
5.0, stearic acid 17.0, stearyl alc. 3.0, iso-Pr myristate 10.0, BHT 0.1, and
sorbic acid 0.2 g.
INCL 424401000; 514714000; 424400000; 514337000; 514559000; 514024000;
514029000; 514646000; 514569000; 514772000
[I,A]; A61K0031-203 [I,A]; A61K0031-7056 [I,A]; A61K0031-7048 [I,A];
A61K0031-136 [I,A]; A61K0031-192 [I,A]; A61K0047-44 [I,A]; A61P0031-00
[I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,A];
A61Q0019-00 [I,A]; A61P0031-04 [I,A]; A61P0017-00 [I,A]; A61P0017-10
[I,A]; A61K0031-327 [I,A]
[I,A]; A61K0031-192 [I,A]; A61K0031-203 [I,A]; A61K0031-327 [I,A];
A61K0031-4436 [I,A]; A61K0031-7048 [I,A]; A61K0031-7056 [I,A]; A61K0047-44
[I,A]; A61P0017-00 [I,A]; A61P0017-10 [I,A]; A61P0031-00 [I,A];
A61P0031-04 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0035-00
[I,A]; A61Q0019-00 [I,A]
NCL 424/401.000; 424/400.000; 514/024.000; 514/029.000; 514/337.000;
514/559.000; 514/569.000; 514/646.000; 514/714.000; 514/772.000
ST pharmaceutical cosmetic benzoyl peroxide
IT Resins
USES (Uses)
(Manila elemi; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
Page 33 of 158
IT Essential oils
USES (Uses)
(Melaleuca; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(animal; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
IT Skin disease
(bacterial; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Materials
(fatty; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
IT Shear
(high; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(hydrogenated; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Carboxylic acids
USES (Uses)
(hydroxy; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(kokum; pharmaceutical or cosmetic compns. comprising benzoyl
peroxide)
USES (Uses)
(mango kernel; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Fluidization
(microfluidization; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Acne
Animal virus
Antibiotics
Antitumor agents
Antiviral agents
Beeswax
Butter
Ceiba pentandra
Drug delivery systems
Emulsifying agents
Fungi
Fungicides
Grease (food-derived)
Mammary gland, neoplasm
Melanoma
Melting point
Neoplasm
Page 34 of 158
Rosacea
Skin
Stability
Tinea pedis
Vitiligo
Wart
Witch hazel
peroxide)
IT Alkanes
Carnauba wax
Castor oil
Coal tar
Cocoa butter
Coconut oil
Corticosteroids
Cottonseed oil
Estrogens
Fats and Glyceridic oils
Glucocorticoids
Glycerides
Hydrocarbon oils
Jojoba oil
Lanolin
Lard
Olive oil
Palm oil
Paraffin oils
Petroleum
Polyesters
Polyoxyalkylenes
Progestogens
Retinoids
Steroids
Tallow
Triglycerides
Vitamins
USES (Uses)
peroxide)
IT Resins
USES (Uses)
(podophyllum; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Polyethers
USES (Uses)
(polyester-, block, diblock; pharmaceutical or cosmetic compns.
IT Polyesters
USES (Uses)
(polyether-, block, diblock; pharmaceutical or cosmetic compns.
IT Pharmaceutical injections
Page 35 of 158
(s.c. injections; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(shea butter; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Nail disease
(tinea unguium; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(vegetable; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
USES (Uses)
(wheat germ; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT Antibiotics
(-lactam; pharmaceutical or cosmetic compns. comprising
benzoyl peroxide)
IT 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,
Prednisolone 50-78-2, Acetylsalicylic acid 50-81-7, Vitamin C,
biological studies 51-21-8, Fluorouracil 56-25-7, Cantharidin
57-10-3, Palmitic acid, biological studies 57-10-3D, Palmitic acid,
esters 57-11-4, Stearic acid, biological studies 57-11-4D, Stearic
acid, esters 57-62-5, Chlortetracycline 59-05-2, Methotrexate
60-54-8, Tetracycline 67-45-8, Furazolidone 68-26-8, Retinol
69-72-7, Salicylic acid, biological studies 70-10-0, Ticlatone
76-25-5, Triamcinolone acetonide 77-52-1, Ursolic acid 79-14-1,
Glycolic acid, biological studies 94-36-0, Benzoyl
peroxide, biological studies 97-00-7, 2,4-Dinitrochlorobenzene
106-79-6, Dimethyl sebacate 108-46-3, Resorcinol, biological studies
111-01-3, Squalane 111-46-6, Diethylene glycol, biological studies
112-37-8, Undecanoic acid 112-53-8, 1-Dodecanol 112-86-7, Erucic acid
112-95-8, Eicosane 114-07-8, Erythromycin 123-76-2, Levulinic acid
124-18-5, Decane 124-94-7, Triamcinolone 126-07-8, Griseofulvin
130-26-7, Clioquinol 143-07-7, Lauric acid, biological studies
154-21-2, Lincomycin 302-79-4, Retinoic acid 334-48-5, Decanoic acid
338-98-7, Isoflupredone acetate 356-12-7, Fluocinonide 378-44-9,
Betamethasone 472-15-1, Betulinic acid 508-02-1, Oleanolic acid
536-59-4, Perillyl alcohol 538-24-9, Trilaurin 544-63-8, Myristic
acid, biological studies 564-25-0, Doxycycline 593-45-3, Octadecane
626-86-8, Adipic acid monoethyl ester 629-94-7, Heneicosane 777-11-7,
Haloprogin 859-18-7, Lincomycin hydrochloride 1143-38-0, Anthralin
1314-13-2, Zinc oxide, biological studies 1397-89-3, Amphotericin B
1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-04-2, Neomycin
1404-26-8, Polymyxin B 1405-87-4, Bacitracin 1406-16-2, Vitamin D
1406-18-4, Vitamin E 2022-85-7, Flucytosine 2098-66-0, Cyproterone
2135-17-3, Flumethasone 2152-44-5, Betamethasone 17-valerate
2398-96-1, Tolnaftate 3055-97-8, Heptaethylene glycol monododecyl ether
3093-35-4, Halcinonide 3116-76-5, Dicloxacillin 4419-39-0,
Beclomethasone 4759-48-2, Isotretinoin 5593-20-4, Betamethasone
dipropionate 5633-20-5, Oxybutynin 6713-27-5, Moronic acid
7681-93-8, Natamycin 7704-34-9, Sulfur, biological studies 7733-02-0,
Zinc sulfate 7761-88-8, Silver nitrate, biological studies 10118-90-8,
Minocycline 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 11103-57-4,
Page 36 of 158
Vitamin A 11111-12-9, Cephalosporin 12001-76-2, Vitamin B
12650-69-0, Mupirocin 15387-18-5, Fezatione 18323-44-9, Clindamycin
21462-39-5, Clindamycin hydrochloride 22832-87-7, Miconazole nitrate
22916-47-8, Miconazole 23214-92-8, Doxorubicin 23593-75-1,
Clotrimazole 24169-02-6, Econazole nitrate 24729-96-2, Clindamycin
phosphate 25036-49-1, Poly(Diethylene glycol adipate) 25322-68-3,
Polyethylene glycol 27196-00-5, Tetradecanol 27523-40-6, Isoconazole
28069-65-0, Cuprimyxin 29342-05-0, Ciclopirox 30303-65-2, Docosanol
33069-62-4, Paclitaxel 39809-25-1, Penciclovir 55079-83-9, Acitretin
56049-79-7, Diethylene glycol monotetradecyl ether 56093-45-9, Selenium
sulfide 56420-45-2, Epirubicin 59277-89-3, Acyclovir 60628-96-8,
Bifonazole 61318-91-0, Sulconazole nitrate 64872-76-0, Butoconazole
65277-42-1, Ketoconazole 65899-73-2, Tioconazole 67392-87-4,
Drospirenone 67915-31-5, Terconazole 78613-35-1, Amorolfine
80474-14-2, Fluticasone propionate 84625-61-6, Itraconazole 85213-14-5
86386-73-4, Fluconazole 90566-53-3, Fluticasone 91161-71-6,
Terbinafine 99011-02-6, Imiquimod 101530-10-3, Lanoconazole
101828-21-1, Butenafine 104227-87-4, Famciclovir 104987-11-3,
Tacrolimus 105102-22-5 106685-40-9, Adapalene 107868-30-4, Aromasin
112809-51-5, Letrozole 114977-28-5, Docetaxel 118292-40-3, Tazarotene
120511-73-1, Anastrazole 124832-26-4, Valaciclovir 130726-68-0,
Neticonazole 137071-32-0, Pimecrolimus 137234-62-9, Voriconazole
153559-49-0, Bexarotene 171228-49-2, Posaconazole 184475-35-2,
Gefitinib 918504-65-1, Vemurafenib 1006879-72-6
USES (Uses)
peroxide)
Page 37 of 158
TITLE: Surfactant-free, water-free, foamable compositions and
breakable foams and their uses
INVENTOR(S): Tamarkin, Dov; Gazal, Elana; Papiashvili, Irakliy;
Hazot, Yohan; Schuz, David; Keynan, Rita
PATENT ASSIGNEE(S): Foamix Ltd., Israel
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2011064631 A1 20110603 WO 2010-IB2613 20101001
GB 2474930 A 20110504 GB 2010-16546 20101001
GB 2474930 B 20120704
CA 2776471 A1 20110603 CA 2010-2776471 20101001
CA 2776482 A1 20111110 CA 2011-2776482 20110504
WO 2011138678 A2 20111110 WO 2011-IB1374 20110504
US 20110281827 A1 20111117 US 2011-100724 20110504
US 2010-322148P P 20100408
US 2010-331126P P 20100504
US 2010-349911P P 20100531
US 2010-380568P P 20100907
US 2010-385385P P 20100922
US 2010-388884P P 20101001
WO 2010-IB2612 A 20101001
WO 2010-IB2613 W 20101001
WO 2010-IB2617 A 20101001
WO 2011-IB1374 W 20110504
AB A substantially surface active agent-free and foam adjuvant- free compn. which
includes a hydrophobic solvent, a wax and a propellant. A substantially surface
active agent-free and foam adjuvant- free compn., further comprising, a
tetracycline antibiotic, or one or more other active agents. A method of
treatment, using a substantially surface active agent- free and substantially
foam adjuvant-free compn. For example, a foamable compn. of the present
invention was fomrulated from heavy mineral oil 79, paraffin 51-53 20,
minocycline hydrochloride 1, and propellant AP-70 8 part.
IPCI A61K0009-12 [I,A]
IPCR A61K0009-12 [I,A]
IT Essential oils
USES (Uses)
(Melaleuca; surfactant-free, water-free, foamable compns. and
breakable foams and their uses)
(anti-acne agents; surfactant-free, water-free, foamable
compns. and breakable foams and their uses)
IT Acne
(comedo; surfactant-free, water-free, foamable compns. and
breakable foams and their uses)
IT Abscess
Acaricides
Acne
Allergy inhibitors
Alopecia
Page 38 of 158
Analgesics
Anti-infective agents
Antiaging cosmetics
Antibiotics
Antidandruff hair preparations
Antidepressants
Antihistamines
Antimicrobial agents
Antioxidants
Antiproliferative agents
Antitumor agents
Antiviral agents
Astringents
Atopic dermatitis
Beeswax
Blister
Bullous pemphigoid
Burn
Cellulitis
Cholesteatoma
Corn
Cosmetic foams
Decubitus ulcer
Disinfectants
Ectodermal dysplasia
Eczema
Erysipelas
Erythema nodosum
Erythroderma
Foams
Folliculitis
Fungicides
Furunculosis
Hair growth inhibitors
Hair growth stimulants
Herpes
Herpes labialis
Hirsutism
Human
Human herpesvirus 3
Hyperhidrosis
Hypnotics and Sedatives
Hypolipemic agents
Ichthyosis
Immunomodulators
Immunostimulants
Immunosuppressants
Impetigo
Injury
Insect repellents
Insecticides
Kaposi sarcoma
Keratosis
Lichen planus
Lubricants
Lymphadenitis
Mastocytosis
Page 39 of 158
Measles
Melanoma
Mucosal drug delivery systems
Myositis
Natural products, pharmaceutical
Necrosis
Neurodermatitis
Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oxidizing agents
Parasiticides
Pediculus humanus capitis
Pemphigus
Pesticides
Pharmaceutical foams
Pigmentation disorders
Pityriasis lichenoides
Pityriasis rosea
Pruritus
Psoriasis
Purpura (disease)
Radical scavengers
Rhus toxicodendron
Rubella
Scar
Scleroderma
Skin
Skin, neoplasm
Skin disease
Skin infection
Skin rash
Skin ulcer
Staphylococcal scalded-skin syndrome
Sunburn
Sunscreens
Sunspots
Suntanning products
Tinea pedis
Toxic epidermal necrolysis
UV stabilizers
Urticaria
Varicella
Vasoconstrictors
Vasodilators
Vitiligo
Wound healing promoters
Zea mays
(surfactant-free, water-free, foamable compns. and breakable foams and
their uses)
IT Acne
(vulgaris; surfactant-free, water-free, foamable compns. and breakable
foams and their uses)
IT 50-81-7, Vitamin C, biological studies 57-83-0, Progesterone, biological
studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid, C12-15
alkyl derivs. 68-26-8, Vitamin A 74-98-6, Propane, biological studies
75-28-5, Isobutane 94-36-0, Benzoyl peroxide
Page 40 of 158
, biological studies 103-23-1, Diethylhexyl adipate 104-76-7D,
2-Ethylhexanol, coco fatty acyl derivs. 106-97-8, Butane, biological
studies 110-27-0, Isopropyl myristate 110-36-1, Butyl myristate
112-10-7, Isopropyl stearate 115-83-3, Pentaerythrityl tetrastearate
122-62-3, Dioctyl sebacate 123-95-5, Butyl stearate 124-07-2D,
Octanoic acid, C12-15 alkyl derivs. 126-30-7D, Neopentylglycol,
dicaprylate/dicaprate 137-58-6, Lidocaine 140-25-0, Benzyl laurate
142-91-6, Isopropyl palmitate 149-57-5D, 2-Ethylhexanoic acid, C16-18
alkyl derivs. 293-51-6, Cyclotetrasiloxane 295-01-2, Cyclohexasiloxane
538-23-8, Glyceryl trioctanoate 540-10-3, Cetyl palmitate 540-97-6,
Dow corning 246 556-67-2, Dow corning 244 564-25-0, Doxycycline
620-67-7, Glycerol triheptanoate 629-70-9, Cetyl acetate 1190-63-2,
Hexadecyl stearate 1323-03-1, Myristyl lactate 2599-01-1, Cetyl
myristate 2915-57-3, Di-2-ethylhexyl succinate 3234-85-3, Myristyl
myristate 3687-45-4, Oleyl oleate 3687-46-5, Decyl oleate
6144-28-1D, Bis(octyldodecylstearoyl) 6221-95-0, Myristyl propionate
6283-92-7, Lauryl lactate 6309-51-9, Isoamyl laurate 6938-94-9,
Diisopropyl adipate 7384-98-7, Propylene glycol dicaprylate 7425-14-1,
2-Ethylhexyl 2-ethylhexanoate 7491-02-3, Diisopropyl sebacate
7735-26-4, Diethyleneglycol dioctanoate 9003-13-8, Polypropylene glycol
butyl ether 9003-27-4, Polyisobutylene 9005-12-3,
Methylphenylpolysiloxane 9006-65-9, Dimethicone 9035-85-2,
PolyPropylene glycol hexadecyl ether 9064-14-6, PolyPropylene glycol
lauryl ether 10118-90-8, Minocycline 10233-13-3, Isopropyl laurate
10401-55-5, Cetyl ricinoleate 11103-57-4, Vitamin A 12001-76-2,
Vitamin B 12001-79-5, Vitamin K 13552-80-2, Glyceryl triundecanoate
13614-98-7, Minocycline hydrochloride 14303-70-9, Propyl myristate
15763-02-7, Dioctyl malate 17673-56-2, Oleyl erucate 17955-88-3,
Caprylyl methicone 22047-49-0, Ethylhexyl stearate 25231-21-4,
PolyPropylene glycol stearyl ether 25322-69-4D, PolyPropylene glycol,
alkyl ethers 25339-09-7, Isocetyl stearate 26896-18-4D, Isononanoic
acid, C16-18 alkyl derivs. 27841-06-1, Neopentylglycol dicaprate
29710-25-6, 2-Ethylhexyl hydroxystearate 29710-31-4, Cetyl octanoate
29759-38-4, Tetrafluoroethane 29806-73-3, 2-Ethylhexyl palmitate
31161-71-4, Benzyl myristate 31692-79-2, Dimethiconol 31807-55-3,
Isododecane 32222-06-3, Calcitriol 34316-64-8, Hexyl laurate
34513-50-3, Octyl dodecanol 34689-06-0, Stearyl caprate 34962-91-9,
Isodecyl 2-ethylhexanoate 35274-05-6, Cetyl lactate 36078-10-1,
Dodecyl oleate 36148-84-2 36311-34-9, Isohexadecanol 36311-34-9D,
Isocetyl alcohol, lanolate 37220-82-9, Glyceryl oleate 37286-64-9,
PolyPropylene glycol methyl ether 41395-89-5, Isodecyl isononanoate
41669-30-1, Isostearyl isostearate 41755-60-6, Benzyl palmitate
42131-25-9, Isononyl isononanoate 42131-27-1, Isotridecyl isononanoate
42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate 42233-14-7,
Arachidyl behenate 42557-10-8 52581-71-2 52663-48-6, Stearyl
propionate 53824-77-4, Propylene glycol dicaprate 56235-92-8,
Di-2-ethylhexyl malate 57569-76-3 58958-60-4, Isostearyl neopentanoate
59130-69-7, Cetyl 2-ethylhexanoate 59231-34-4, Isodecyl oleate
59587-44-9, 2-Ethylhexyl pelargonate 60908-77-2, Isohexadecane
63793-60-2, PolyPropylene glycol myristyl ether 65591-14-2, Arachidyl
propionate 66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl
isostearate 71566-49-9, 2-Ethylhexyl isononanoate 72269-52-4
72576-80-8, Isostearyl palmitate 83919-23-7, Mometasone furoate
84605-09-4 90052-75-8, Octyldodecyl stearoyl stearate 93385-14-9,
Triisocetyl citrate 93596-79-3 93682-38-3, Isostearyl malate
94247-28-6, Isocetyl behenate 94248-76-7, Isocetyl octanoate
97338-28-8 111517-88-5, Propylene glycol ricinoleate 113431-53-1
125804-07-1 125804-08-2, 2-Octyldodecyl behenate 125804-16-2,
Isostearyl behenate 125804-18-4, Tridecyl isononanoate 127358-80-9,
Isostearyl linoleate 127770-27-8, Isocetyl palmitate 135326-54-4,
Page 41 of 158
Propylene glycol myristyl ether acetate 138208-67-0, Isohexyl decanoate
138208-68-1, Isocetyl salicylate 144610-93-5, Myristyl neopentanoate
156048-34-9, Dimethylsilanediol-diphenylsilanediol copolymer
159317-32-5, Isostearyl glycolate 163564-45-2, Isostearyl isononanoate
172670-81-4, Isononyl octanoate 190282-37-2, Diethyleneglycol
diisononanoate 195868-36-1, Phenyl trimethicone 308122-33-0,
2-Octyldodecyl hydroxystearate 383419-35-0 1008098-31-4 1286715-16-9
1286715-17-0 1287647-89-5
USES (Uses)
(surfactant-free, water-free, foamable compns. and breakable foams and
their uses)
Page 42 of 158
TITLE: Topical tetracycline compositions comprising
hydrophobic oils and viscosity-modifying agents
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2011039638 A2 20110407 WO 2010-IB2617 20101001
WO 2011039638 A3 20110526
CA 2776474 A1 20110407 CA 2010-2776474 20101001
GB 2474930 A 20110504 GB 2010-16546 20101001
GB 2474930 B 20120704
EP 2482788 A2 20120808 EP 2010-819992 20101001
CN 102686205 A 20120919 CN 2010-80054424 20101001
CA 2776482 A1 20111110 CA 2011-2776482 20110504
WO 2011138678 A2 20111110 WO 2011-IB1374 20110504
US 20110281827 A1 20111117 US 2011-100724 20110504
MX 2012003985 A 20120625 MX 2012-3985 20120402
US 2010-322148P P 20100408
US 2010-331126P P 20100504
US 2010-349911P P 20100531
US 2010-380568P P 20100907
US 2010-385385P P 20100922
US 2010-388884P P 20101001
WO 2010-IB2612 A 20101001
WO 2010-IB2613 A 20101001
WO 2010-IB2617 W 20101001
WO 2011-IB1374 W 20110504
AB A topical therapeutic hydrophobic breakable compn. includes a carrier comprising
(a) about 60% to 99% by wt. of at least one hydrophobic oil; (b) at least one
viscosity-modifying agents selected from the group consisting of a fatty alc., a
fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that
at least part of the tetracycline antibiotic is suspended in the compn. The
viscosity of the compn. is at least about 30% higher than the viscosity of the
carrier without the tetracycline antibiotic, and is higher than the viscosity of
the hydrophobic oil and the tetracycline antibiotic without the viscosity
modifying agents,. The amt. of viscosity modifying agents can optionally be
reduced by at least an amt. by wt. that would have increased the viscosity of
the carrier without the tetracycline antibiotic by at least 30%. The
tetracycline is chem. stable in the compn. for at least 6 mo, wherein more than
about 90% of the tetracycline has not broken down. When the compn. is packaged
in an aerosol container to which is added a liquefied or compressed gas
propellant, the compn. affords upon release from the container a breakable foam
of at least good quality that breaks easily upon application of shear force.
Thus, a mineral oil-based oleaginous formulation with improved viscosity
contained minocycline HCl, a mixt. of heavy and light mineral oils,
cyclomethicone, stearyl alc., beeswax, stearic acid, hydrogenated castor oil,
behenyl alc., cetostearyl alc., and silica. The formulation viscosity was
directly related to the concn. of the tetracycline, reaching a plateau when the
active ingredient is present at a concn. of about 0.50%.
IPCI A61K0031-65 [I,A]; A61K0008-02 [I,A]
IPCR A61K0031-65 [I,A]
Page 43 of 158
IT Essential oils
(Melaleuca alternifolia; topical tetracycline compns. with
carriers contg. hydrophobic oils and viscosity-modifying agents)
(anti-acne agents; topical tetracycline compns. with carriers
contg. hydrophobic oils and viscosity-modifying agents)
IT Acne
(comedo; topical tetracycline compns. with carriers contg.
hydrophobic oils and viscosity-modifying agents)
IT Acne
(nodular papulopustular acne; topical tetracycline compns.
with carriers contg. hydrophobic oils and viscosity-modifying agents)
IT AIDS (disease)
Abscess
Acaricides
Acne
Allergy inhibitors
Alopecia
Anal disease
Analgesics
Anthelmintics
Antibiotics
Antidepressants
Antihistamines
Antitumor agents
Antiviral agents
Anus neoplasm
Astringents
Atopic dermatitis
Barrier cosmetics
Beeswax
Blepharitis
Blindness
Blister
Bullous pemphigoid
Callosity
Candidiasis
Cataract
Cellulitis
Cervix, neoplasm
Chlamydia infection
Cholesteatoma
Combination chemotherapy
Condyloma acuminatum
Conjunctivitis
Constipation
Crohn disease
Decubitus ulcer
Disinfectants
Drug bioavailability
Drug toxicity
Drugs
Page 44 of 158
Ear disease
Eczema
Endometritis
Erysipelas
Erythema nodosum
Erythroderma
Eye disease
Eye disease
Female reproductive system disease
Folliculitis
Fungicides
Furunculosis
Giant cell arteritis
Glaucoma
HIV infection
Hemorrhoid
Hepatitis B
Herpes
Herpes labialis
Hirsutism
Human herpesvirus 3
Human herpesvirus 3
Human papillomavirus
Hydrophobicity
Hyperhidrosis
Hypolipemic agents
Ichthyosis
Immunomodulators
Immunostimulants
Immunosuppressants
Impetigo
Insect repellents
Insecticides
Iritis
Kaposi sarcoma
Keratoconus
Lichen planus
Lubricants
Lyme disease
Lymphadenitis
Macular degeneration
Mastocytosis
Measles
Melanoma
Molluscum contagiosum virus
Mouth disease
Myasthenia gravis
Neurodermatitis
Nevus
Nose disease
Oophoritis
Oxidizing agents
Pemphigus
Pesticides
Pharmaceutical aerosols
Page 45 of 158
Photosensitivity disorders
Photosensitizers, pharmaceutical
Pityriasis rosea
Propellants (sprays and foams)
Prophylaxis
Pruritus
Pruritus
Psoriasis
Pterygium
Purpura (disease)
Radical scavengers
Reproductive system, neoplasm
Respiratory system disease
Retinal detachment
Rhus toxicodendron
Rosacea
Rubella
Sarcoidosis
Scabies
Scar
Scar
Scleritis
Scleroderma
Seborrhea
Sinusitis
Skin, neoplasm
Skin disease
Skin rash
Skin ulcer
Sunburn
Sunless tanning products
Tinea pedis
Trachoma
Urticaria
Uveitis
Vagina, neoplasm
Vaginal disease
Varicella
Varicella
Vasoconstrictors
Vasodilators
Viscosity
Vision disorders
Vitiligo
Vulva disease
Wart
(topical tetracycline compns. with carriers contg. hydrophobic oils and
Page 46 of 158
viscosity-modifying agents)
IT Acne
(vulgaris; topical tetracycline compns. with carriers contg.
hydrophobic oils and viscosity-modifying agents)
IT 50-81-7, Vitamin C, biological studies 57-10-3, Hexadecanoic acid,
biological studies 57-11-4, Octadecanoic acid, biological studies
57-83-0, Progesterone, biological studies 57-88-5, Cholesterol,
biological studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid,
alkyl esters 94-36-0, Benzoyl peroxide,
biological studies 103-23-1, Diethylhexyl adipate 104-76-7D,
2-Ethylhexanol, coco fatty acid esters 106-14-9, 12-Hydroxystearic acid
109-36-4, Octyl stearate 110-27-0, Isopropyl myristate 110-36-1, Butyl
myristate 112-10-7, Isopropyl stearate 112-53-8, Lauryl alcohol
112-72-1, Myristyl alcohol 112-85-6, Docosanoic acid 112-92-5, Stearyl
alcohol 115-83-3, Pentaerythrityl tetrastearate 122-62-3, Dioctyl
sebacate 123-95-5, Butyl stearate 124-07-2D, Octanoic acid, alkyl
esters 140-25-0, Benzyl laurate 142-91-6, Isopropyl palmitate
143-07-7, Dodecanoic acid, biological studies 149-57-5D, Ethylhexanoic
acid, cetearyl esters 506-12-7, Heptadecanoic acid 506-30-9,
Eicosanoic acid 506-46-7, Hexacosanoic acid 506-48-9, Octacosanoic
acid 506-50-3, Triacontanoic acid 506-51-4, Tetracosanol 506-52-5,
Hexacosanol 538-23-8, Glyceryl trioctanoate 540-10-3, Cetyl palmitate
544-63-8, Tetradecanoic acid, biological studies 557-59-5, Tetracosanoic
acid 557-61-9, Octacosanol 593-50-0, Triacontanol 620-67-7, Glycerol
triheptanoate 629-70-9, Cetyl acetate 629-96-9, Arachidyl alcohol
661-19-8, Behenyl alcohol 1190-63-2, Hexadecyl stearate 1323-03-1,
Myristyl lactate 1406-16-2, Vitamin D 2599-01-1, Cetyl myristate
2915-57-3 3234-85-3, Myristyl myristate 3625-52-3, Dotriacontanoic
acid 3687-45-4, Oleyl oleate 3687-46-5, Decyl oleate 6221-95-0,
Myristyl propionate 6283-92-7, Lauryl lactate 6309-51-9, Isoamyl
laurate 6938-94-9, Diisopropyl adipate 7138-40-1, Heptacosanoic acid
7384-98-7, Propylene glycol dicaprylate 7425-14-1 7491-02-3,
Diisopropyl sebacate 7631-86-9, Silicon dioxide, biological studies
7735-26-4, Diethylene glycol dioctanoate 9003-13-8, Polypropylene glycol
butyl ether 9003-27-4, Polyisobutylene 9006-65-9, Dimethicone
9035-85-2, Polypropylene glycol cetyl ether 9064-14-6, Polypropylene
glycol lauryl ether 10233-13-3, Isopropyl laurate 10401-55-5, Cetyl
ricinoleate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5,
Vitamin K 13552-80-2, Glyceryl triundecanoate 14303-70-9, Propyl
myristate 15763-02-7, Dioctyl malate 16958-85-3, Octyl palmitate
17673-56-2, Oleyl erucate 22047-49-0, Ethylhexyl stearate 25231-21-4,
Polypropylene glycol stearyl ether 25322-69-4D, Polypropylene glycol,
alkyl ethers 25339-09-7, Isocetyl stearate 25496-72-4, Glyceryl oleate
26896-18-4D, Isononanoic acid, cetearyl esters 27841-06-1, Neopentyl
glycol dicaprate 27841-06-1D, Neopentylglycol dicaprate, mixed esters
with neopentylglycol and octanoic acid 28484-70-0, 1-Tetratriacontanol
29710-25-6, 2-Ethylhexyl hydroxystearate 29710-31-4, Cetyl octanoate
29806-73-3, 2-Ethylhexyl palmitate 30399-84-9, Isostearic acid
31161-71-4, Benzyl myristate 31335-74-7D, Neopentylglycol dicaprylate,
mixed esters with neopentylglycol and octanoic acid 31807-55-3,
Isododecane 34316-64-8, Hexyl laurate 34513-50-3, Octyldodecanol
34689-06-0, Stearyl caprate 34962-91-9 35274-05-6, Cetyl lactate
36078-10-1, Dodecyl oleate 36653-82-4, Cetyl alcohol 37286-64-9,
Polypropylene glycol methyl ether 38232-03-0, Tritriacontanoic acid
38232-04-1, Tetratriacontanoic acid 38232-05-2, Pentatriacontanoic acid
41395-89-5, Isodecyl isononanoate 41669-30-1, Isostearyl isostearate
41755-60-6, Benzyl palmitate 42131-25-9, Isononyl isononanoate
42131-27-1, Isotridecyl isononanoate 42131-28-2, Isostearyl lactate
42175-36-0, Oleyl lactate 42233-14-7, Arachidyl behenate 42557-10-8
51744-92-4, -Tocopheryl linoleate 52581-71-2 52663-48-6,
Page 47 of 158
Stearyl propionate 53824-77-4, Propylene glycol dicaprate 56235-92-8
57569-76-3, Glycereth-7 triacetate 58958-60-4, Isostearyl neopentanoate
59130-69-7, Cetyl 2-ethylhexanoate 59231-34-4, Isodecyl oleate
59587-44-9, 2-Ethylhexyl pelargonate 60908-77-2, Isohexadecane
63793-60-2, Polypropylene glycol myristyl ether 65591-14-2, Arachidyl
propionate 66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl
isostearate 71566-49-9, 2-Ethylhexyl isononanoate 72269-52-4
72576-80-8, Isostearyl palmitate 83826-43-1, Octyldodecyl myristate
84605-09-4 90052-75-8, Octyldodecyl stearoyl stearate 93385-14-9,
Triisocetyl citrate 93596-79-3, Polypropylene glycol isocetyl ether
93682-38-3, Isostearyl malate 93705-18-1 94247-28-6, Isocetyl behenate
97338-28-8 102767-64-6, Propellant A 46 111517-88-5, Propylene glycol
ricinoleate 113431-53-1, Diisostearyl fumarate 125804-07-1
125804-08-2 125804-16-2, Isostearyl behenate 125804-18-4, Tridecyl
isononanoate 127358-80-9, Isostearyl linoleate 127770-27-8, Isocetyl
palmitate 135326-54-4, Propylene glycol myristyl ether acetate
138208-67-0, Isohexyl decanoate 138208-68-1, Isocetyl salicylate
144610-93-5, Myristyl neopentanoate 159317-32-5, Isostearyl glycolate
163564-45-2, Isostearyl isononanoate 172670-81-4, Isononyl octanoate
190282-37-2, Diethylene glycol diisononanoate 195868-36-1, Phenyl
trimethicone 308122-33-0, 2-Octyldodecyl hydroxystearate 1008098-31-4,
Isostearyl citrate 1186139-12-7 1257338-52-5, Schercemol DISD
1286715-16-9 1286715-17-0
(topical tetracycline compns. with carriers contg. hydrophobic oils and
viscosity-modifying agents)
Page 48 of 158
TITLE: Surfactant-free, water-free foamable tetracycline
compositions, breakable foams and gels and their uses
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2011039637 A2 20110407 WO 2010-IB2612 20101001
WO 2011039637 A3 20110630
CA 2776366 A1 20110407 CA 2010-2776366 20101001
GB 2474930 A 20110504 GB 2010-16546 20101001
GB 2474930 B 20120704
AU 2010302350 A1 20120524
AU 2010-302350 20101001
CA 2776482 A1 20111110
CA 2011-2776482 20110504
WO 2011138678 A2 20111110
WO 2011-IB1374 20110504
US 20110281827 A1 20111117
US 2011-100724 20110504
US 2010-322148P P 20100408
US 2010-331126P P 20100504
US 2010-349911P P 20100531
US 2010-380568P P 20100907
US 2010-385385P P 20100922
US 2010-388884P P 20101001
WO 2010-IB2612 W 20101001
WO 2010-IB2613 A 20101001
WO 2010-IB2617 A 20101001
WO 2011-IB1374 W 20110504
AB A surfactant-free oleaginous foamable compn. comprising a hydrophobic solvent, a
petrolatum, a paraffin wax, a fatty alc., a fatty acid and/or a wax and/or shea
butter, with and without a propellant is provided. A substantially surface
active agent-free compn. further comprises a tetracycline antibiotic, or a
vitamin D deriv., or one or more other active agents. A method of using a
substantially surface active agent-free compn. for intradermal delivery of the
active agent into the skin with minimal or negligible transdermal delivery for
treatment, among others, eye infections and dermatol. or mucosal disorders is
described. A minocycline oleaginous compn. contg. soybean oil, octyldodecanol,
medium-chain triglycerides oil and coconut oil was proposed.
IPCI A61K0009-12 [I,A]
IPCR A61K0009-12 [I,A]
IT Essential oils
(Melaleuca; surfactant- and water-free foamable compns.,
breakable foams and gels, and therapeutic uses thereof)
(anti-acne agents; surfactant- and water-free foamable
compns., breakable foams and gels, and therapeutic uses thereof)
IT Acne
(nodular papulopustular; surfactant- and water-free foamable compns.,
breakable foams and gels, and therapeutic uses thereof)
IT AIDS (disease)
Abscess
Page 49 of 158
Acaricides
Acinetobacter
Acne
Albinism
Allergy
Allergy inhibitors
Alopecia
Anal disease
Analgesics
Anthelmintics
Antibiotics
Antidepressants
Antihistamines
Antioxidants
Antitumor agents
Antiviral agents
Anus neoplasm
Arthralgia
Arthritis
Aspergillus niger
Astringents
Atopic dermatitis
Bacterial infection
Bacteroides
Barrier cosmetics
Beeswax
Blister
Bullous pemphigoid
Candida albicans
Cellulitis
Cervix, neoplasm
Chlamydia infection
Cholesteatoma
Constipation
Crohn disease
Decubitus ulcer
Dermatomycosis
Drug toxicity
Drugs
Dysmenorrhea
Dysplastic nevus
Ear disease
Eczema
Endometriosis
Endometritis
Erysipelas
Erythema nodosum
Erythroderma
Escherichia coli
Female reproductive system, neoplasm
Female reproductive system disease
Folliculitis
Fungicides
Furunculosis
Page 50 of 158
Gestational trophoblastic disease
HIV infection
Haemophilus
Hemorrhoid
Hepatitis B
Herpes
Herpes labialis
Herpes simplex
Human herpesvirus 3
Human papillomavirus
Hyperhidrosis
Hyperkeratosis
Hypolipemic agents
Ichthyosis
Immunomodulators
Immunostimulants
Immunosuppressants
Impetigo
Inflammation
Insect repellents
Insecticides
Kaposi sarcoma
Keloid
Lichen planus
Lubricants
Lymphadenitis
Lymphogranuloma venereum
Mastocytosis
Measles
Melanoma
Melasma
Molluscum contagiosum virus
Myalgia
Mycobacterium leprae
Mycosis
Neisseria meningitidis
Neoplasm
Neurodermatitis
Nocardia
Nose disease
Oophoritis
Ophthalmic drug delivery systems
Osteoarthritis
Ovary, neoplasm
Oxidizing agents
Pain
Parasitic infection
Parasiticides
Pemphigus
Pesticides
Photosensitizers, pharmaceutical
Pityriasis rosea
Page 51 of 158
Premenstrual syndrome
Preservatives
Propellants (sprays and foams)
Prophylaxis
Propionibacterium acnes
Pruritus
Pseudomonas aeruginosa
Psoriasis
Purpura (disease)
Radical scavengers
Respiratory system disease
Rhus diversiloba
Rhus toxicodendron
Rubella
Scabies
Scar
Scleroderma
Sexual disorders
Sexually transmitted diseases
Skin disease
Skin ulcer
Stability
Staphylococcus aureus
Streptococcus
Streptococcus pyogenes
Sunburn
Sunless tanning products
Surfactants
Tinea pedis
Trichomonas vaginalis
Urticaria
Uterine cervicitis
Vagina, neoplasm
Vaginal disease
Varicella
Vasoconstrictors
Vasodilators
Vesiculobullous
Viral infection
Vitiligo
Vulva disease
Wound
(surfactant- and water-free foamable compns., breakable foams and gels,
and therapeutic uses thereof)
IT Acne
(vulgaris; surfactant- and water-free foamable compns., breakable foams
and gels, and therapeutic uses thereof)
IT 50-81-7, Vitamin C, biological studies 57-11-4, Stearic acid, biological
studies 57-50-1D, Sucrose, stearic acid esters 57-88-5, Cholesterol,
biological studies 58-95-7, Tocopheryl acetate 65-85-0D, Benzoic acid,
alkyl esters 75-28-5, Isobutane 94-36-0, Benzoyl
peroxide, biological studies 103-23-1, Diethylhexyl adipate
109-36-4, Octyl stearate 110-27-0, Isopropyl myristate 110-36-1, Butyl
myristate 112-10-7, Isopropyl stearate 112-72-1, Myristyl alcohol
112-92-5, Stearyl alcohol 115-83-3, Pentaerythrityl tetrastearate
Page 52 of 158
122-62-3, Dioctyl sebacate 123-95-5, Butyl stearate 124-07-2D,
Octanoic acid, alkyl esters 140-25-0, Benzyl laurate 142-91-6,
Isopropyl palmitate 149-57-5D, Ethylhexanoic acid, cetearyl esters
293-51-6, Cyclotetrasiloxane 294-40-6, Cyclopentasiloxane 295-01-2,
Cyclohexasiloxane 443-48-1, Metronidazole 538-23-8, Glyceryl
trioctanoate 540-10-3, Cetyl palmitate 540-97-6, Dow Corning 246 Fluid
556-67-2, Dow Corning 244 Fluid 564-25-0, Doxycycline 620-67-7,
Glycerol triheptanoate 629-70-9, Cetyl acetate 661-19-8, Behenyl
alcohol 1190-63-2, Hexadecyl stearate 1323-03-1, Myristyl lactate
1406-16-2, Vitamin D 2152-44-5, Betamethasone valerate 2599-01-1,
Cetyl myristate 2915-57-3 3234-85-3, Myristyl myristate 3687-45-4,
Oleyl oleate 3687-46-5, Decyl oleate 6221-95-0, Myristyl propionate
6283-92-7, Lauryl lactate 6309-51-9, Isoamyl laurate 6938-94-9,
Diisopropyl adipate 7384-98-7, Propylene glycol dicaprylate 7425-14-1
7491-02-3, Diisopropyl sebacate 7735-26-4, Diethylene glycol dioctanoate
9003-13-8, Polypropylene glycolbutyl ether 9003-27-4, Polyisobutylene
9006-65-9, Dimethicone 9006-65-9D, Dimethicone, PEG/PPG derivs.
9035-85-2, PPG cetyl ether 9064-14-6, Polypropylene glycol lauryl ether
10118-90-8, Minocycline 10233-13-3, Isopropyl laurate 10401-55-5,
Cetyl ricinoleate 11103-57-4, Vitamin A 12001-76-2, Vitamin B
12001-79-5, Vitamin K 13552-80-2, Glyceryl triundecanoate 13614-98-7,
Minocycline hydrochloride 14303-70-9, Propyl myristate 15763-02-7,
Dioctyl malate 16958-85-3, Octyl palmitate 17673-56-2, Oleyl erucate
17955-88-3, Caprylyl methicone 22047-49-0, Ethylhexyl stearate
22204-53-1, Naproxen 24390-14-5, Doxycycline hyclate 25231-21-4,
Polypropylene glycol stearyl ether 25322-69-4D, Polypropylene glycol,
alkyl ethers 25339-09-7, Isocetyl stearate 26896-18-4D, Isononanoic
acid, cetearyl esters 27841-06-1, Neopentyl glycol dicaprate
29710-25-6 29710-31-4, Cetyl octanoate 29806-73-3 30399-84-9,
Isostearic acid 31161-71-4, Benzyl myristate 31335-74-7, Neopentyl
glycol dicaprylate 31692-79-2, Dimethiconol 31807-55-3, Isododecane
32222-06-3, Calcitriol 34316-64-8, Hexyl laurate 34513-50-3,
Octyldodecanol 34689-06-0, Stearyl caprate 34962-91-9 35274-05-6,
Cetyl lactate 36078-10-1, Dodecyl oleate 36148-84-2 36311-34-9,
Isohexadecanol 36653-82-4, Cetyl alcohol 37220-82-9, Glyceryl oleate
37286-64-9, Polypropylene glycol methyl ether 41395-89-5, Isodecyl
isononanoate 41669-30-1, Isostearyl isostearate 41755-60-6, Benzyl
palmitate 42131-25-9, Isononyl isononanoate 42131-27-1, Isotridecyl
isononanoate 42131-28-2, Isostearyl lactate 42175-36-0, Oleyl lactate
42233-14-7, Arachidyl behenate 42557-10-8 52581-71-2 52663-48-6
53824-77-4, Propylene glycol dicaprate 56235-92-8 57569-76-3
58958-60-4, Isostearyl neopentanoate 59130-69-7 59231-34-4, Isodecyl
oleate 59587-44-9 60908-77-2, Isohexadecane 63793-60-2,
Polypropylene glycol myristyl ether 65591-14-2, Arachidyl propionate
66009-41-4, Stearyl heptanoate 68171-33-5, Isopropyl isostearate
71566-49-9 72269-52-4 72576-80-8, Isostearyl palmitate 83826-43-1,
Octyldodecyl myristate 83919-23-7, Mometasone furoate 84605-09-4
90052-75-8, Octyldodecyl stearoyl stearate 91161-71-6, Terbinafine
93385-14-9, Triisocetyl citrate 93596-79-3 93682-38-3, Isostearyl
malate 94247-28-6, Isocetyl behenate 97338-28-8 111517-88-5,
Propylene glycol ricinoleate 112965-21-6, Calcipotriol 113431-53-1
125804-07-1 125804-08-2, 2-Octyldodecyl behenate 125804-16-2
125804-18-4, Tridecyl isononanoate 127358-80-9, Isostearyl linoleate
127770-27-8, Isocetyl palmitate 135326-54-4, Propylene glycol myristyl
ether acetate 138208-67-0, Isohexyl decanoate 138208-68-1, Isocetyl
salicylate 144610-93-5 156048-34-9 159317-32-5, Isostearyl glycolate
163564-45-2, Isostearyl isononanoate 172670-81-4, Isononyl octanoate
190282-37-2, Diethylene glycol diisononanoate 195868-36-1,
Phenyltrimethicone 308122-33-0, 2-Octyldodecyl hydroxystearate
383419-35-0 1008098-31-4 1286715-16-9 1286715-17-0 1287647-89-5
Page 53 of 158
(surfactant- and water-free foamable compns., breakable foams and gels,
and therapeutic uses thereof)
Page 54 of 158
TITLE: Nanoemulsion compositions for treatment and prevention
of acne, methods of making the compositions, and
methods of use thereof
INVENTOR(S): Sutcliffe, Joyce A.; Ciotti, Susan M.; Baker, James
R., Jr.
PATENT ASSIGNEE(S): NanoBio Corporation, USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2010087964 A2 20100805 WO 2010-US236 20100128
WO 2010087964 A3 20110616
CA 2750233 A1 20100805
CA 2010-2750233 20100128
US 20100226983 A1 20100909
US 2010-656421 20100128
EP 2391342 A2 20111207
EP 2010-703377 20100128
WO 2010-US236 W 20100128
AB The present invention relates to methods for treating and preventing acne or
Propionibacterium acnes infection in a subject comprising topically
administering to the subject in need thereof an anti-acne nanoemulsion compn.
Thus, nanoemulsions comprised, in an aq. medium, soybean oil, Tween 20 as a
nonionic surfactant, ethanol, cetylpyridinium chloride (CPC) as a cationic
surfactant, EDTA, and water, and optionally, a thickening agent for the gel
formulation. The nanoemulsions showed relevant microbiol. and bactericidal
activity against a collection of recent clin. isolates of P. acnes, including
multidrug-resistant strains. Combinations of the nanoemulsion with 0.5% benzoyl
peroxide or 2% salicylic acid were as effective as nanoemulsion alone.
IPCI A61K0009-107 [I,A]; A61K0009-00 [I,A]; A61K0008-06 [I,A]
IPCR A61K0009-107 [I,A]; A61K0008-06 [I,A]; A61K0009-00 [I,A]
ST antibacterial nanoemulsion topical acne Propionibacterium infection
RL: NANO (Nanomaterial); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(Chile oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Alcohols
USES (Uses)
(C1-12; nanoemulsion compns. for treatment and prevention of
acne)
IT Alcohols
USES (Uses)
(C11-15-secondary, ethoxylated; nanoemulsion compns. for treatment and
prevention of acne)
USES (Uses)
(Kuki nut oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
Page 55 of 158
(Marhoram flower oil; nanoemulsion compns. for treatment and prevention
of acne)
IT Polysiloxanes
USES (Uses)
(Me Ph; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(Melaleuca; nanoemulsion compns. for treatment and prevention
of acne)
IT Bacterial infection
(Propionibacterium acnes; nanoemulsion compns. for treatment and
prevention of acne)
IT Saponins
USES (Uses)
(Quillaja bark; nanoemulsion compns. for treatment and prevention of
acne)
IT Amides
Carbohydrates
Waxes
USES (Uses)
(alkoxylated; nanoemulsion compns. for treatment and prevention of
acne)
IT Phenols
USES (Uses)
(alkyl, ethoxylated; nanoemulsion compns. for treatment and prevention
of acne)
IT Betaines
USES (Uses)
(alkyl; nanoemulsion compns. for treatment and prevention of
acne)
IT Quaternary ammonium compounds
USES (Uses)
(alkylbenzyldimethyl, chlorides; nanoemulsion compns. for treatment and
prevention of acne)
USES (Uses)
(alkylbenzyldimethyl; nanoemulsion compns. for treatment and prevention
of acne)
USES (Uses)
(alkyltrimethyl, chlorides; nanoemulsion compns. for treatment and
prevention of acne)
IT Essential oils
USES (Uses)
(allspice oil; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
Page 56 of 158
(almond; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(animal; nanoemulsion compns. for treatment and prevention of
acne)
IT Polyelectrolytes
Surfactants
(anionic; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(anise; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(apricot kernel; nanoemulsion compns. for treatment and prevention of
acne)
IT Solvents
(aprotic; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(avocado; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(basil, Ocimum basilicum; nanoemulsion compns. for treatment and
prevention of acne)
IT Essential oils
USES (Uses)
(bay leaf oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(bergamot; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(berry oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(camphor; nanoemulsion compns. for treatment and prevention of
acne)
IT Antiflatulents
(carminatives; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
Page 57 of 158
(cassia bark oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Polyelectrolytes
Surfactants
(cationic; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(cedarwood; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(celery seed; nanoemulsion compns. for treatment and prevention of
acne)
IT Polysiloxanes
USES (Uses)
(cetyl Me, di-Me, cetyl dimethicone; nanoemulsion compns. for treatment
and prevention of acne)
IT Essential oils
USES (Uses)
(chamomile; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(cinnamon; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(clary sage; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(clove; nanoemulsion compns. for treatment and prevention of
acne)
IT Monoglycerides
USES (Uses)
(coco monoglycerides; nanoemulsion compns. for treatment and prevention
of acne)
IT Amides
USES (Uses)
(coco, N-(hydroxyethyl), ethoxylated; nanoemulsion compns. for
treatment and prevention of acne)
IT Essential oils
USES (Uses)
(cumin; nanoemulsion compns. for treatment and prevention of
acne)
IT Cyclosiloxanes
USES (Uses)
(di-Me; nanoemulsion compns. for treatment and prevention of
Page 58 of 158
acne)
USES (Uses)
(dialkyldimethyl, chlorides; nanoemulsion compns. for treatment and
prevention of acne)
IT Fatty acids
USES (Uses)
(esters, Ceraphyls; nanoemulsion compns. for treatment and prevention
of acne)
IT Carboxylic acids
Fatty acids
USES (Uses)
(esters; nanoemulsion compns. for treatment and prevention of
acne)
IT Castor oil
Fatty acids
Lanolin
USES (Uses)
(ethoxylated; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(eucalyptus; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(fish; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(geranium; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(ginger; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(gourd oil; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(grape seed; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(grapefruit; nanoemulsion compns. for treatment and prevention of
acne)
Page 59 of 158
USES (Uses)
(hazelnut; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(hemp oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Castor oil
USES (Uses)
(hydrogenated, ethoxylated; nanoemulsion compns. for treatment and
prevention of acne)
IT Essential oils
USES (Uses)
(hyssop oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Controlled-release drug delivery systems
(immediate-release; nanoemulsion compns. for treatment and prevention
of acne)
IT Propionibacterium acnes
(infection; nanoemulsion compns. for treatment and prevention of
acne)
IT Surfactants
(ionic; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(jasmine; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(juniper; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(lavender; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(lemon; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(lemongrass; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(lime; nanoemulsion compns. for treatment and prevention of
acne)
Page 60 of 158
USES (Uses)
(macadamia nut; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(manuka oil; nanoemulsion compns. for treatment and prevention of
acne)
IT Triglycerides
USES (Uses)
(medium-chain; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(mustard; nanoemulsion compns. for treatment and prevention of
acne)
IT Perfumes
(myrrh; nanoemulsion compns. for treatment and prevention of
acne)
IT Acne
Bile
Buffers
Chelating agents
Human
Nonpolar solvents
Pharmaceutical nanoemulsions
Polar solvents
Preservatives
Prophylaxis
Sebaceous gland
Sebum
Stability
Surfactants
Viscosity
(nanoemulsion compns. for treatment and prevention of acne)
IT Canola oil
Coconut oil
Corn oil
Cottonseed oil
Cyclosiloxanes
Essential oils
Glycols
Hydrocarbon oils
Isoalkanes
Jojoba oil
Linseed oil
Monoterpenes
Oils
Olive oil
Palm oil
Paraffin oils
Peanut oil
Petrolatum
Phenolic resins
Phosphates
Page 61 of 158
Polyesters
Polymers
Polyoxyalkylenes
Polysiloxanes
Quaternary ammonium compounds
Rape oil
Safflower oil
Sesquiterpenes
Soybean oil
Steroids
Sulfates
Sunflower oil
Terpenes
USES (Uses)
IT Retinoids
IT Surfactants
(nonionic; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(nutmeg; nanoemulsion compns. for treatment and prevention of
acne)
IT Chenopodium
Valeriana
(oil; nanoemulsion compns. for treatment and prevention of acne
)
IT Resins
USES (Uses)
(olibanum; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(orange, sweet; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(oregano; nanoemulsion compns. for treatment and prevention of
acne)
IT Solvents
(org.; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(patchouli; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(peppermint; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
Page 62 of 158
USES (Uses)
(pine leaf; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(pine seed; nanoemulsion compns. for treatment and prevention of
acne)
IT Polyoxyalkylenes
USES (Uses)
(polyester-; nanoemulsion compns. for treatment and prevention of
acne)
IT Polyesters
USES (Uses)
(polyoxyalkylene-; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(poppyseed; nanoemulsion compns. for treatment and prevention of
acne)
IT Solvents
(protic; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(pumpkin seed; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(rice bran; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(rose; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(rosemary; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(rosewood; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(sage, Salvia officinalis; nanoemulsion compns. for treatment and
prevention of acne)
IT Carboxylic acids
Sulfonic acids
Page 63 of 158
USES (Uses)
(salts; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(sandalwood; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(sassafras; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(sesame; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(sour orange neroli; nanoemulsion compns. for treatment and prevention
of acne)
IT Essential oils
USES (Uses)
(sour orange; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(spearmint; nanoemulsion compns. for treatment and prevention of
acne)
IT Amines
USES (Uses)
(tallow alkyl, 1,3-diaminopropane derivs., ethoxylated; nanoemulsion
compns. for treatment and prevention of acne)
IT Essential oils
USES (Uses)
(tangerine peel oil; nanoemulsion compns. for treatment and prevention
of acne)
USES (Uses)
(teaseed; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(thyme, Thymus vulgaris; nanoemulsion compns. for treatment and
prevention of acne)
IT Pharmaceutical gels
(topical gels; nanoemulsion compns. for treatment and prevention of
acne)
IT Alcohols
USES (Uses)
Page 64 of 158
(trihydric; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(trimethoxysilyl; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(truffle oil; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(vegetable; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(walnut kernel oil; nanoemulsion compns. for treatment and prevention
of acne)
IT Vitamins
USES (Uses)
(water-insol.; nanoemulsion compns. for treatment and prevention of
acne)
USES (Uses)
(wheat germ; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(wintergreen; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(yarrow; nanoemulsion compns. for treatment and prevention of
acne)
IT Essential oils
USES (Uses)
(ylang-ylang; nanoemulsion compns. for treatment and prevention of
acne)
IT Surfactants
(zwitterionic; nanoemulsion compns. for treatment and prevention of
acne)
IT 60-54-8, Tetracycline 69-72-7, Salicylic acid, biological studies
114-07-8, Erythromycin 18323-44-9, Clindamycin
RL: NANO (Nanomaterial); PAC (Pharmacological activity); THU (Therapeutic
IT 50-21-5D, Lactic acid, C12-15 alkyl esters 50-70-4, Sorbitol, biological
studies 50-81-7, Ascorbic acid, biological studies 52-51-7, Bronopol
55-56-1, Chlorohexidine 56-81-5, Glycerol, biological studies
56-81-5D, Glycerol, lanolin esters 56-81-5D, Glycerin, mono- and
Page 65 of 158
diesters 57-09-0, Hexadecyltrimethylammonium bromide 57-55-6,
Propylene glycol, biological studies 57-88-5, Cholesterol, biological
studies 59-02-9, -Tocopherol 59-50-7, Chlorocresol 59-52-9,
Dimercaprol 60-00-4, Ethylenediaminetetraacetic acid, biological studies
60-29-7, Diethyl ether, biological studies 60-33-3, Linoleic acid,
biological studies 64-17-5, Ethanol, biological studies 64-18-6,
Formic acid, biological studies 64-19-7, Acetic acid, biological studies
65-85-0, Benzoic acid, biological studies 67-56-1, Methanol, biological
studies 67-63-0, Isopropyl alcohol, biological studies 67-64-1,
Acetone, biological studies 67-66-3, Chloroform, biological studies
67-68-5, Dimethyl sulfoxide, biological studies 68-12-2,
Dimethylformamide, biological studies 71-23-8, n-Propanol, biological
studies 71-36-3, n-Butanol, biological studies 71-43-2, Benzene,
biological studies 75-05-8, Acetonitrile, biological studies 75-09-2,
Dichloromethane, biological studies 76-22-2, Camphor 77-92-9, Citric
acid, biological studies 78-70-6, Linalool 81-23-2, Dehydrocholic acid
81-25-4, Cholic acid 83-44-3, Deoxycholic acid 83-46-5,
-Sitosterol 89-78-1, Menthol 89-83-8, Thymol 97-78-9,
N-Lauroylsarcosine 100-51-6, Benzyl alcohol, biological studies
102-76-1, Triacetin 106-22-9, Citronellol 106-23-0, Citronellal
106-24-1, Geraniol 106-25-2, Nerol 107-15-3, Ethylenediamine,
biological studies 108-88-3, Toluene, biological studies 108-95-2,
Phenol, biological studies 109-76-2D, 1,3-Propanediamine, N-tallow
derivs., ethoxylated 109-99-9, Tetrahydrofuran, biological studies
110-27-0, Isopropyl myristate 110-44-1, Sorbic acid 110-54-3, Hexane,
biological studies 111-02-4, Squalene 112-10-7, Isopropyl stearate
112-80-1, Oleic acid, biological studies 118-60-5 121-54-0 122-18-9,
Benzyldimethylhexadecylammonium chloride 122-62-3, Dioctyl sebacate
122-99-6, Phenoxyethanol 123-03-5, Cetylpyridinium chloride 123-46-6
123-91-1, 1,4-Dioxane, biological studies 123-95-5, Butyl stearate
124-03-8, Ethylhexadecyldimethylammonium bromide 126-73-8, Tri-n-butyl
phosphate, biological studies 126-92-1, Sodium octyl sulfate 128-13-2,
Ursodeoxycholic acid 128-37-0, Butylated hydroxytoluene, biological
studies 134-03-2, Sodium ascorbate 134-09-8, Menthyl anthranilate
136-44-7, Glyceryl PABA 137-16-6, N-Lauroylsarcosine sodium salt
137-66-6, Ascorbyl palmitate 138-86-3, Limonene 139-07-1, Dodecyl
dimethyl benzylammonium chloride 139-08-2,
Benzyldimethyltetradecylammonium chloride 139-88-8, Niaproof 4
141-78-6, Ethyl acetate, biological studies 142-50-7, Nerolidol
142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 143-62-4,
Digitoxigenin 145-42-6, Sodium taurocholate 151-21-3, Sodium lauryl
sulfate, biological studies 275-51-4, Azulene 302-95-4, Sodium
deoxycholate 360-65-6, Glycodeoxycholic acid 361-09-1, Sodium cholate
474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic acid 489-84-9,
Guaiazulene 502-61-4, Farnesene 512-85-6, Ascaridole 515-69-5,
Bisabolol 529-05-5, Chamazulene 536-59-4, Perillyl alcohol 540-10-3,
Cetyl palmitate 540-84-1, Isooctane 541-02-6,
Decamethylcyclopentasiloxane 541-05-9, Hexamethylcyclotrisiloxane
542-44-9, Glyceryl palmitate 546-80-5, Thujone 553-08-2, Thonzonium
bromide 556-67-2, Octamethylcyclotetrasiloxane 577-11-7, Triton GR-5M
638-11-9, Isopropyl n-butyrate 863-57-0, Glycocholic acid sodium salt
1118-68-9D, alkyl derivs. 1119-94-4, Dodecyltrimethylammonium bromide
1119-97-7, Trimethyl(tetradecyl)ammonium bromide 1323-03-1, Myristyl
lactate 1323-38-2, Glyceryl ricinoleate 1323-83-7, Glyceryl distearate
1330-85-4 1338-10-9 1338-39-2, Sorbitan monolaurate 1338-41-6,
Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1643-20-5,
N,N-Dimethyldodecylamine N-oxide 2044-56-6, Lithium dodecyl sulfate
2281-11-0 2311-46-8, Isopropyl n-hexanoate 2311-59-3, Isopropyl
n-decanoate 2386-53-0, Sodium 1-dodecanesulfonate 2386-54-1, Sodium
1-butanesulfonate 2420-29-3, Hexaethylene glycol monooctadecyl ether
Page 66 of 158
2646-38-0, Chenodeoxycholic acid sodium salt 2832-45-3, Sodium
hexanesulfonate 3033-62-3D, alkyl derivs., chlorides 3055-94-5,
Triethylene glycol monododecyl ether 3055-95-6, Pentaethylene glycol
monododecyl ether 3055-96-7, Hexaethylene glycol monododecyl ether
3055-97-8, Heptaethylene glycol monododecyl ether 3055-98-9,
Octaethylene glycol monododecyl ether 3055-99-0, Nonaethylene glycol
monododecyl ether 3245-38-3, Deoxycholic acid methyl ester 3687-46-5,
Decyl oleate 3700-67-2, Dimethyldioctadecylammonium bromide 4263-52-9,
Sodium 2-bromoethanesulfonate 4292-10-8 4478-97-1, Pentaethylene
glycol monohexadecyl ether 4484-59-7, Triethylene glycol monohexadecyl
ether 4602-84-0, Farnesol 4669-23-2, Triethylene glycol monodecyl
ether 4719-04-4 5157-04-0, Hexaethylene glycol monotetradecyl ether
5168-91-2, Hexaethylene glycol monohexadecyl ether 5274-68-0,
Tetraethylene glycol monododecyl ether 5324-84-5, 1-Octanesulfonic acid
sodium salt 5392-40-5, Citral 5538-94-3, Dioctyl dimethylammonium
chloride 5698-39-5, Octaethylene glycol monohexadecyl ether 5703-94-6,
Tetraethylene glycol monodecyl ether 6009-98-9, Taurochenodeoxycholic
acid sodium salt 6283-92-7, Lauryl lactate 6938-94-9, Diisopropyl
adipate 7173-51-5, 1-Decanaminium-N-decyl-N,N-dimethyl chloride
7281-04-1, Benzyldodecyldimethylammonium bromide 7664-38-2D, Phosphoric
acid, di- and trialkyl esters 7681-57-4, Sodium metabisulfite
8050-81-5, Simethicone 9002-92-0, Polyoxyethylene lauryl ether
9002-93-1, Triton X-100 9003-11-6D, Ethylene oxide-propylene oxide
copolymer, tetra-functional copolymers 9003-27-4, Polyisobutene
9003-35-4D, Phenol-formaldehyde copolymer, alkyl derivs., alkoxylated
9004-64-2, Klucel 9004-81-3, Polyoxyethylene laurate 9004-95-9, Brij
56 9004-98-2, Brij 92V 9004-99-3, Polyoxyethylene stearate
9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene
dilaurate 9005-08-7, Polyoxyethylene distearate 9005-64-5 9005-65-6
9005-66-7 9005-67-8 9005-70-3, TWEEN 85 9005-71-4, TWEEN 65
9006-65-9, Dimethicone 9011-14-7D, Poly(methyl methacrylate), graft
copolymers, PEO side chains-contg. 9014-93-1, Triton X-207 9016-45-9,
Ethoxylated nonylphenol 9036-19-5, Igepal CA-630 10361-16-7
11024-24-1, Digitonin 11099-07-3, Glyceryl stearate 11105-10-5, Triton
QS 15 11139-88-1, Glyceryl caprate 11140-02-6 11140-04-8, Glyceryl
caprylate 12298-68-9, Lugol's solution 12441-09-7D, Sorbitan, esters,
ethoxylated 13149-87-6 13177-41-8 13419-61-9, Sodium
1-decanesulfonate 14533-63-2, Sodium 1-propanesulfonate 14912-44-8,
Ylangene 14933-08-5 14933-09-6 14974-53-9, Glyceryl thioglycolate
15163-36-7 15178-76-4 16409-34-0, Glycodeoxycholic acid sodium salt
16564-43-5, Glycochenodeoxycholic acid sodium salt 16958-85-3, Octyl
palmitate 18449-82-6, Tetradecyl--D-maltoside 19327-38-9,
Triethylene glycol monooctyl ether 19327-40-3, Pentaethylene glycol
monooctyl ether 22767-49-3, Sodium pentanesulfonate 22767-50-6, Sodium
1-heptanesulfonate 23244-49-7, Pentaethylene glycol monodecyl ether
24233-81-6, Octaethylene glycol monodecyl ether 24634-61-5, Potassium
sorbate 24938-91-8, Polyoxyethylene tridecyl ether 25013-16-5,
Butylated hydroxyanisole 25155-18-4 25265-75-2, Butylene glycol
25301-02-4, Tyloxapol 25322-68-3D, fatty ethers 25496-72-4, Glyceryl
oleate 25637-84-7, Glyceryl dioleate 26027-38-3, Nonoxynol-14
26266-57-9, Sorbitan monopalmitate 26266-58-0, Span 85 26403-72-5,
Polyethylene glycol diglycidyl ether 26658-19-5, Span 65 26826-30-2,
Triethylene glycol monotetradecyl ether 27306-76-9, Polyoxyethylene
cetylstearyl ether
USES (Uses)
IT 27306-79-2, Polyoxyethylene myristyl ether 27321-96-6, Polyoxyethylene
cholesteryl ether 27458-93-1, Isostearyl alcohol 27479-28-3,
Quaternium 14 27638-00-2, Glyceryl dilaurate 27668-52-6 27841-06-1D,
Page 67 of 158
Neopentyl glycol dicaprate, cetol derivs. 27847-86-5, Octaethylene
glycol monotetradecyl ether 28063-42-5, Glyceryl monoerucate
28854-76-4D, Aminopropionic acid*, N-alkyl derivs. 29710-31-4, Cetyl
octanoate 29781-81-5, n-Decyl -D-glucopyranoside 29836-26-8,
Octyl--D-glucopyranoside 31692-79-2, Dimethiconol 31807-55-3,
Isododecane 32426-11-2, Octyl decyl dimethylammonium chloride
34398-01-1 35192-74-6, Sodium 1-nonanesulfonate 35274-05-6, Cetyl
lactate 35807-85-3, Tauroursodeoxycholic acid sodium salt 37211-53-3,
Triton CF 21 37211-54-4, Triton CF 32 37220-82-9, Glyceryl oleate
37281-47-3, Triton DF 12 37318-95-9, Glyceryl laurate 37336-15-5,
Resin Oil 37348-65-5, Glyceryl linoleate 38411-85-7, Sodium
taurohyodeoxycholate 39034-24-7, Tetraethylene glycol monotetradecyl
ether 39236-46-9, Imidazolidinyl urea 39840-09-0, Heptaethylene glycol
monodecyl ether 40036-79-1, Heptaethylene glycol monotetradecyl ether
42233-08-9, Tridecyl behenate 42557-10-8 50996-85-5 51668-30-5
52623-95-7, Triton QS-44 52845-07-5, Isoeicosane 53563-63-6, Glyceryl
dimyristate 55348-40-8, Triton X-200 58229-81-5, Triton DF 16
58958-60-4, Isostearyl neopentanoate 59979-06-5, Triton X 151
60828-78-6, Tergitol TMN 10 60908-77-2, Isohexadecane 61332-02-3,
Glyceryl isostearate 64114-57-4 64936-82-9 64936-83-0 68207-00-1,
Dodecylethyldimethylammonium bromide 69227-93-6, n-Dodecyl
-D-maltoside 69364-63-2, Polyoxyethylene isohexadecyl ether
70005-86-6, Undecyl -D-glucopyranoside 71093-13-5, Pentaethylene
glycol monooctadecyl ether 71611-21-7, W 1 (detergent) 72006-34-9,
Polyhydroxystearic acid 72175-39-4 75621-03-3, CHAPS 82473-24-3,
CHAPSO 82494-09-5, Decyl -D-maltopyranoside 83826-43-1,
Octyldodecyl myristate 85261-20-7, N-Decanoyl-N-methylglucamine
86674-95-5, Pentaethylene glycol monohexyl ether 90052-75-8
91490-94-7, Diisodecyl dimethylammonium chloride 94271-01-9 97338-28-8
98060-40-3 98064-96-1, n-Hexadecyl -D-maltoside 100929-89-3,
Glycolithocholic acid ethyl ester 104365-63-1, Glyceryl hydroxystearate
106392-12-5, Ethylene oxide-propylene oxide block copolymer 108084-06-6,
Octylphenoxyethoxyethyl dimethyl benzylammonium chloride 110026-03-4,
Taurodeoxycholic acid sodium salt monohydrate 114355-44-1, Poloxamer 182
Dibenzoate 115457-83-5, Methyl-6-O-(N-heptylcarbamoyl)--D-
glucopyranoside 116183-64-3, n-Dodecyl -D-maltoside
121309-88-4, Benzyltrimethylammonium tetrachloroiodate 134216-08-3,
n-Dodecanoyl-N-methylglucamide 141265-32-9, N-Nonanoyl-N-methylglucamine
144975-21-3, Isotetracosane 153190-98-8, Poloxamer 105 Benzoate
195868-36-1, Phenyltrimethicone 283158-20-3 618113-48-7 691397-13-4,
Poloxamer 188 697765-47-2, Ethylene oxide-propylene oxide diblock
copolymer 1191416-21-3, Lauryl trimethicone 1192493-28-9
USES (Uses)
IT 99-96-7D, 4-Hydroxybenzoic acid, esters
USES (Uses)
(parabens; nanoemulsion compns. for treatment and prevention of
acne)
Page 68 of 158
TITLE: Nanoemulsions comprising drugs such as botulinum toxin
for dermal delivery for treating skin diseases
INVENTOR(S): Edelson, Jonathan; Kotyla, Timothy; Zhang, Boke
PATENT ASSIGNEE(S): Anterios, Inc., USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- --------
-------------------- --------
WO 2009158687 A1 20091230
WO 2009-US48972 20090626
AU 2009261995 A1 20091230
AU 2009-261995 20090626
CA 2726836 A1 20091230
CA 2009-2726836 20090626
KR 2011033243 A 20110330
KR 2011-7001737 20090626
EP 2310000 A1 20110420
EP 2009-771218 20090626
CN 102076333 A 20110525
CN 2009-80124419 20090626
JP 2011526302 T 20111006
JP 2011-516743 20090626
IL 209697 A 20121231
IL 2009-209697 20090626
MX 2010013562 A 20110215
MX 2010-13562 20101209
IN 2011CN00566 A 20111125
IN 2011-CN566 20110127
US 20110212157 A1 20110901
US 2011-509 20110506
WO 2009-US48972 W 20090626
AB The present invention describes systems and methods for treating disorders
and/or conditions assocd. with the dermal level of the skin. Such disorders
include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss,
dermal infection, and/or actinic keratosis. Methods generally involve
administering nanoemulsions (e.g., nanoparticle compns.) comprising at least one
therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions
are prepd., e.g., by high pressure microfluidization, and comprise a particle
size distribution exclusively between 10 nm and 300 nm.
IPCI A61K0009-51 [I,A]; A61K0031-48 [I,A]
IPCR A61K0009-51 [I,A]; A61K0031-48 [I,A]
ST botulinum toxin nanoemulsion nanoparticle skin acne hyperhidrosis
rosacea infection
IT Essential oils
(Melaleuca; nanoemulsions comprising drugs such as botulinum
toxin for dermal delivery for treating skin diseases)
IT Abrasives
Acne
Adsorption
Aloe barbadensis
Alopecia
Antiandrogens
Antibiotics
Antiperspirants
Antiviral agents
Carica papaya
Cavitation
Clostridium botulinum
Cosmetic sticks
Cucurbita
Detergents
Eczema
Page 69 of 158
Human
Hyperhidrosis
Lupus erythematosus
Nanoencapsulation
Oral drug delivery systems
Papaya
Permeation enhancers
Personal deodorants
Pharmaceutical aerosols
Pharmaceutical creams
Pharmaceutical gels
Pharmaceutical injections
Pharmaceutical nanoemulsions
Pharmaceutical nanoparticles
Pharmaceutical patches
Pharmaceutical powders
Pharmaceutical sprays
Polygonum multiflorum
Psoriasis
Raynaud disease
Rosacea
Serenoa repens
Shampoos
Silybum marianum
Skin, neoplasm
Skin emollients
Skin infection
Stability
Surfactants
Urtica
(nanoemulsions comprising drugs such as botulinum toxin for dermal
delivery for treating skin diseases)
IT 51-21-8, 5-Fluorouracil 52-01-7, Spironolactone 53-06-5, Cortisone
57-10-3, Palmitic acid, biological studies 57-88-5D, Cholesterol, esters
58-08-2, Caffeine, biological studies 59-05-2, Methotrexate 60-54-8,
Tetracycline 63-89-8, Dipalmitoylphosphatidylcholine 66-97-7, Psoralen
67-71-0, Methylsulfonylmethane 67-97-0D, Vitamin D3, analogs 68-26-8,
Retinol 69-72-7, Salicylic acid, biological studies 76-03-9,
Trichloroacetic acid, biological studies 83-44-3, Deoxycholic acid
98-92-0, Nicotinamide 110-27-0, Isopropyl myristate 110-40-7, Diethyl
sebacate 112-80-1, Oleic acid, biological studies 114-07-8,
Erythromycin 123-95-5, Butyl stearate 123-99-9, Azelaic acid,
biological studies 124-22-1, Dodecylamine 124-30-1, Stearylamine
127-07-1, Hydroxyurea 143-27-1, Hexadecylamine 143-28-2, Oleyl alcohol
144-80-9, Sulfacetamide 154-42-7, Thioguanine 302-79-4, Tretinoin
382-67-2, Desoximetasone 443-48-1, Metronidazole 446-86-6,
Azathioprine 475-31-0, Glycocholic acid 506-26-3, -Linolenic
acid 538-23-8, Caprylic triglyceride 564-25-0, Doxycycline 599-79-1,
Sulfasalazine 621-71-6, Capric triglyceride 1143-38-0, Dithranol
1190-63-2, Hexadecyl stearate 1323-38-2, Glyceryl ricinoleate
1327-41-9, Aluminum chlorohydrate 1338-39-2, Span 20 1403-66-3,
Gentamicin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7,
Polymyxin 2197-63-9, Dicetyl phosphate 3116-76-5, Dicloxacillin
Page 70 of 158
3380-34-5, Triclosan 4004-05-1, DOPE 4235-95-4, DOPC 4759-48-2,
Isotretinoin 6990-06-3, Fusidic acid 7429-90-5D, Aluminum, -zirconium
compds. 7440-66-6, Zinc, biological studies 7440-67-7D, Zirconium,
-aluminum compds. 7446-70-0, Aluminum chloride, biological studies
7704-34-9, Sulfur, biological studies 7784-25-0, Ammonium alum
9002-92-0 9004-99-3, Polyoxyethylene monostearate 9005-64-5,
Polysorbate 20 9005-65-6, Polysorbate 80 9005-67-8, Polysorbate 60
9005-70-3, Polysorbate 85 9005-71-4, Polysorbate 65 9006-65-9,
Dimethicone 10118-90-8, Minocycline 12441-09-7D, Sorbitan, fatty acid
esters 12619-70-4, Cyclodextrin 12650-69-0, Mupirocin 15307-86-5,
Diclofenac 15686-71-2, Cephalexin 18323-44-9, Clindamycin
18472-51-0, Chlorhexidine gluconate 23593-75-1, Clotrimazole
25301-02-4, Tyloxapol 25322-68-3, Polyethylene glycol 26266-58-0, Span
85 27220-47-9, Econazole 34513-50-3, Octyldodecanol 36653-82-4,
Hexadecanol 38304-91-5, Minoxidil 52645-53-1, Permethrin 56093-45-9,
Selenium sulfide 59277-89-3, Acyclovir 59865-13-3, Cyclosporine
65277-42-1, Ketoconazole 65666-07-1, Silymarin 84625-61-6,
Itraconazole 86386-73-4, Fluconazole 91161-71-6, Terbinafine
93384-43-1, Botulinum toxin type A 93384-44-2, Botulin B 93384-46-4,
Botulin D 93384-47-5, Botulin E 98319-26-7, Finasteride 99011-02-6,
Imiquimod 104162-48-3, DOTMA 104227-87-4, Famciclovir 104987-11-3,
Tacrolimus 106392-12-5, Poloxamer 106685-40-9, Adapalene
107231-12-9, Botulinum toxin 107231-13-0, Botulin C1 107231-14-1,
Botulin C2 107231-15-2, Botulin F 107231-16-3, Botulin G
112965-21-6, Calcipotriol 118292-40-3, Tazarotene 124832-26-4,
Valacyclovir 128794-94-5, Mycophenolate mofetil 134375-99-8, Aluminum
Zirconium Trichlorohydrex Gly 134910-86-4, Aluminum Zirconium
Tetrachlorohydrex Gly 137071-32-0, Pimecrolimus 164656-23-9,
Dutasteride 170277-31-3, Infliximab 174722-31-7, Rituximab
185243-69-0, Etanercept 185463-23-4, DPPG 214745-43-4, Efalizumab
222535-22-0, Alefacept 252023-70-4, Surfactin 331731-18-1, Adalimumab
815610-63-0, Ustekinumab
(nanoemulsions comprising drugs such as botulinum toxin for dermal
delivery for treating skin diseases)
Page 71 of 158
TITLE: Anti-acne sunscreen composition containing
avobenzone and oxybenzoneoxybenzone, octisalate, or
octyl methoxycinnamate
INVENTOR(S): Kunin, Audrey
PATENT ASSIGNEE(S): Dermadoctor, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20090246156 A1 20091001 US 2008-59761 20080331
PRIORITY APPLN. INFO.: US 2008-59761 20080331
AB The present invention is directed to compns. for anti-acne sunscreen. The
sunscreen compn. has the unique ability to treat and prevent acne in addn. to
screen both UVA and UVB radiation. In particular, the sunscreen compn. includes
a sunscreen base, at least one UVA deactivator, at least one UVB deactivator,
and at least one anti-acne agent. The UVA deactivator may be avobenzone and the
UVB deactivator may be selected from one of the following oxybenzone,
octisalate, octyl methoxycinnamate, or a mixt. thereof. No formulation example
is presented.
INCL 424060000; 424059000
IPCI A61K0008-33 [I,A]; A61K0008-30 [I,A]; A61Q0017-04 [I,A]
IPCR A61K0008-33 [I,A]; A61K0008-30 [I,A]; A61Q0017-04 [I,A]
NCL 424/060.000; 424/059.000
ST anti acne sunscreen avobenzone oxybenzoneoxybenzone octisalate octyl
methoxycinnamate
IT Essential oils
(Melaleuca alternifolia; anti-acne sunscreen compn.
contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl
methoxycinnamate)
(almond, ethoxylated; anti-acne sunscreen compn. contg.
avobenzone and oxybenzoneoxybenzone, octisalate, or octyl
methoxycinnamate)
IT Achillea
Anacyclus pyrethrum
Arnica montana
Boswellia serrata
Cosmetic creams
Cosmetic gels
Cosmetic liquids
Cosmetic lotions
Cosmetic ointments
Cosmetic packs
Cucumber
Cucumis sativus
Cyclooxygenase 2 inhibitors
Evodia rutaecarpa
Filipendula
Filipendula ulmaria
Hamamelis virginiana
Page 72 of 158
Human
Rumex crispus
Salix alba
Shampoos
Skin cleansers
Sunscreens
Witch hazel
(anti-acne sunscreen compn. contg. avobenzone and
oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate)
IT Soaps
IT Cyclosiloxanes
(di-Me; anti-acne sunscreen compn. contg. avobenzone and
IT Essential oils
(eucalyptus; anti-acne sunscreen compn. contg. avobenzone and
IT Natural products, pharmaceutical
(licorice; anti-acne sunscreen compn. contg. avobenzone and
IT Cosmetics and Personal care products
(patches, strips, serums, scrubs; anti-acne sunscreen compn.
contg. avobenzone and oxybenzoneoxybenzone, octisalate, or octyl
methoxycinnamate)
IT Glycyrrhiza glabra
(root ext.; anti-acne sunscreen compn. contg. avobenzone and
IT Acne
(treating agent; anti-acne sunscreen compn. contg. avobenzone
and oxybenzoneoxybenzone, octisalate, or octyl methoxycinnamate)
IT Proteins
(-binding; anti-acne sunscreen compn. contg.
avobenzone and oxybenzoneoxybenzone, octisalate, or octyl
methoxycinnamate)
IT 52-01-7, Spironolactone 56-81-5, Glycerine, biological studies
57-55-6, Propylene glycol, biological studies 58-95-7, Tocopheryl
acetate 79-10-7D, Acrylic acid, esters, polymers 94-13-3,
Propylparaben 94-26-8, Butylparaben 99-76-3, Methylparaben 120-47-8,
Ethylparaben 122-99-6, Phenoxyethanol 139-33-3, Disodium EDTA
427-51-0, Cyproterone acetate 500-38-9, Nordihydroguaiaretic acid
508-02-1, Oleanolic acid 1117-86-8, Caprylyl glycol 5451-09-2,
Aminolevulinic acid hydrochloride 9067-32-7, Sodium hyaluronate
13311-84-7, Flutamide 25265-75-2, Butylene glycol 25777-71-3
37318-79-9, Sorbitan oleate 98319-26-7, Finasteride 170277-31-3,
Infliximab 185243-69-0, Etanercept 190085-41-7, Butyloctyl salicylate
331731-18-1, Adalimumab
IT 67392-87-4, Drospirenone
RL: BSU (Biological study, unclassified); COS (Cosmetic use); BIOL
IT 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-78-2, Acetylsalicylic
Page 73 of 158
acid 53-03-2, Prednisone 53-06-5, Cortisone 57-13-6, Urea,
biological studies 57-63-6, Ethinyl estradiol 59-05-2, Methotrexate
60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline
64-19-7, Acetic acid, biological studies 69-72-7, Salicylic acid,
biological studies 79-14-1, Glycolic acid, biological studies 80-08-0,
Atrisone 94-36-0, Benzoyl peroxide,
biological studies 103-90-2, Acetaminophen 108-46-3, Resorcinol,
biological studies 114-07-8, Erythromycin 117-39-5, Quercetin
123-99-9, Azelaic acid, biological studies 144-80-9, Sulfacetamide
302-79-4, Tretinoin 443-48-1, Metronidazole 446-86-6, Azathioprine
564-25-0, Doxycycline 738-70-5, Trimethoprim 992-21-2, Lymecycline
1314-13-2, Zinc oxide, biological studies 2375-03-3, Solumedrol
4759-48-2, Isotretinoin 7704-34-9, Sulfur, biological studies
7733-02-0, Zinc sulfate 10043-01-3, Alum 10118-90-8, Minocycline
13463-41-7, Pyrithione zinc 18323-44-9, Clindamycin 22916-47-8,
Miconazole 35891-70-4, Myriocin 53123-88-9, Sirolimus 59865-13-3,
Cyclosporine 65277-42-1, Ketoconazole 83905-01-5, Azithromycin
99011-02-6, Imiquimod 104987-11-3, Tacrolimus 106685-40-9, Adapalene
162359-55-9, Fingolimod
IT 118-60-5, Octisalate 131-57-7, Oxybenzone 5466-77-3, Octyl
methoxycinnamate 70356-09-1, Avobenzone
USES (Uses)
IT 521-18-6, 5-Dihydrotestosterone
(inhibitors; anti-acne sunscreen compn. contg. avobenzone and
IT 329900-75-6
(inhibitors; anti-acne sunscreen compn. contg. avobenzone and
Page 74 of 158
TITLE: Peptide-based antiacne reagents
INVENTOR(S): O'Brien, John P.; Wang, Hong; Wilkins, Antoinette E.
PATENT ASSIGNEE(S): E. I. du Pont de Nemours and Company, USA
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20090143295 A1 20090604 US 2008-273778 20081119
AB Peptide-based antiacne reagents, formed by coupling a skin-binding peptide with
an antiacne agent, are described. The skin-binding peptide portion of the
peptide-based antiacne reagent binds strongly to the skin, thus keeping the
antiacne agent coupled to the skin for a long lasting effect. Skin care compns.
comprising the peptide-based antiacne reagents are also provided as well as a
method of treating or preventing skin acne.
INCL 514012000; 514773000; 514162000; 514718000; 514002000; 514013000;
514014000; 514015000
[I,A]; A61K0038-10 [I,A]; A61K0038-08 [I,A]; A61P0017-10 [I,A]
[I,A]; A61K0038-08 [I,A]; A61K0038-10 [I,A]; A61P0017-10 [I,A]
NCL 514/001.100; 514/162.000; 514/718.000; 514/773.000
CC 1-12 (Pharmacology)
ST antiacne skin binding peptide antimicrobial acne
IT Essential oils
(Melaleuca alternifolia; peptide-based antiacne
reagents)
IT DNA
(assocd. peptide-skin complexes; peptide-based antiacne
reagents)
IT Proteins
(attacins; peptide-based antiacne reagents)
IT Eubacteria
Ribosome
Yeast
(display; peptide-based antiacne reagents)
IT mRNA
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(display; peptide-based antiacne reagents)
IT Keratins
(keratolytics; peptide-based antiacne reagents)
IT Peptides
(lantibiotic; peptide-based antiacne reagents)
IT Acne
Antibiotics
Page 75 of 158
Antimicrobial peptides
Combinatorial library
Human
Latex
Peptide library
Phage display
Pharmaceutical capsules
Protein sequences
(peptide-based antiacne reagents)
IT Polymers
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
IT Antimicrobial peptides
IT Bile salts
IT Retinoids
IT Sebaceous gland
(sebocyte, sebostats; peptide-based antiacne reagents)
IT Amino acids
Amino acids
(sulfur-contg.; peptide-based antiacne reagents)
IT Amino acids
(D-, sulfur-contg.; peptide-based antiacne reagents)
IT 108433-95-0, Magainin II 115966-68-2 121798-56-9 142547-17-9
150398-24-6 155709-76-5 162096-67-5 207452-60-6 223762-50-3
230974-91-1 230974-92-2 313227-98-4 370102-12-8 466691-12-3
466691-39-4 470663-44-6 478181-94-1 506412-23-3 643745-56-6
684212-63-3 700814-11-5 700814-15-9 700814-18-2 700814-23-9
700814-26-2 700814-28-4 700814-30-8 700814-32-0 700814-35-3
700814-38-6 700814-41-1 700814-44-4 700814-47-7 700814-50-2
700814-52-4 700814-55-7 700814-57-9 700814-60-4 700814-65-9
700814-71-7 700814-76-2 846056-18-6 846056-19-7 846056-20-0
846056-21-1 846056-22-2 846056-23-3 847143-38-8 847143-41-3
847774-72-5 908606-19-9 908606-20-2 908606-21-3 908606-23-5
908606-24-6 908606-25-7 908606-26-8 908606-27-9 908606-28-0
908606-29-1 908606-30-4 908606-31-5 908606-32-6 911288-83-0
911288-84-1 911288-85-2 911288-86-3 911288-87-4 932013-55-3
932013-57-5 932013-58-6 932013-61-1 932013-62-2 932013-63-3
932013-64-4 932013-65-5 936251-53-5 936251-54-6 936251-55-7
936251-56-8 940910-74-7 1159631-98-7 1159631-99-8 1159632-00-4
1160082-33-6
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
(amino acid sequence; peptide-based antiacne reagents)
Page 76 of 158
IT 9003-53-6, Polystyrene 9003-55-8, Styrene-Butadiene copolymer
9011-14-7, Polymethylmethacrylate 9017-21-4, Polyvinyltoluene
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
IT 52-90-4, Cysteine, occurrence 56-84-8, Aspartic acid, occurrence
56-87-1, Lysine, occurrence 107-21-1, Ethylene glycol, occurrence
141-43-5, Ethanol amine, occurrence 147-85-3, Proline, occurrence
9002-88-4, Polyethylene
RL: OCU (Occurrence, unclassified); OCCU (Occurrence)
IT 60-54-8, Tetracycline 94-36-0, Benzoyl
peroxide, biological studies 98-92-0, Nicotinamide 101-20-2,
3,4,4'-Trichlorocarbanilide 114-07-8, Erythromycin 122-99-6,
Phenoxyethanol 123-99-9, Azelaic acid, biological studies 141-78-6,
Ethyl acetate, biological studies 302-79-4, Tretinoin 770-35-4,
Phenoxyisopropanol 1200-22-2, Lipoic acid 2013-58-3, Meclocycline
3380-34-5, 2,4,4'-Trichloro-2'-hydroxy diphenyl ether 18323-44-9,
Clindamycin 18472-51-0, Chlorhexidine gluconate 37231-28-0, Melittin
41593-38-8, Phenoxypropanol 68890-66-4, Octopirox 80802-79-5, Cecropin
97762-98-6, Brevinin 103220-14-0, Defensin 106685-40-9, Adapalene
113041-69-3, Magainin 118292-40-3, Tazarotene 123781-17-9, Histatin
162011-90-7, Rofecoxib 384340-80-1, Novispirin G10
Page 77 of 158
TITLE: Anti-infection augmentation foamable compositions and
kit and uses thereof
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir
SOURCE: U.S. Pat. Appl. Publ., 43pp., Cont.-in-part of U.S.
Ser. No. 448,490.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20070292355 A1 20071220 US 2007-732547 20070404
WO 2004037225 A2 20040506 WO 2003-IB5527 20031024
WO 2004037225 A3 20041229
US 7820145 B2 20101026 US 2004-835505 20040428
US 20050031547 A1 20050210
US 20050069566 A1 20050331 US 2004-911367 20040804
CA 2776692 A1 20050303 CA 2004-2776692 20040820
US 7700076 B2 20100420 US 2004-922358 20040820
US 20050074414 A1 20050407
US 20100040561 A9 20100218
EP 2422768 A2 20120229 EP 2011-190124 20040820
EP 2422768 A3 20120509
AU 2004313285 A1 20050929 AU 2004-313285 20041216
ZA 2005007018 A 20080227 ZA 2005-7018 20041216
US 20050186142 A1 20050825 US 2005-41921 20050124
ZA 2005003298 A 20060830 ZA 2005-3298 20050425
US 20060140984 A1 20060629 US 2005-532618 20051222
AU 2006201878 A1 20070927 AU 2006-201878 20060504
US 20060269485 A1 20061130 US 2006-448490 20060607
AU 2006339311 A2 20070907 AU 2006-339311 20060607
AU 2006339311 A1 20070907
CA 2611577 A1 20070907 CA 2006-2611577 20060607
WO 2007099396 A2 20070907 WO 2006-IB3975 20060607
WO 2007099396 A3 20080313
EP 1919449 A2 20080514 EP 2006-847249 20060607
AU 2007355106 A1 20081218 AU 2007-355106 20071129
WO 2008152444 A2 20081218 WO 2007-IB4628 20071129
WO 2008152444 A3 20090618
EP 2097065 A2 20090909 EP 2007-874548 20071129
IL 198688 A 20121031 IL 2007-198688 20071129
IN 2007KN04925 A 20080704 IN 2007-KN4925 20071218
PRIORITY APPLN. INFO.: IL 2002-152486 A 20021025
US 2002-429546P P 20021129
US 2003-492385P P 20030804
US 2003-497648P P 20030825
WO 2003-IB5527 W 20031024
US 2003-530015P P 20031216
US 2004-835505 A2 20040428
US 2004-911367 A2 20040804
US 2004-922358 A2 20040820
US 2005-41921 A2 20050124
US 2005-688244P P 20050607
US 2005-532618 A2 20051222
US 2006-789186P P 20060404
US 2006-448490 A2 20060607
US 2006-861620P P 20061129
Page 78 of 158
US 2007-880434P P 20070112
CA 2004-2536482 A3 20040820
EP 2004-769356 A3 20040820
WO 2006-IB3975 W 20060607
WO 2007-IB4628 W 20071129
AB This invention relates to anti-infective foamable compn. and kits include a
foamable carrier; a therapeutically safe and effective concn. of an anti-
infective agent; an augmenting agent selected from the group consisting of a
keratolytic agent and a skin penetration enhancer; and a propellant. The compn.
is housed in a container and upon release is expandable to form a breakable
foam. The foamable carrier is selected to generate a foam of good or excellent
quality in the presence of the augmenting agent and anti-infective agent.
Methods for treating, alleviating or preventing a disorder of the skin, a body
cavity or mucosal surface, wherein the disorder involves a fungal, bacterial, or
viral infection as one of its etiol. factors, is described. Thus, foamable
compn. was prepd. contg. PEG 400 91.65%, hydroxypropyl cellulose 0.475, steareth
2 1.88%, salicylic acid 5.0%, and ciclopiroxolamine 1.0%.
INCL 424043000; 424725000; 514002000; 514220000; 514253090; 514263370;
514263400; 514027000; 514274000; 514307000
[I,A]; A61K0031-425 [I,A]; A61K0031-433 [I,A]; A61K0031-44 [I,A];
A61K0031-497 [I,A]; A61P0011-00 [I,A]; A61P0035-00 [I,A]; A61P0031-18
[I,A]; A61P0031-12 [I,A]; A61P0031-10 [I,A]; A61P0027-16 [I,A];
A61P0017-00 [I,A]; A61K0031-505 [I,A]; A61K0031-52 [I,A]; A61K0031-522
[I,A]; A61K0031-551 [I,A]; A61K0031-70 [I,A]; A61K0036-00 [I,A];
A61K0038-00 [I,A]
[I,A]; A61K0031-425 [I,A]; A61K0031-433 [I,A]; A61K0031-44 [I,A];
A61K0031-497 [I,A]; A61K0031-505 [I,A]; A61K0031-52 [I,A]; A61K0031-522
[I,A]; A61K0031-551 [I,A]; A61K0031-70 [I,A]; A61K0036-00 [I,A];
A61K0038-00 [I,A]; A61P0011-00 [I,A]; A61P0017-00 [I,A]; A61P0027-16
[I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0031-18 [I,A];
A61P0035-00 [I,A]
NCL 424/043.000; 424/725.000; 514/003.500; 514/003.700; 514/007.400;
514/009.400; 514/018.800; 514/027.000; 514/220.000; 514/253.090;
514/263.370; 514/263.400; 514/274.000; 514/307.000; 514/361.000;
514/365.000; 514/396.000; 514/406.000; 514/766.000
IT Essential oils
(Melaleuca; anti-infection augmentation foamable compns. and
kit and uses thereof)
(anti-acne agents; anti-infection augmentation foamable
compns. and kit and uses thereof)
IT Acne
(vulgaris; anti-infection augmentation foamable compns. and kit and
uses thereof)
IT 50-21-5, Lactic acid, biological studies 50-70-4D, Sorbitol, ester
50-81-7, Ascorbic acid, biological studies 50-81-7D, Vitamin C, deriv.
51-17-2, Benzimidazole 56-03-1, Biguanide 56-81-5, Glycerol,
biological studies 57-10-3, Hexadecanoic acid, biological studies
57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological
studies 57-50-1D, Sucrose, ester 57-55-6, Propylene glycol, biological
studies 58-95-7, Tocopheryl acetate 61-57-4, Niridazole 63-74-1,
Sulfonamide 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2,
Dimethylformamide, biological studies 68-26-8, Retinol 68-26-8D,
Retinol, ascorbic acid derivs. 69-72-7, Salicylic acid, biological
studies 76-30-2, Dihydroxytartaric acid 76-93-7, biological studies
77-92-9, Citric acid, biological studies 77-95-2, Quinic acid 79-09-4,
Page 79 of 158
Methylacetic acid, biological studies 79-14-1, Glycolic acid, biological
studies 79-81-2, Retinyl palmitate 80-08-0, Dapsone 80-69-3,
Tartronic acid 84-65-1, Anthraquinone 87-69-4, Tartaric acid,
biological studies 87-73-0, Saccharic acid 90-64-2, Mandelic acid
103-82-2, Phenylacetic acid, biological studies 106-14-9,
12-Hydroxystearic acid 107-11-9, Allylamine 107-21-1, Ethylene glycol,
biological studies 107-41-5, Hexylene glycol 108-95-2, Phenol,
biological studies 109-97-7, Azole 110-15-6, Succinic acid, biological
studies 110-27-0, Isopropyl myristate 110-91-8D, Morpholine, deriv.
110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-20-6, Sebacic acid,
biological studies 111-46-6, Diethylene glycol, biological studies
112-53-8, Lauryl alcohol 112-72-1, Myristyl alcohol 112-85-6, Behenic
acid 112-92-5, Stearyl alcohol 115-83-3, Pentaerythrityl tetrastearate
116-31-4, Retinal 120-62-7, Sulfoxide 122-32-7, Triolein 123-86-4,
Butyl acetate 123-99-9, Azelaic acid, biological studies 124-04-9,
Adipic acid, biological studies 124-07-2D, Caprylic acid, dialkylamino
acetates, biological studies 126-07-8D, Griseofulvin, deriv.
126-30-7D, Neopentyl glycol, dicaprylate/dicaprate derivs. 127-17-3,
Pyruvic acid, biological studies 127-19-5, Dimethylacetamide 127-40-2,
Lutein 127-47-9, Retinyl acetate 138-39-6, Mafenide 138-86-3,
Limonene 141-78-6, Ethyl acetate, biological studies 141-82-2, Malonic
acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7,
Lauric acid, biological studies 144-68-3D, Zeaxanthin, deriv.
147-73-9, Erythraric acid 148-79-8, Thiabendazole 288-13-1, Pyrazole
288-32-4, Imidazole, biological studies 288-42-6, Oxazole 288-47-1,
Thiazole 289-06-5, Thiadiazole 289-07-6, 1,2,3,4-Thiatriazole
289-95-2, Pyrimidine 302-79-4, Retinoic acid 320-77-4, Isocitric acid
432-70-2, Carotene 443-48-1, Metronidazole 473-81-4, Glyceric
acid 502-65-8, Lycopene 505-48-6, Suberic acid 505-52-2,
1,13-Tridecanedioic acid 506-30-9, Arachidic acid 506-48-9,
Octacosanoic acid 515-30-0, Atrolactic acid 526-99-8, Galactaric acid
527-00-4, Allaric acid 551-92-8, Dimetridazole 552-63-6, Tropic acid
554-12-1 593-50-0, 1-Triacontanol 597-44-4, Citramalic acid
629-70-9, Cetyl acetate 629-96-9, Arachidyl alcohol 646-06-0,
Dioxolane 661-19-8, Behenyl alcohol 666-99-9, Agaricic acid
685-73-4, Galacturonic acid 693-23-2, 1,12-Dodecanedioic acid
768-94-5, Amantadine 821-38-5D, 1,14-Tetradecanedioic acid, deriv.
1113-60-6, Hydroxypyruvic acid 1323-03-1, Myristyl lactate 1338-41-6,
Sorbitan monostearate 1393-12-0, Rimocidin 1394-02-1D, Trichomycin,
deriv. 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-61-8, Fradicin
1403-71-0, Hamycin 1403-95-8, Mediocidin 1404-63-3, Sistomycosin
1406-16-2D, Vitamin D, deriv. 1406-18-4D, Vitamin E, deriv. 1490-04-6,
Menthol 1852-04-6, Undecanedioic acid 2022-85-7, Flucytosine
2040-64-4, Dodecyl myristate 2398-96-1, Tolnaftate 3056-17-5,
Stavudine 3079-30-9, Methyl dodecyl sulfoxide 3234-85-3, Myristyl
myristate 3366-95-8, Secnidazole 3687-46-5, Decyl oleate 3689-76-7,
Chlormidazole 4353-06-4, 2-(n-Nonyl)-1,3-dioxolane 4759-48-2,
Isotretinoin 5306-85-4, Dimethylisosorbide 5536-17-4, Vidarabine
5627-26-9, D-Gularic acid 5666-23-9, Altraric acid 5768-54-7, Idaric
acid 6006-56-0, Triguanide 6506-37-2, Nimorazole 6543-97-1, Mannaric
acid 6556-12-3, Glucuronic acid 6703-05-5, Lyxaric acid 6834-98-6,
Pentamycin 6915-15-7, Malic acid 6938-94-9, Diisopropyl adipate
7235-40-7, all-trans- Carotene 7439-92-1, Lead, biological studies
7439-97-6, Mercury, biological studies 7440-22-4, Silver, biological
studies 7440-31-5, Tin, biological studies 7440-43-9, Cadmium,
biological studies 7440-47-3, Chromium, biological studies 7440-50-8,
Copper, biological studies 7440-57-5, Gold, biological studies
7440-66-6, Zinc, biological studies 7440-69-9, Bismuth, biological
studies 7481-89-2, Zalcitabine 7553-56-2, Iodine, biological studies
Page 80 of 158
7681-93-8, Natamycin 7722-84-1, Hydrogen peroxide, biological studies
8065-41-6, Aureofungin 9002-92-0, Laureth 4 9004-32-4, Sodium
carboxymethyl cellulose 9004-64-2, Klucel EF 9004-65-3, Hydroxy propyl
methyl cellulose 9004-67-5, Methyl cellulose 9004-95-9, Polyethylene
glycol cetyl ether 9004-99-3, PEG-40 stearate 9005-00-9, Steareth 21
9005-65-6, Polysorbate 80 9005-67-8, Polysorbate 60 10158-64-2D,
Xylaric acid, deriv. 10401-55-5, Cetyl ricinoleate 11006-22-7,
Flavofungin 11014-70-3, Levorin 11016-07-2, Perimycin 11078-21-0,
Filipin 11096-49-4, Partricin 11099-07-3, Glyceryl stearate
11103-57-4D, Vitamin A, deriv. 11121-32-7, Mepartricin 11138-66-2,
Xanthan gum 12001-76-2D, Vitamin B, deriv. 12001-79-5D, Vitamin K,
deriv. 12633-72-6, Amphotericin 12633-72-6D, Amphotericin, Me derivs.
12650-69-0, Mupirocin 12676-71-0, Niphimycin 12689-28-0, Proticin
13058-67-8, Lucensomycin 13182-89-3, Metronidazole benzoate 13312-52-2
13392-28-4, Rimantadine 13444-71-8, Periodic acid (HIO4) 14333-13-2,
Permanganate 14380-61-1, Hypochlorite 14797-73-0, Perchlorate
15387-18-5, Fezatione 15454-31-6, Iodate 16260-26-7, Octyl myristate
16773-42-5, Ornidazole 16958-85-3, Octyl palmitate 17812-24-7, Ribonic
acid 17941-34-3, Aleuritic acid 18323-44-9, Clindamycin 19045-66-0,
Carbamothioic acid 19387-91-8, Tinidazole 20246-53-1, Gulonic acid
22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23593-75-1,
Clotrimazole 25231-21-4, PPG 15 stearyl ether 25322-68-3, Polyethylene
glycol 25322-68-3D, alkylyl ether 25496-72-4, Glyceryl oleate
25525-21-7, Glucaric acid 27220-47-9, Econazole 27523-40-6,
Isoconazole 29342-05-0, Ciclopirox 30516-87-1, Zidovudine
31566-31-1, Glyceryl monostearate 33012-62-3, Ribaric acid 34513-50-3,
Octyldodecanol 35274-05-6, Cetyl lactate 35554-44-0, Enilconazole
36574-66-0D, N-coco acyl derivs 36653-82-4, Cetyl alcohol 36791-04-5,
Ribavirin 37217-63-3 37217-65-5, Candimycin 37306-44-8, Triazole
38083-17-9, Climbazole 41621-49-2, Ciclopiroxolamine
(anti-infection augmentation foamable compns. and kit and uses thereof)
Page 81 of 158
TITLE: Tea tree oil and benzoyl peroxide for
treatment of acne
INVENTOR(S): Liegeois, Nanette
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20070207115 A1 20070906 US 2006-307969 20060301
AB This invention relates to compn. consisting of tea tree oil used alone or in
combination with conventional over-the-counter strength anti-acne agents. A
system is created whereby Tea tree oil is used in combination with other anti-
acne therapies, particularly benzoyl peroxide. Subsequent steps utilize
conventional anti-acne treatments.
INCL 424074000; 424769000; 514568000
IPCI A61K0008-97 [I,A]; A61K0031-192 [I,A]; A61K0036-61 [I,A]
IPCR A61K0008-97 [I,A]; A61K0031-192 [I,A]; A61K0036-61 [I,A]
NCL 424/074.000; 424/769.000; 514/568.000
ST tea tree oil benzoyl peroxide acne
IT Essential oils
USES (Uses)
(Melaleuca; tea tree oil and
benzoyl peroxide for treatment of acne)
IT Acne
(tea tree oil and benzoyl
peroxide for treatment of acne)
Benzoyl peroxide, biological studies 302-79-4,
Tretinoin
USES (Uses)
(tea tree oil and benzoyl
peroxide for treatment of acne)
Page 82 of 158
TITLE: Cosmetic composition comprising hydrophobic and
hydrophilic silica particles
INVENTOR(S): Ingman, Dov
PATENT ASSIGNEE(S): Or-Le-Or Ltd., Israel
SOURCE: Eur. Pat. Appl., 30 pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
EP 1685824 A1 20060802 EP 2006-100458 20060117
CA 2534306 A1 20060730 CA 2006-2534306 20060130
US 20060257437 A1 20061116 US 2006-341872 20060130
AB The present invention relates to a new topical cosmetic compn. formulated for
concealing wrinkles and for eliminating or reducing damages to the skin
appearance resulted from a wide variety of disorders, such as for example, acne.
The compn. comprises water, optionally contg. 25 to 400 ppm of Ag, hydrophobic
particles, preferably hydrophobic silica, having a diam., ranged from about 5 to
about 150 nm, and/or hydrophilic particles, preferably hydrophilic silica,
having a diam., ranged from about 5 to about 150 nm and a sol. electrolyte,
capable of releasing free ions in an aq. environment. Thus, a hypotonic compn.
for treating acne comprised Dead Sea salt 0.2, zinc sulfate 1, hydrophobic
silica 5, hydrophilic silica 5, tea tree oil 2, sea buckthorn oil 3, vitamin A
0.1, vitamin C 1.5, vitamin E acetate 0.1, methylparaben 0.1, propylene glycol
2, and water 80%, resp. A compn. comprising water, optionally contg. Ag 25 to
400 ppm, 10 wt.% Aerosil 380, 2.5 wt.% Aerosil R812, 1 to 20 wt.% Dead Sea salt,
and optionally one or more conventional skincare and/or anti-acne agent,
selected from evening primrose oil, sweet almond oil, sea buckthorn oil, tea
tree oil, Finsolv TN, (C12-15 alkyl benzoate), octyl hydroxystearate, salicylic
acid, vitamin C, citric acid, azelaic acid, benzoyl peroxide, zinc acetate and
sulfur. The compn. was highly effective in treating acne. The concn. of the
salt in such compn. was detd. according to the treated skin type (dried, oily,
etc.) and the particular acne type, grade and state of the treated individual.
Compns. contg. higher concns. of salt (10 to 20 wt.%) are preferred for treating
an oily skin and an intensive acne state.
IPCI A61K0008-25 [I,A]; A61K0008-19 [I,A]; A61Q0019-06 [I,A]; A61Q0019-08 [I,A]
IPCR A61K0008-25 [I,A]; A61K0008-19 [I,A]; A61Q0019-06 [I,A]; A61Q0019-08 [I,A]
IT Essential oils
(Melaleuca; cosmetic compn. contg. silica particles,
electrolytes and optionally silver for concealing wrinkles and treating
and/or improving skin disorders and hair loss)
IT Acne
Alopecia
Cosmetics
Eczema
Electrolytes, biological
Encapsulation
Mycosis
Particle size
Particles
Psoriasis
Seborrhea
Skin preparations (pharmaceutical)
Page 83 of 158
Wart
(cosmetic compn. contg. silica particles, electrolytes and optionally
silver for concealing wrinkles and treating and/or improving skin
disorders and hair loss)
IT 50-81-7, Ascorbic acid, biological studies 58-95-7, Vitamin E acetate
65-85-0D, Benzoic acid, C12-15 alkyl esters 69-72-7, Salicylic acid,
biological studies 69-93-2, Uric acid, biological studies 77-92-9,
Citric acid, biological studies 79-81-2, Retinyl palmitate
123-99-9, Azelaic acid, biological studies 471-34-1, Calcium carbonate,
biological studies 501-30-4, Kojic acid 557-34-6, Zinc acetate
1309-37-1, Ferric oxide, biological studies 1344-28-1, Alumina,
biological studies 1344-43-0, Manganous oxide, biological studies
7440-22-4, Silver, biological studies 7704-34-9, Sulfur, biological
studies 7705-08-0, Ferric chloride, biological studies 7733-02-0, Zinc
sulfate 7758-98-7, Copper sulfate, biological studies 7778-18-9,
Calcium sulfate 13463-67-7, Titania, biological studies 38304-91-5,
Minoxidil 39236-46-9, Imidazolidinyl urea 74565-11-0, Finsolv TN
112153-71-6, Aerosil R 812 148718-35-8, Octyl hydroxystearate
200135-89-3, Dead Sea salt
(cosmetic compn. contg. silica particles, electrolytes and optionally
silver for concealing wrinkles and treating and/or improving skin
disorders and hair loss)
Page 84 of 158
TITLE: Topical treatment of skin conditions
INVENTOR(S): Khaiat, Alain V.; Gomes, Anna; Bhide, Vaishali
PATENT ASSIGNEE(S): Singapore
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 20040228822 A1 20041118 US 2003-439735 20030516
US 20040228885 A1 20041118 US 2003-663238 20030916
US 20050031571 A1 20050210 US 2004-844809 20040513
AU 2004240615 A1 20041202 AU 2004-240615 20040514
CA 2524868 A1 20041202 CA 2004-2524868 20040514
WO 2004103321 A2 20041202 WO 2004-US15053 20040514
WO 2004103321 A3 20050224
WO 2004103353 A2 20041202 WO 2004-US15054 20040514
WO 2004103353 A3 20050224
EP 1626779 A2 20060222 EP 2004-752156 20040514
BR 2004010358 A 20060530 BR 2004-10358 20040514
CN 1787806 A 20060614 CN 2004-80013144 20040514
JP 2007502326 T 20070208 JP 2006-533040 20040514
MX 2005012381 A 20060525 MX 2005-12381 20051116
US 20060228321 A1 20061012 US 2006-451163 20060612
US 7252831 B2 20070807
PRIORITY APPLN. INFO.: US 2003-439735 A2 20030516
US 2003-663238 A2 20030916
US 2004-844809 A1 20040513
WO 2004-US15054 W 20040514
AB This invention relates to improved compns. and methods for treating skin
conditions contg. sebum redn. agents; keratolytic agents and anti-inflammatory
agents that results in unexpectedly superior control of skin conditions such as
acne.
INCL 424070140
IPCI A61K0007-06 [ICM,7]; A61K0007-11 [ICS,7]
[I,A]; A61K0008-64 [I,A]; A61K0008-67 [I,A]; A61K0008-97 [I,A];
A61Q0007-00 [I,A]; A61Q0009-00 [I,A]; A61Q0019-00 [I,A]
NCL 424/070.140
ST bacterial lipase inhibitor antiinflammatory acne sebum skin prepn
IT Essential oils
(Melaleuca; topical treatment of skin conditions)
IT Acne
Sebum
(topical treatment of skin conditions)
IT 56-40-6, Glycine, biological studies 58-95-7, Tocopheryl acetate
69-72-7, Salicylic acid, biological studies 94-36-0,
Allantoin 108-46-3, Resorcinol, biological studies 114-07-8,
Erythromycin 515-69-5, -Bisabolol 7488-56-4, Selenium disulfide
Page 85 of 158
9081-34-9, 5-Alpha-reductase 18323-44-9, Clindamycin 68797-35-3,
Dipotassium glycyrrhizinate
(topical treatment of skin conditions)
Page 86 of 158
TITLE: Pharmaceutical and cosmetic carrier or composition for
topical application containing a fatty acid, a fatty
alcohol and an oil
INVENTOR(S): Eini, Meir; Tamarkin, Dov
PATENT ASSIGNEE(S): Thixo Ltd., Israel
SOURCE: PCT Int. Appl., 76 pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 2001051014 A1 20010719 WO 2001-IL25 20010110
US 6348229 B1 20020219 US 2000-526509 20000316
US 6967023 B1 20051122 US 2000-653267 20000831
CA 2397068 A1 20010719 CA 2001-2397068 20010110
AU 2001023937 A 20010724 AU 2001-23937 20010110
AU 782515 B2 20050804
EP 1250116 A1 20021023 EP 2001-900239 20010110
JP 2003528821 T 20030930 JP 2001-551438 20010110
NZ 520014 A 20050527 NZ 2001-520014 20010110
IN 2002CN01082 A 20070921 IN 2002-CN1082 20020710
IN 2002CN01062 A 20071012 IN 2002-CN1062 20020710
IN 221380 A1 20080912
US 20040253275 A1 20041216 US 2002-169897 20021231
US 6911211 B2 20050628
US 20030157138 A1 20030821 US 2003-392071 20030319
US 6994863 B2 20060207
US 20060088561 A1 20060427 US 2005-294318 20051205
US 7682623 B2 20100323
US 20100137198 A1 20100603
US 2010-705219 20100212
IL 2000-133969 A 20000110
US 2000-526509 A 20000316
IL 2000-137051 A 20000627
IL 2000-137052 A 20000627
US 2000-216162P P 20000703
US 2000-653267 A 20000831
WO 2001-IL25 W 20010110
US 2003-392071 A1 20030319
US 2005-294318 A1 20051205
AB A pharmaceutical or cosmetic carrier or compn. for topical application,
characterized by rheol. properties which render the carrier or compn. semi-solid
at rest and a liq. upon application of shear forces, is described. The compn.
or carrier are prepd. by mixing (by wt.) 1-25% of a solidifying agent, such as a
long-chain fatty alc. and a fatty acid, and 75-99% of a hydrophobic solvent,
such as an animal, mineral, silicone, or plant-derived oil, wherein at least one
of them has therapeutic or cosmetic benefits, in the presence or absence of a
biol. active substance. For example, behenic acid (10 g) was heated to 80 and
mixed with light paraffin oil (90 g) preheated to the same temp. Then glycerin
(10 g), tristearin (10 g), and an antioxidant mixt. (1 g) were added by
agitation. Bifunazole (1.2 g) and diflucortolone valerate (0.12 g) were added
and the mixt. was poured into containers (5 g tubes) and was allowed to cool
spontaneously. While the mixt. cooled to ambient temp. it gradually turned into
a semisolid, i.e., an ointment contg. the antifungal agent.
IPCI A61K0007-00 [ICM,7]; A61K0009-00 [ICS,7]; A61K0009-06 [ICS,7]; A61K0009-08
[ICS,7]; A61K0009-10 [ICS,7]; A61K0009-70 [ICS,7]; A61K0047-00 [ICS,7];
A61K0047-02 [ICS,7]; A61K0047-10 [ICS,7]
Page 87 of 158
IPCR A21D0002-14 [I,A]; A21D0002-16 [I,A]; A21D0013-08 [I,A]; A23C0009-13
[I,A]; A23C0011-04 [I,A]; A23C0013-12 [I,A]; A23C0015-16 [I,A];
A23C0019-055 [I,A]; A23C0019-093 [I,A]; A23D0007-00 [I,A]; A23D0007-005
[I,A]; A23D0007-01 [I,A]; A23D0009-007 [I,A]; A23D0009-02 [I,A];
A23G0001-00 [I,A]; A23G0001-30 [I,A]; A23G0001-36 [I,A]; A23G0001-38
[I,A]; A23G0003-34 [I,A]; A23G0009-32 [I,A]; A23G0009-44 [I,A];
A23G0009-52 [I,A]; A23J0003-22 [I,A]; A23L0001-00 [I,A]; A23L0001-16
[I,A]; A23L0001-164 [I,A]; A23L0001-18 [I,A]; A23L0001-19 [I,A];
A23L0001-217 [I,A]; A23L0001-30 [I,A]; A23L0001-314 [I,A]; A23L0001-40
[I,A]; A61K [I,S]; A61K0008-00 [I,A]; A61K0008-02 [I,A]; A61K0008-06
[I,A]; A61K0008-18 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A];
A61K0008-365 [I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A]; A61K0008-98
[I,A]; A61K0009-00 [I,A]; A61K0009-06 [I,A]; A61K0031-07 [I,A];
A61K0031-197 [I,A]; A61K0031-225 [I,A]; A61K0031-351 [I,A]; A61K0031-355
[I,A]; A61K0031-357 [I,A]; A61K0031-4188 [I,A]; A61K0031-43 [I,A];
A61K0031-4415 [I,A]; A61K0031-455 [I,A]; A61K0031-496 [I,A]; A61K0031-51
[I,A]; A61K0031-525 [I,A]; A61K0031-545 [I,A]; A61K0031-57 [I,A];
A61K0031-59 [I,A]; A61K0031-65 [I,A]; A61K0031-714 [I,A]; A61K0033-04
[I,A]; A61K0033-06 [I,A]; A61K0033-14 [I,A]; A61K0033-18 [I,A];
A61K0033-24 [I,A]; A61K0033-26 [I,A]; A61K0033-30 [I,A]; A61K0033-32
[I,A]; A61K0033-34 [I,A]; A61K0035-60 [I,A]; A61K0036-00 [I,A];
A61K0036-738 [I,A]; A61K0036-899 [I,A]; A61K0045-00 [I,A]; A61K0045-06
[I,A]; A61K0047-06 [I,A]; A61K0047-10 [I,A]; A61K0047-12 [I,A];
A61K0047-14 [N,A]; A61K0047-44 [I,A]; A61P0001-10 [I,A]; A61P0001-14
[I,A]; A61P0003-02 [I,A]; A61P0003-06 [I,A]; A61P0003-10 [I,A];
A61P0007-02 [I,A]; A61P0007-04 [I,A]; A61P0009-10 [I,A]; A61P0009-12
[I,A]; A61P0013-12 [I,A]; A61P0017-00 [I,A]; A61P0017-02 [I,A];
A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0017-08 [I,A]; A61P0017-10
[I,A]; A61P0029-00 [I,A]; A61P0031-04 [I,A]; A61P0035-00 [I,A];
A61P0037-02 [I,A]; A61Q0019-00 [I,A]
Section cross-reference(s): 1, 2, 62
IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Melaleuca; topical compns. contg. fatty acid, fatty alc. and
oil for pharmaceutical and cosmetic uses)
IT Acne
Antibiotics
Antihistamines
Antiulcer agents
Antiviral agents
Autoimmune disease
Cosmetics
Eczema
Erythema
Fungicides
Immunosuppressants
Mucous membrane
Psoriasis
Seborrhea
(topical compns. contg. fatty acid, fatty alc. and oil for
pharmaceutical and cosmetic uses)
IT 50-23-7, Hydrocortisone 56-75-7, Chloramphenicol 60-54-8, Tetracycline
67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide
98-92-0, vitamin B3 106-14-9, 12-Hydroxystearic acid 114-07-8,
Page 88 of 158
Erythromycin 118-74-1, Hexachlorobenzene 120-51-4, Benzyl benzoate
121-75-5, Malathion 126-07-8, Griseofulvin 302-79-4, Tretinoin
483-63-6, Crotamiton 768-94-5, Amantadine 1229-29-4, Doxepine
hydrochloride 1397-89-3, Amphotericin B 1406-05-9, Penicillin
2022-85-7, Flucytosine 2152-44-5, Betamethasone valerate 3056-17-5,
Stavudine 3093-35-4, Halcinonide 4759-48-2, Isotretinoin 5536-17-4,
Vidarabine 5593-20-4, Betamethasone dipropionate 7681-11-0, Potassium
iodide, biological studies 12650-69-0, Mupirocin 13392-28-4,
Rimantadine 18323-44-9, Clindamycin 22916-47-8, Miconazole
23593-75-1, Clotrimazole 25122-46-7, Clobetasol propionate 29342-05-0,
Ciclopirox 30516-87-1, Zidovudine 36791-04-5, Ribavirin 57524-89-7,
Hydrocortisone valerate 59198-70-8, Diflucortolone valerate
59277-89-3, Acyclovir 60628-96-8, Bifonazole 65277-42-1, Ketoconazole
66852-54-8, Halobetasol propionate 78613-35-1, Amorolfine 79217-60-0,
Cyclosporin 82410-32-0, Gancyclovir 84625-61-6, Itraconazole
86386-73-4, Fluconazole 91161-71-6, Terbinafine 106685-40-9, Adapalene
108436-80-2, Rociclovir 127779-20-8, Saquinavir 129618-40-2,
Nevirapine 134678-17-4, Lamivudine 136817-59-9, Delavirdine
150378-17-9, Indinavir 155213-67-5, Ritonavir 159989-64-7, Nelfinavir
(topical compns. contg. fatty acid, fatty alc. and oil for
pharmaceutical and cosmetic uses)
Page 89 of 158
TITLE: Formulations and methods for reducing skin irritation
INVENTOR(S): Hahn, Gary S.; Thueson, David O.
PATENT ASSIGNEE(S): Cosmederm Technologies, USA
SOURCE: U.S., 30 pp., Cont.-in-part of U.S. 5,716,625.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 6139850 A 20001031 US 1997-860993 19970623
US 5716625 A 19980210 US 1994-362100 19941221
WO 9619184 A1 19960627 WO 1995-US16985 19951221
EP 1136065 A1 20010926 EP 2001-115074 19951221
EP 1136065 B1 20041124
US 20030124202 A1 20030703US 2002-189344 20020703
PRIORITY APPLN. INFO.: US 1994-362100 A2 19941221
WO 1995-US16985 W 19951221
EP 1995-944548 A3 19951221
US 1997-860993 A2 19970623
US 2000-685992 B1 20001010
US 2001-33194 A1 20011024
AB Compns. and methods are provided for inhibiting skin irritation attributable to
chem. irritants or environmental conditions, by the application of an anti-
irritant amt. of water-sol. strontium cation. The compns. can be
antiperspirants, deodorants, sunscreens, insect repellents, depilatories, hair
dyes, hair bleaches, mouthwashes, ointments, suppositories, etc. Glycolic acid
(6 % in 10 % ethanol-in-water) was used as a skin irritant. Strontium nitrate
was coadministered as an anti-irritant to subject panels and was shown to
inhibit cumulative irritation by 64-84 % at concns. ranging from 250 nM to 500
nM.
INCL 424401000
IPCI A61K0007-48 [ICM,7]
[I,A]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-23 [I,A];
A61K0008-24 [I,A]; A61K0008-29 [I,A]; A61K0008-30 [I,A]; A61K0008-33
[I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A]; A61K0008-362 [I,A];
A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37 [I,A]; A61K0008-38
[I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A]; A61K0008-44 [I,A];
A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-60 [I,A]; A61K0008-64
[I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A]; A61K0031-28 [I,A];
A61K0033-24 [I,A]; A61K0036-81 [I,A]; A61K0036-82 [I,A]; A61K0036-886
[I,A]; A61Q0001-02 [I,A]; A61Q0001-06 [I,A]; A61Q0005-00 [I,A];
A61Q0005-02 [I,A]; A61Q0005-04 [I,A]; A61Q0005-08 [I,A]; A61Q0005-10
[I,A]; A61Q0005-12 [I,A]; A61Q0007-00 [I,A]; A61Q0009-02 [I,A];
A61Q0011-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0017-04
[I,A]; A61Q0019-00 [I,A]; A61Q0019-10 [I,A]; G02F0001-13357 [I,A]
NCL 424/401.000; 424/722.000; 424/760.000; 514/847.000; 514/848.000;
514/859.000; 514/881.000; 514/887.000
IT Essential oils
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Melaleuca; strontium compds. for reducing skin irritation
due to ingredients in compns.)
IT Acne
(inhibitors; strontium compds. for reducing skin irritation due to
Page 90 of 158
ingredients in compns.)
IT 50-21-5, Lactic acid, biological studies 57-13-6, Urea, biological
studies 58-08-2, Caffeine, biological studies 64-19-7, Acetic acid,
biological studies 68-26-8, Retinol 69-72-7, biological studies
76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological
studies 77-92-9, biological studies 79-14-1, biological studies
87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2
97-59-6, Allantoin 98-79-3 108-95-2, Phenol, biological studies
116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7,
Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4,
Capsaicin. 515-69-5, -Bisabolol 526-95-4, D-Gluconic acid
617-73-2, -Hydroxy octanoic acid 1405-86-3, Glycyrrhizic acid
5393-81-7, -Hydroxy decanoic acid 6915-15-7 70424-62-3
126094-21-1
RL: ADV (Adverse effect, including toxicity); BUU (Biological use,
unclassified); BIOL (Biological study); USES (Uses)
(strontium compds. for reducing skin irritation due to ingredients in
compns.)
Page 91 of 158
TITLE: Skin-treatment compositions containing natural
products
INVENTOR(S): Oliver, Benjamin
SOURCE: U.S., 4 pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 5869062 A 19990209 US 1997-863733 19970527
AB An improved skin treatment compn. is provided. The compn. comprises calamine 8-
20%, an antioxidant 0.05-3%, an herbal antibacterial substance 0.25-4%, and a
base 25-60%. These ingredients are combined with a base, preferably comprised
of water and glycerin, to prep. the inventive compn. A topical compn. for the
treatment of acne contained water 25.25, glycerin 20, calamine 18, ZnO 18, witch
hazel 5, ascorbic acid 0.88, peroxide (3% strength) 5, golden seal 2, ethanol 5,
tea tree oil 0.7, and vitamin E 0.16%.
INCL 424195100
IPCI A61K0035-78 [ICM,6]; A61K0039-385 [ICS,6]; A61K0033-32 [ICS,6]
IPCR A61K0033-32 [I,C*]; A61K0033-32 [I,A]; A61K0036-185 [I,C*]; A61K0036-185
[I,A]; A61K0036-28 [I,A]; A61K0036-48 [I,A]; A61K0036-61 [I,A];
A61K0036-71 [I,A]; A61K0036-80 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962
[I,A]; A61K0039-385 [I,C*]; A61K0039-385 [I,A]
NCL 424/726.000; 424/616.000; 424/641.000; 424/737.000; 514/458.000;
514/474.000; 514/557.000; 514/714.000; 514/725.000; 514/859.000
ST topical calamine antioxidant herbal antibacterial acne
IT Essential oils
(Melaleuca; anti-acne compns. contg. calamine and
antioxidants and antibacterials)
IT Acne
Aloe barbadensis
Clover (Trifolium pratense)
Echinacea
Garlic (Allium sativum)
Golden seal (Hydrastis)
Tabebuia
Witch hazel
(anti-acne compns. contg. calamine and antioxidants and
antibacterials)
IT Tocopherols
antibacterials)
IT Carboxylic acids
(hydroxy; anti-acne compns. contg. calamine and antioxidants
and antibacterials)
IT Drug delivery systems
(topical; anti-acne compns. contg. calamine and antioxidants
and antibacterials)
IT 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerin, biological
studies 57-55-6, Propylene glycol, biological studies 64-17-5, Ethyl
alcohol, biological studies 67-63-0, Isopropyl alcohol, biological
Page 92 of 158
studies 94-17-7, p-Chlorobenzoyl peroxide 94-36-0,
tert-Butyl peroxide 110-22-5, Acetyl peroxide 1314-13-2, Zinc oxide,
biological studies 1338-23-4, Methyl ethyl ketone peroxide. 1406-18-4,
Vitamin E 7235-40-7, -Carotene 7722-84-1, Hydrogen peroxide,
biological studies 8011-96-9, Calamine
antibacterials)
Page 93 of 158
ORIGINAL REFERENCE NO.: 127:4501a
TITLE: Cosmetic and pharmaceutical delivery vehicles
comprising a volatile cyclosiloxane, a particulate
carbohydrate and an oil or a glyceride ester
INVENTOR(S): Berndt, Dieter
PATENT ASSIGNEE(S): Safe & Dry Co., Inc., USA
SOURCE: U.S., 11 pp.
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
US 5626856 A 19970506 US 1995-497454 19950630
AB A novel delivery system for cosmetic and topical pharmaceutical products
contains a volatile cyclosiloxane, a particulate carbohydrate and an oil or a
glyceride ester. The carbohydrate and oil or glyceride ester are included in
wt. ratios which will produce a translucent film after the evapn. of the
volatile cyclosiloxane from the compn. In addn., a no. of other components may
also be added to the delivery system including bioactive agents such as
antiperspirant salts and antifungal agents, film-formers, surfactants,
emollients, fragrances, coloring agents, preservatives, medicinal agents and
related components depending upon the desired characteristics and the purpose
for which the system and final product is designed. An antiperspirant compn.
contained cyclomethicone 45, starch 10, white petrolatum 15, iso-Pr palmitate 5,
zirconium aluminum chlorhydrex 25, and fragrance q.s. 100%.
INCL 424401000
IPCI A61K0009-48 [ICM,6]
[I,A]; A61K0009-70 [I,A]; A61K0047-00 [I,A]; A61K0047-06 [N,A];
A61K0047-24 [N,A]; A61K0047-36 [N,A]; A61Q0001-12 [I,A]; A61Q0015-00
[I,A]; A61Q0017-04 [I,A]; A61Q0019-00 [I,A]
NCL 424/401.000; 424/059.000; 424/065.000; 424/066.000; 424/068.000;
424/069.000; 514/844.000; 514/846.000
IT Essential oils
(Melaleuca; cosmetic and pharmaceutical delivery vehicles
comprising volatile cyclosiloxane, particulate carbohydrate and oil or
glyceride ester)
IT Acne
Pruritus
(inhibitors; cosmetic and pharmaceutical delivery vehicles comprising
volatile cyclosiloxane, particulate carbohydrate and oil or glyceride
ester)
IT 58-95-7, Tocopheryl acetate 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-,
biological studies 76-22-2, Camphor 89-78-1, Menthol 94-36-0
, Benzoyl peroxide, biological studies 112-80-1,
Oleic acid, biological studies 404-86-4, Capsaicin 463-40-1
540-97-6, Dodecamethylcyclohexasiloxane 541-02-6 556-67-2 1314-13-2,
Zinc oxide, biological studies 1327-41-9D, Aluminum chlorhydroxide,
salts 1406-16-2, Vitamin d 1406-18-4, Vitamin e 7704-34-9, Sulfur,
biological studies 9004-34-6, Cellulose, biological studies
9004-34-6D, Cellulose, ethers, biological studies 9004-53-9, Dextrin
9005-25-8, Starch, biological studies 9005-79-2, Glycogen, biological
Page 94 of 158
studies 9005-82-7, Amylose 9037-22-3, Amylopectin 11103-57-4,
Vitamin a 18428-88-1, Zirconyl hydroxychloride 134910-86-4, Aluminum
zirconium tetrachlorhydrex glycine
(cosmetic and pharmaceutical delivery vehicles comprising volatile
cyclosiloxane, particulate carbohydrate and oil or glyceride ester)
Page 95 of 158
ORIGINAL REFERENCE NO.: 125:28063a,28066a
TITLE: Anti-irritant skin formulations containing aluminum or
tin cations
INVENTOR(S): Hahn, Gary Scott; Thueson, David Orel
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 9619183 A1 19960627 WO 1995-US16765 19951221
CA 2208078 A1 19960627 CA 1995-2208078 19951221
CA 2208078 C 20090623
AU 9645285 A 19960710 AU 1996-45285 19951221
EP 801554 A1 19971022 EP 1995-943956 19951221
EP 801554 B1 20030416
BR 9510478 A 19981215 BR 1995-10478 19951221
JP 11502504 T 19990302 JP 1996-520010 19951221
AT 237298 T 20030515 AT 1995-943956 19951221
PT 801554 E 20030829 PT 1995-943956 19951221
ES 2192586 T3 20031016 ES 1995-943956 19951221
US 6455076 B1 20020924 US 1997-860206 19970623
JP 2005314437 A 20051110 JP 2005-217695 20050727
PRIORITY APPLN. INFO.: US 1994-362058 A 19941221
JP 1996-520010 A3 19951221
WO 1995-US16765 W 19951221
AB Cosmetic and pharmaceutical compns. for inhibiting skin irritation attributable
to chem. irritants or environment conditions, contain an anti-irritant amt. of
aq.-sol. trivalent aluminum cation or divalent tin cation. A soln. of 250 mM
stannous chloride decreased the skin irritation caused by application of 7.5%
lactic acid in 10% ethanol by 50%.
IPCI A61K0007-00 [ICM,6]
[I,A]; A61K0008-21 [I,A]; A61K0008-22 [I,A]; A61K0008-23 [I,A];
A61K0008-24 [I,A]; A61K0008-26 [I,A]; A61K0008-29 [I,A]; A61K0008-30
[I,A]; A61K0008-33 [I,A]; A61K0008-34 [I,A]; A61K0008-36 [I,A];
A61K0008-362 [I,A]; A61K0008-365 [I,A]; A61K0008-368 [I,A]; A61K0008-37
[I,A]; A61K0008-38 [I,A]; A61K0008-40 [I,A]; A61K0008-42 [I,A];
A61K0008-44 [I,A]; A61K0008-46 [I,A]; A61K0008-49 [I,A]; A61K0008-60
[I,A]; A61K0008-64 [I,A]; A61K0008-92 [I,A]; A61K0008-97 [I,A];
A61K0009-00 [I,A]; A61K0031-00 [I,A]; A61K0033-06 [I,A]; A61K0033-24
[I,A]; A61K0045-06 [I,A]; A61K0047-02 [I,A]; A61P0001-00 [I,A];
A61P0011-00 [I,A]; A61P0013-02 [I,A]; A61P0015-00 [I,A]; A61P0017-00
[I,A]; A61Q0005-00 [I,A]; A61Q0005-02 [I,A]; A61Q0005-04 [I,A];
A61Q0005-08 [I,A]; A61Q0005-10 [I,A]; A61Q0007-00 [I,A]; A61Q0009-00
[I,A]; A61Q0011-00 [I,A]; A61Q0015-00 [I,A]; A61Q0017-00 [I,A];
A61Q0017-04 [I,A]; A61Q0019-00 [I,A]; C11D0007-04 [I,A]; C11D0007-26 [I,A]
IT Acne
(inhibitors; anti-irritant skin formulations contg. aluminum or tin
cations)
IT Essential oils
(Melaleuca, ext.; anti-irritant skin formulations contg.
Page 96 of 158
aluminum or tin cations)
IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts
64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7,
biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid,
biological studies 76-93-7, biological studies 77-92-9, biological
studies 77-92-9D, salts 79-14-1, biological studies 79-14-1D, salts
87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2,
Gluconolactone 94-36-0, Benzoyl peroxide,
biological studies 98-79-3 108-95-2, Phenol, biological studies
Capsaicin 526-95-4, Gluconic acid 5393-81-7, -Hydroxy decanoic
acid 6915-15-7, Malic acid 70424-62-3 126094-21-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant skin formulations contg. aluminum or tin cations)
Page 97 of 158
TITLE: Anti-irritant skin formulations containing magnesium,
manganese, or lanthanide cations
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 9619182 A1 19960627 WO 1995-US16763 19951221
CA 2208500 A1 19960627 CA 1995-2208500 19951221
AU 9646064 A 19960710 AU 1996-46064 19951221
EP 799018 A1 19971008 EP 1995-944200 19951221
WO 1995-US16763 W 19951221
aq.-sol. divalent magnesium cation or divalent manganese cation, or trivalent
lanthanide cations of at. nos. 56-71. A soln. of 250 mM manganese acetate
decreased the skin irritation caused by application of 7.5% lactic acid in 10%
ethanol by 65%.
IPCI A61K0007-00 [ICM,6]
[I,A]; A61Q0005-00 [I,A]; A61Q0009-00 [I,A]; A61Q0015-00 [I,A];
A61Q0017-00 [I,A]; A61Q0019-00 [I,A]
IT Acne
(inhibitors; anti-irritant skin formulations contg. magnesium,
manganese, or lanthanide cations)
IT Essential oils
magnesium, manganese, or lanthanide cations)
IT 50-21-5, Lactic acid, biological studies 64-19-7, Acetic acid,
biological studies 68-26-8, Retinol 69-72-7, biological studies
69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies
76-93-7, biological studies 77-92-9, biological studies 79-14-1,
biological studies 79-14-1D, magnesium and manganese and lanthanide
salts 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2,
acid 6915-15-7, Malic acid 10024-66-5, Manganese citrate 70424-62-3
126094-21-1
(anti-irritant skin formulations contg. magnesium, manganese, or
lanthanide cations)
Page 98 of 158
TITLE: Anti-irritant skin formulations containing potassium
or lithium cations
LANGUAGE: English
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
WO 9619181 A1 19960627 WO 1995-US16751 19951221
US 5756107 A 19980526 US 1994-362055 19941221
CA 2208079 A1 19960627 CA 1995-2208079 19951221
AU 9646060 A 19960710 AU 1996-46060 19951221
EP 796078 A1 19970924 EP 1995-944196 19951221
WO 1995-US16751 W 19951221
aq.-sol. potassium or lithium cation. A soln. of 250 mM lithium acetate
decreased the skin irritation caused by application of 7.5% lactic acid in 10%
ethanol by 70%.
IPCI A61K0007-00 [ICM,6]
[I,A]; A61K0036-82 [I,A]; A61Q0005-00 [I,A]; A61Q0009-00 [I,A];
A61Q0015-00 [I,A]; A61Q0017-00 [I,A]; A61Q0019-00 [I,A]
IT Acne
(inhibitors; anti-irritant skin formulations contg. potassium or
lithium cations)
IT Essential oils
potassium or lithium cations)
IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, salts
64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7,
biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid,
biological studies 76-93-7, biological studies 77-92-9, biological
studies 77-92-9D, salts 79-14-1, biological studies 79-14-1D, salts
87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2,
acid 6915-15-7, Malic acid 70424-62-3 126094-21-1
(anti-irritant skin formulations contg. potassium or lithium cations)
Page 99 of 158
TITLE: Make-up soap compositions containing tea tree
oil and benzoyl peroxide
INVENTOR(S): Lee, Yu-soon
PATENT ASSIGNEE(S): Lg Chemical Co., Ltd., S. Korea
SOURCE: Repub. Korea, No pp. given
LANGUAGE: Korean
PATENT INFORMATION:

--------------- ---- -------- -------------------- --------
KR 9607395 B1 19960531 KR 1993-25419 19931126
PRIORITY APPLN. INFO.: KR 1993-25419 19931126
AB The cosmetic soap is composed of 0.01-5% tea tree oil, 1-10% benzoyl peroxide
and the rest of cosmetic soap base without over-fat. The used tea tree oil
comprises 2-6% 1,8-cineole and more than 30% terpinene-4-ol. The proper
contents of the components reduce pimple by sterilizing pimple and removing
sebum, and give good workability during soap making process.
IPCI C11D0009-50 [ICM,6]
IPCR C11D0009-50 [I,A]
CC 46-2 (Surface Active Agents and Detergents)
ST tea tree oil benzoyl peroxide soap
IT Essential oils
RL: BUU (Biological use, unclassified); TEM (Technical or engineered
material use); BIOL (Biological study); USES (Uses)
(Melaleuca; make-up soap compns. contg. tea
tree oil and benzoyl peroxide)
IT Soaps
(make-up soap compns. contg. tea tree oil
and benzoyl peroxide)
IT 94-36-0, Benzoyl peroxide, uses
(make-up soap compns. contg. tea tree oil
and benzoyl peroxide)
Page 100 of 158

L56 ANSWER 39 OF 199 USPATFULL on STN
ACCESSION NUMBER: 2012:368486 USPATFULL Full-text
TITLE: NANOPARTICLE COMPOSITIONS
INVENTOR(S): EDELSON, Jonathan, Scarsdale, NY, UNITED STATES
KOTYLA, Timothy, Lowell, MA, UNITED STATES
THEOBALD, Klaus, Paoli, PA, UNITED STATES
PATENT ASSIGNEE(S): ANTERIOS, INC., New York, NY, UNITED STATES (U.S.
corporation)
NUMBER KIND DATE

---------------- ------ --------
PATENT INFORMATION: US 20120328702 A1 20121227 [Family]
APPLICATION INFO.: US 2012-356621 A1 20120123 (13)
NUMBER DATE
------------------- --------
PRIORITY INFORMATION: US 2011-435780P 20110124 (61)
AB The present invention describes novel nanoparticle compositions, and systems
and methods utilizing them for treating disorders and/or conditions associated
with the epidermal and/or dermal level of the skin. Such disorders include
acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal
infection, actinic keratosis, facial wrinkles, muscle contracture, and
headache. Methods generally involve administering nanoparticle compositions to
the skin.
AB . . . utilizing them for treating disorders and/or conditions associated
with the epidermal and/or dermal level of the skin. Such disorders include
acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal
infection, actinic keratosis, facial wrinkles, muscle contracture, and
headache. Methods generally involve administering. . .
SUMM . . . from them, and current treatments are not very successful and
often have undesirable side effects. For example, according to studies,
acne often leads to reduced self esteem, and sometimes even to
depression or suicide (see, e.g., Goodman, 2006, Aust. Fam. Physician.
. .
DETD . . . known to have a particular biological effect on sebaceous
glands include botulinum toxin, cleansers or soaps, a topical
bactericidal (e.g., benzoyl peroxide, triclosan, and/or
chlorhexidine gluconate), topical antibiotics (e.g., externally-applied
erythromycin, clindamycin, tetracycline, etc.), oral antibiotics (e.g.,
erythromycin, tetracycline, oxytetracycline, doxycycline, minocycline,.
. . treatments (e.g., estrogen/progestogen oral contraceptives, low
dose spironolactone, cortisone, etc.), a keratolytic (i.e., a substance
that dissolves keratin plugging pores), benzoyl peroxide, a topical
retinoid (e.g., tretinoin [RETIN-A], adapalene [DIFFERIN], and
tazarotene [TAZORAC], retinol, isotretinoin, etc.), oral retinoids
(e.g., isotretinoin [ACCUTANE, AMNESTEEM.TM., SOTRET.TM.,
CLARAVIS.TM.]), retinoic acids, a natural product with anti-acne
activity (e.g., aloe vera, aruna, haldi [i.e., turmeric], papaya, etc.),
azelaic acid (brand names AZELEX.TM., FINACEA, FINEVIN,
SKINOREN, etc.), anti-inflammatory agents (e.g., naproxen, ibuprofen,
rofecoxib, etc.), nicotinamide (i.e., vitamin B3), tea tree oil
(melaleuca oil), aminolevulinic acid, azithromycin,
methylaminolevuninate, nadifloxacine, PRK124, talarozole, zileuton,
rofecoxib, zinc, an agent described in Krowchuk (2000, Pediatric. . .
DETD . . . disorders, or conditions include, but are not limited to, a
condition associated with sweat glands or sebaceous glands, such as
acne; hyperhidrosis; unwanted sweating; bromhidrosis; body odor;
chromhidrosis; hair loss; psoriasis; actinic keratosis; dermal
infection; eczematous dermatitis (e.g., atopic dermatitis, etc.);. . .
DETD . . . form of reducing the frequency of that symptom. To give but a
Page 101 of 158

few examples, where the condition in question is acne, symptoms of
that condition are reduced when the (e.g., diameter, volume, etc.)
and/or severity (e.g., redness, inflammatory response, etc.) of. . .
DETD In some embodiments, the present invention provides methods and
compositions for the treatment and/or prevention of one or more of
acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis,
chromhidrosis, rosacea, hair loss, psoriasis, actinic keratosis,
eczematous dermatitis (e.g., atopic dermatitis, etc.), excess. . .
DETD . . . some permanent redness with papules and/or pustules, which
typically last 1 to 4 days. This subtype is commonly confused with
acne. "Phymatous rosacea" is most commonly associated with rhinophyma,
an enlargement of the nose. Symptoms include thickening skin, irregular
surface nodularities,. . .
DETD Acne
DETD In some embodiments, provided compositions are useful for treating
and/or preventing acne vulgaris (commonly referred to as "acne"), a
skin disease caused by changes in the pilosebaceous units (i.e., skin
structures comprising a hair follicle and its associated sebaceous
gland). In some embodiments, acne is inflammatory. In some
embodiments, acne is noninflammatory. While not life-threatening,
acne vulgaris can cause significant problems for affected individuals.
Depending on its severity and other factors, recalcitrant acne can be
psychologically debilitating, and can impose significant financial and
emotional costs on those whom it afflicts. Despite some recent successes
in acne therapy, treatment failures are still common, especially in
adult women. While many adults "outgrow" this disease, there are some
who continue to be afflicted during much of adulthood, despite continued
medical advances. Unfortunately, the most potent acne medication in
current use is administered systemically via a treatment that is
teratogenic, an important issue for many women. There is an unfilled
need for a more localized and effective treatment for acne, one with
minimal side effects.
DETD In general, acne develops as a result of blockages in follicles. The
pathology centers on the pilosebaceous units, comprising a sebaceous
gland, a follicle (i.e., pore), and a vellus hair. Among the first
events leading to acne are hyperkeratinization and formation of a plug
of keratin and sebum (a "microcomedo"), obstructing the upper region of
a follicle.. . . an increase in sebum production occur with increased
androgen production at adrenarche. A microcomedo may enlarge to form an
open comedo (a "blackhead") or closed comedo (a "whitehead"). In
these conditions the naturally occurring largely commensual bacteria
Propionibacterium acnes can cause inflammation, leading to inflammatory
lesions (papules, infected pustules, or nodules) in the dermis around
the microcomedo or comedo, which results in redness and may result in
scarring or hyperpigmentation.
DETD . . . sulfate (DHEAS). Increased androgen levels are thought to cause
sebaceous glands to enlarge and to increase sebum production. While most
acne patients have normal hormone levels, there are reasons to
conclude that increased sebum production plays a role in acne. For
example, there may be a correlation between the rate of sebum production
and the severity of acne. In addition, acne patients typically
produce sebum that is deficient in linoleic acid, which is a potential
cause of abnormal keratinization and follicular. . .
DETD . . . acnes, a relatively slow growing, typically aerotolerant
anaerobic gram positive, diphtheroid bacterium, often colonizes the
sebaceous follicles. P. acnes exacerbates acne by acting as a
chemo-attractant for neutrophils. Neutrophils ingest P. acnes, and in
doing so release various hydrolytic enzymes that. . .
DETD Follicles are lined with squamous epithelium, a layer of cells that is
contiguous with the skin surface. In an acne-prone individual, the
Page 102 of 158

shedding of cells from this lining is often impeded, perhaps due to an
increased level of intercellular adhesion that promotes the retention of
cells. Retained cells can obstruct follicles, resulting in comedones.
Such inhibited shedding may be related to abnormalities in epidermal
differentiation and/or to abnormal sebum composition (e.g., a deficiency
in. . . can irritate keratinocytes, causing the release of
interleukin-1, which in turn can cause follicular hyperkeratinization.
In general, each of these acne-causing routes, which are not mutually
exclusive, is associated with follicular obstruction.
DETD Several factors are known to be linked to acne, including, but not
limited to, family and/or genetic history (see, e.g., Ballanger et al.,
2006, Dermatology, 212:145-149; incorporated herein by. . .
DETD In some embodiments, acne treatments work via one or more of the
following mechanisms: (1) normalizing shedding into the pore to prevent
blockage; (2). . .
DETD The present invention provides methods of treating and/or preventing
acne comprising administration of a provided composition to a subject
suffering from, susceptible to, and/or displaying symptoms of acne. In
some embodiments, such a provided composition is administered locally to
an affected site (e.g., face, neck, back, arms, chest,. . .
DETD In some embodiments, provided compositions for treatment of acne are
formulated into a cream, liniment, lotion, gel, sunscreen, etc.
DETD Exemplary current treatments for acne include, but are not limited to,
botulinum toxin, cleansers or soaps; topical bactericidals (e.g.,
benzoyl peroxide, triclosan, chlorhexidine gluconate, etc.); topical
antibiotics (e.g., externally-applied erythromycin, clindamycin,
tetracycline, etc.); oral antibiotics (e.g., erythromycin, tetracycline,
oxytetracycline, doxycycline, minocycline,. . . ibuprofen, rofecoxib
[Tehrani and Dharmalingam, 2004, Indian J. Dermatol. Venereol. Leprol.,
70:345-348; incorporated herein by reference], etc.); nicotinamide
[vitamin B3]; tea tree oil [melaleuca oil]; rofecoxib; zinc (Dreno
et al., 1989, Acta Derm. Venereol., 69:541-3; and Dreno et al., 2001,
Dermatology, 203:135-40;. . .
DETD Alternative or additional current therapies for the treatment and/or
prevention of acne include, but are not limited to, phototherapy
(e.g., alternating blue and red light); photodynamic therapy (e.g.,
intense blue/violet light); laser. . .
DETD It is known in the art that short-term improvement of acne can be
achieved with sunlight, but studies have shown that sunlight worsens
acne long-term. More recently, visible light has been successfully
employed to treat acne (i.e., "phototherapy")--in particular, intense
violet light (405 nm-420 nm) generated by purpose-built fluorescent
lighting, dichroic bulbs, LEDs, and/or lasers. Used twice weekly, this
has been shown to reduce the number of acne lesions by about 64%
(Kawada et al., 2002, J. Dermatol. Sci., 30:129-35; incorporated herein
by reference) and is even more. . .
DETD . . . some evidence that photodynamic therapy (e.g., therapy with
intense blue/violet light (405 nm-425 nm)) can decrease the number of
inflammatory acne lesion by 60%-70% in 4 weeks of therapy,
particularly when P. acnes is pretreated with delta-aminolevulinic acid
(ALA), which increases. . .
DETD Laser surgery has been in use for some time to reduce the scars left
behind by acne, but research has been done on lasers for prevention of
acne formation itself In general, laser is used to burn away the
follicle sac from which the hair grows, to burn. . .
DETD Local heating therapies are sometimes used, for example, to kill
bacteria in a developing pimple, thereby expediting healing.
DETD In some embodiments, provided compositions for treatment and/or
prevention of acne are formulated into a cream, liniment, lotion, gel,
sunscreen, etc.
Page 103 of 158

prevention of acne are administered locally to an affected site (e.g.,
axillae, hands, feet, face, neck, back, arms, chest, etc.).
DETD . . . the skin. Hyperpigmentation is often due to skin damage due to
sun exposure, medications, and/or inflammation (including inflammation
due to acne vulgaris). Melasma is a condition of dark, irregular
patches of skin found most usually on the upper cheek, nose, lips,. .
.
DETD . . . In certain embodiments, the pharmaceutical pack or kit includes
an additional approved therapeutic agent (e.g., benzoyl peroxide for
treatment of acne; aluminum compounds for treatment of hyperhidrosis;
etc.) for use in combination therapies. Optionally associated with such
container(s) can be a. . .
CLM What is claimed is:
. . . composition, lotion, or pharmaceutical composition is administered
for treatment of a condition or disorder selected from the group
consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis,
body odor, chromhidrosis, excess sebum-producing disorders, seborrhea,
seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections,
viral. . .
. . . wherein the nanoparticle composition, lotion, or pharmaceutical
composition is administered for treatment of hyperhidrosis, unwanted
sweating, bromhidrosis, body odor, chromhidrosis, acne, wrinkles,
headache, or any combination thereof.
Page 104 of 158

TITLE: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND
USES THEREFOR
corporation)
NUMBER KIND DATE

---------------- ------ --------
NUMBER DATE
------------------- --------
AB The present invention describes novel nanoparticle compositions, and systems
and methods utilizing them for treating disorders and/or conditions. Methods
generally involve administering nanoparticle compositions (e.g., nanoparticle
compositions comprising at least one known therapeutic agent and/or
independently active biologically active agent; and/or empty nanoparticle
compositions) to a subject in need thereof.
SUMM . . . known to have a particular biological effect on sebaceous
. . treatments (e.g., estrogen/progesterone oral contraceptives, low
SUMM . . . disorders, or conditions include, but are not limited to, a
SUMM . . . form of reducing the frequency of that symptom. To give but a
Page 105 of 158

DETD Acne
Page 106 of 158

blockage; (2). . .
botulinum toxin; cleansers or soaps; topical bactericidals (e.g.,
Dermatology, 203:135-40;. . .
acne formation itself. In general, laser is used to burn away the
sunscreen, etc.
.
DETD . . . In certain embodiments, the pharmaceutical pack or kit includes
an additional approved therapeutic agent (e.g., benzoyl peroxide for
Page 107 of 158

etc.) for use in combination therapies. Optionally associated with such
container(s) can be a. . .
. . . composition, lotion, or pharmaceutical composition is administered
for treatment of a condition or disorder selected from the group
consisting of acne, hyperhidrosis, unwanted sweating, bromhidrosis,
body odor, chromhidrosis, excess sebum-producing disorders, seborrhea,
seborrheic dermatitis, rosacea, hair loss, psoriasis, dermal infections,
viral. . .
. . . 36, wherein the nanoparticle composition, lotion, or pharmaceutical
composition is administered for treatment of unwanted sweating,
bromhidrosis, body odor, chromhidrosis, acne, wrinkles, headache, or
any combination thereof.
Page 108 of 158

TITLE: NANOPARTICLE COMPOSITIONS AND COMPONENTS THEREOF
corporation)
NUMBER KIND DATE

---------------- ------ --------
NUMBER DATE
------------------- --------
AB The present invention describes systems and methods for treating disorders
and/or conditions associated with the dermal level of the skin. Such disorders
dermal infection, and/or actinic keratosis, among others. Methods generally
involve administering provided compositions to the skin.
AB . . . describes systems and methods for treating disorders and/or
conditions associated with the dermal level of the skin. Such disorders
dermal infection, and/or actinic keratosis, among others. Methods generally
involve administering provided compositions to. . .
SUMM . . . suffer from them. Current treatments are not very successful
and often have undesirable side effects. For example, according to
studies, acne often leads to reduced self esteem, and sometimes even
to depression or suicide (see, e.g., Goodman, 2006, Aust. Fam.
Physician. . .
SUMM . . . glands, sebaceous glands, hair follicles, etc.). Exemplary
conditions or disorders associated with dermal structures include, but
are not limited to, acne, hyperhidrosis, unwanted sweating,
bromhidrosis, body odor, chromhidrosis, rosacea, hair loss, psoriasis,
dermal infection (e.g., herpes simplex virus infection, human
papillomavirus. . .
SUMM . . . invention, provided compositions are useful in various cosmetic
and medical applications. In some embodiments, provided compositions are
utilized to treat acne. In some embodiments, provided compositions are
utilized to treat hyperhidrosis. In some embodiments, provided
compositions are utilized to treat acne. In some embodiments, provided
compositions are utilized to treat unwanted sweating. In some
embodiments, provided compositions are utilized to treat bromhidrosis.
In some embodiments, provided compositions are utilized to treat acne.
In some embodiments, provided compositions are utilized to treat body
odor. In some embodiments, provided compositions are utilized to treat.
. .
SUMM . . . known to have a particular biological effect on sebaceous
. . treatments (e.g., estrogen/progesterone oral contraceptives, low
Page 109 of 158

that condition are reduced when the size (e.g., diameter, volume, etc.)
and/or severity (e.g., redness, inflammatory response, etc.). . .
DETD . . . odor. In some embodiments, the present invention provides
treatments for rosacea. In some embodiments, the present invention
provides treatments for acne. In some embodiments, the present
invention provides treatments for hair loss. In some embodiments, the
present invention provides treatments for. . .
DETD Acne
Page 110 of 158

blockage; (2). . .
Dermatology, 203:135-40;. . .
Page 111 of 158

sunscreen, etc.
.
DETD . . . therapies employed may achieve a desired effect for the same
disorder (for example, an empty nanoparticle composition useful for
treating acne may be administered concurrently with a therapeutic
agent and/or independently active biologically active agent that is also
useful for treating acne), or they may achieve different effects (for
example, an empty nanoparticle composition that is useful for treating
acne may be administered concurrently with a therapeutic agent and/or
independently active biologically active agent that is useful for
alleviating adverse. . .
DETD . . . In some embodiments, the pharmaceutical pack or kit includes an
additional approved therapeutic agent (e.g., benzoyl peroxide for
etc.) for use in combination therapies, as described herein. Optionally
associated with such container(s). . .
DETD . . . or at risk for conditions or disorders associated with the
dermal level of the skin, including, but not limited to, acne,
hyperhidrosis, unwanted sweating, bromhidrosis, body odor,
chromhidrosis, rosacea, hair loss, actinic keratosis, psoriasis,
DETD Exemplary Provided Compositions for Treatment of Acne
DETD Inclusion criteria include a diagnosis of acne.
DETD The clinical investigator wipes a region affected by acne with an
alcohol wipe and then wipe dry with cotton gauze. Using a latex-gloved
finger, the investigator massages the topical. . .
DETD . . . these results, the investigator concludes that topical
treatment using empty nanoemulsions in accordance with the invention is
effective in treating acne.
9. The method of claim 8, wherein the condition or disorder of the
sebaceous glands is acne.
Page 112 of 158

10. The method of claim 9, wherein the step of administering comprises
administering the empty nanoparticle composition so that acne is
reduced or onset is delayed.

. . . of claim 1, wherein the condition or disorder associated with a
dermal structure is selected from the group consisting of acne,
chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic
dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. .
.
. . . of claim 1, wherein the condition or disorder associated with a
dermal structure is selected from the group consisting of acne,
chromhidrosis, excess sebum-producing disorders, seborrhea, seborrheic
dermatitis, rosacea, hair loss, psoriasis, dermal infections, viral. .
.
77. The method of claim 75, wherein the condition or disorder is acne,
hyperhidrosis, bromhidrosis, unwanted sweating, body odor, hair loss, or
any combination thereof.

. . . wherein the step of administering comprises administering the at
least one isolated component of an empty nanoparticle composition so
that acne one or more symptoms is reduced or onset is delayed.
Page 113 of 158

TITLE: SURFACTANT COMPOSITIONS
corporation)
NUMBER KIND DATE

---------------- ------ --------
NUMBER DATE
------------------- --------
AB The present invention provides surfactant compositions and associated methods
and reagents, particularly useful for the treatment of dermatologic
conditions. In some embodiments, provided compositions are formulated for and
achieve transdermal delivery, for example by topical administration.
SUMM . . . surprising discovery, the present invention provides a teaching
that certain surfactant agents are useful in the treatment and/or
prevention of acne. In a still further surprising discovery, the
present invention provides a teaching that certain surfactant agents are
useful in the. . .
DETD Acne
Page 114 of 158

blockage; (2). . .
Page 115 of 158

Dermatology, 203:135-40;. . .
sunscreen, etc.
.
. . . susceptible to hyperhidrosis; suffering from or susceptible to
chromhidrosis; suffering from or susceptible to bromhidrosis; suffering
from or susceptible to acne; suffering from or susceptible to
seborrhea; suffering from or susceptible to psoriasis; suffering from or
susceptible to body odor; or. . .
. . . The method of claim 14, wherein the active component further includes
one or more additional active agents for treatment of acne, unwanted
sweating, hyperhidrosis, body odor, bromhidrosis, chromhidrosis,
rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis,
excess sebum-producing disorders, burns, Raynaud's. . .
30. The method of claim 14, wherein the active component further
includes an anti-acne agent selected from the group consisting of a
topical bactericidal, a topical antibiotic, a topical retinoid, and
combinations thereof.
Page 116 of 158

TITLE: PARABEN COMPOSITIONS
corporation)
NUMBER KIND DATE

---------------- ------ --------
NUMBER DATE
------------------- --------
AB The present invention provides paraben compositions and associated methods and
reagents, particularly useful for the treatment of dermatologic conditions. In
some embodiments, provided compositions are formulated for and achieve
transdermal delivery, for example by topical administration.
SUMM . . . surprising discovery, the present invention provides a teaching
that certain paraben agents are useful in the treatment and/or
prevention of acne. In a still further surprising discovery, the
present invention provides a teaching that certain paraben agents are
useful in the. . .
DETD Acne
Page 117 of 158

blockage; (2). . .
Page 118 of 158

Dermatology, 203:135-40;. . .
acne formation itself In general, laser is used to burn away the
sunscreen, etc.
.
. . . susceptible to hyperhidrosis; suffering from or susceptible to
chromhidrosis; suffering from or susceptible to bromhidrosis; suffering
from or susceptible to acne; suffering from or susceptible to
seborrhea; suffering from or susceptible to psoriasis; suffering from or
susceptible to body odor; or. . .
. . . The method of claim 14, wherein the active component further includes
one or more additional active agents for treatment of acne, unwanted
sweating, hyperhidrosis, body odor, bromhidrosis, chromhidrosis,
rosacea, hair loss, psoriasis, actinic keratosis, eczematous dermatitis,
excess sebum-producing disorders, burns, Raynaud's. . .
30. The method of claim 14, wherein the active component further
includes an anti-acne agent selected from the group consisting of a
topical bactericidal, a topical antibiotic, a topical retinoid, and
combinations thereof.
Page 119 of 158

TITLE: REVERSELY THERMO-REVERSIBLE HYDROGEL COMPOSITIONS
INVENTOR(S): Lu, Shao Xiang, Shanghai, CHINA
Lu, Jeffrey, Shanghai, CHINA
Liu, Letian, Shanghai, CHINA
PATENT ASSIGNEE(S): Broda Technologies Co., Ltd., Shanghai, CHINA (non-U.S.
corporation)
NUMBER KIND DATE

---------------- ------ --------
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2011-CN462, filed on 21 Mar
2011, PENDING
AB A reversely thermo-reversible hydrogel composition comprising a water soluble
block copolymer comprising at least two blocks of polyethylene oxide and at
least one block of polypropylene oxide, and at least one associative gelling
adjuvant having water solubility less than 0.5 g/100 ml, preferably less than
0.3 g/100 ml at 20 C., and being capable of forming water soluble inter-
molecular complexes with the water soluble block copolymer in water. The
hydrogel composition exhibits improved gelling efficiency, enhanced solubility
and/or stability for water sparely soluble and insoluble pharmaceutical
agents. The hydrogel compositions are useful in a variety of pharmaceutical
and cosmetic products and applications, such as esophageal, otic, vaginal,
rectal, ophthalmic, treatments of disorders and imperfections of the skin, and
treating and/or preventing alopecia and restoring and/or promoting hair
growth.
SUMM . . . active ingredients in such aqueous liquid solutions. For
example, the use of Salicylic acid or its derivatives for treating
dandruff, acne, skin wrinkling, skin pigmentation, warts, freckles, or
skin-related problems is well known in the preparation of dermatologic
and cosmetic formulations.. . .
DETD . . . stabilize sparely soluble or insoluble active ingredients. For
example, the use of Salicylic acid or its derivatives for treating
dandruff, acne, skin wrinkling, skin pigmentation, warts, freckles, or
skin-related problems is well known in the preparation of dermatologic
and cosmetic formulations.. . .
DETD . . . Botulinum toxin, interferon, substance P enkephalins, epidermal
growth factor, eyederived growth factor, fibronectin, insulin-like
growth factor and mesodermal growth factor;
(17) Acne treatment agents, such as salicylic acid and its derivatives,
sulfur, lactic acid, glycolic, pyruvic acid, azelaic acid, benzoyl
peroxide, urea,. . .
DETD . . . composition of cosmetic active ingredients. The cosmetic may be
skincare products such as facial hydrogel, hands and foot care
hydrogels; acne treatment hydrogel, shaving hydrogel, cleansing
hydrogel; antiperspirant; hair remover hydrogel, tooth whitening
hydrogel, color makeup products such as makeup base,. . .
DETD . . . compositions of the present invention can be essential oils,
moisture retention agents, skin-beautifying agents, sun screen,
antiperspirants, vitamins, amino acids, anti-acne agents, antiseptics
or antibacterial agents, zinc salts, tooth whitening agents, depilatory
agents, fragrance oils, insect repellants, antioxidants, chelating
agents, refrigerants,. . . or the nucleic acids include
deoxyribonucleic acid; and examples of the hormones include estradiol
and ethenyl estradiol, and the like;
(8) Anti-acne agents, such as salicylic acid and its derivatives, sulfur,
lactic acid, glycolic, pyruvic acid, azelaic acid, benzoyl peroxide,
urea, tea tree oil, resorcinol and N-acetylcysteine, and retinoids,
Page 120 of 158

such as retinoic acid, and its derivatives, and the like;
(9) Antiseptics or antibacterial agents. . .
DETD The following ACNE treatment hydrogel compositions are prepared:
. . . agents, amoebacidal compounds, trichomonacidal agents, analgesics,
anti-arthritics, anti-asthmatics, anti-coagulants, anti-convulsants,
anti-depressants, anti-diabetics, anti-neoplastics, anti-psychotics,
anti-hypertensive agents, muscle relaxants, proteins, peptides, acne
treatment agents, lubricating agents, and mixtures thereof.

29. The composition of claim 20, comprising an acne treatment
pharmaceutical hydrogel composition.

30. The composition of claim 29, wherein the acne treatment
pharmaceutical hydrogel composition comprising at least one acne
treatment agent is selected from the group consisting of salicylic acid
or its derivatives, sulfur, lactic acid, glycolic acid, pyruvic acid,
azelaic acid, benzoyl peroxide, urea, resorcinol, N-acetylcysteine,
retinoids and their derivatives, and mixtures thereof.

31. The composition of claim 30, wherein the acne treatment agent is
salicylic acid, or its derivatives.

32. The composition of claim 29, wherein the acne treatment
pharmaceutical hydrogel comprising an alcohol-free composition.

. . . is selected from the group consisting of essential oils, moisture
retention agents, skin-beautifying agents, sun screens, antiperspirants,
vitamins, amino acids, anti-acne agents, antiseptics, antibacterial
agents, zinc salts, tooth whitening agents, depilatory agents, fragrance
oils, insect repellants, antioxidants, chelating agents, refrigerants,
anti-inflammatory. . .
. . . tooth whitening, antiseptic and antibacterial, depilatory,
antiperspirant or deodorant, insect repellant, perfume, sunscreen, baby
diaper rash, shaving, hair coloring, and anti-acne cosmetic hydrogel
compositions.

59. The composition of claim 53, wherein the at least one cosmetic
active ingredient is an anti-acne agent selected from the group
consisting of salicylic acid and its derivatives, sulfur, lactic acid,
glycolic acid, pyruvic acid, azelaic acid, benzoyl peroxide, urea,
tea tree oil, resorcinol and N-acetylcysteine, retinoids and their
derivatives, and mixtures thereof.

60. The composition of claim 59, wherein the anti-acne agent (s) is
salicylic acid or its derivatives.
Page 121 of 158

TITLE: HIGH LOAD DISPERSIONS
INVENTOR(S): Supamahitorn, Jai, Buffalo, NY, UNITED STATES
McMillan, Lauren, Hamburg, NY, UNITED STATES
PATENT ASSIGNEE(S): AUSTIN RESEARCH LABS CORP., Buffalo, NY, UNITED STATES
(U.S. corporation)
NUMBER KIND DATE

---------------- ------ --------
NUMBER DATE
------------------- --------
AB The present invention relates to the field of carrier and delivery systems for
active molecular compounds. In particular, the present invention provides
aqueous dispersions for delivery of active molecular compounds.
SUMM . . . the present invention in the preparation of a medicament for
treating one or more conditions including, but not limited to: acne,
infection, wound infection, etc.
DETD Embodiments of the present invention provide ointments, creams, lotions,
gels, and or liquids for the topical treatment of acne in a subject.
Such compositions find use in treatment of acne in infants, children,
adolescents, teenagers, and/or adults would suffer from various forms of
acne. In some embodiments, acne-treatment compositions find use in
treating and/or killing Propionibacterium acnes, Staphylococcus aureus,
etc. In some embodiments, the active agent in acne treatment
compositions include, but are not limited to: benzethonium chloride,
hydrophobically modified salicylate, salicylic acid, benzoyl
peroxide, acetone, tea tree oil, isotretinoin (for rosasea, cystic
acne), allantoin.
DETD . . . anti-itch treatment. Active agents in anti-itch treatment
compositions include, but are not limited to: benzethonium chloride,
isotretinoin (for rosasea, cystic acne), clotrimazole, steroids
(corticosteroid), hydrocortisone, allantoin, econasole nitrate, etc.
Page 122 of 158

L56 ANSWER 132 OF 199 PCTFULL COPYRIGHT 2013 LNU on STN
ACCESSION NUMBER: 2012177986 PCTFULL Full-text
ENTRY DATE: 20121231
TITLE (ENGLISH): CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
TITLE (FRENCH): PROMEDICAMENTS ANTIFONGIQUES ET ANTIBACTERIENS A BASE
D'UN CONJUGUE
INVENTOR(S): BAPAT, Abhijit S., C-5/128, Milan Vihar, 72 I.P.
Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES:
IN], for US only
MAHESH, Gauthami, 5-C, Sanchar Lok, Near Max Hospital,
Patparganj, East Delhi 110092, IN, [NAT: IN, RES: IN],
for US only
GOKHALE, Rajesh S., Director's Bunglow, Type VI-I, CRRI
Colony, C.V. Raman Marg, Maharani Bagh, New Delhi
110065, IN, [NAT: IN, RES: IN], for US only
SHAH, Sayali S., 5-C, Sanchar Lok, Near Max Hospital,
for US only
SENGUPTA, Shiladitya, 606 South Street, Apt. #C,
Waltham, Massachusetts 02453, US, [NAT: IN, RES: US],
for US only
PRASAD, Sudhanand, A/204, Eldeco Appartments, Sector 4,
Vaishali, Ghaziabad, Uttar Pradesh 201010, IN, [NAT:
IN, RES: IN], for US only
GHOSH, Sumana, Ashoka Enclave, Dwarka Sector-11, Plot
No-8A, Flat No. 2703, New Delhi 110065, IN, [NAT: IN,
RES: IN], for US only
CHAWRAI, Suresh R., 66, Vidhi Appartments, Plot No.
116, I.P. Extension, Patparganj, Delhi 110092, IN,
[NAT: IN, RES: IN], for US only
ARORA, Nidhi, G-1, Mansarover Garden (Ground Floor),
New Delhi 110015, IN, [NAT: CA, RES: IN], for US only
REDDY, D. Sreedhar, Ramachandrapuram, Nelakondapally
(MD), Khammam (Dt), Andhra Pradesh 507160, IN, [NAT:
MISHRA, Mallika, SF 66, Vardan Apartment, Abhaykhand 3,
Module 19 & 20, Indirapuram, Ghaziabad 201014, IN,
BAJAJ, Kirti, H. No. 1135, Ward No. 9, Mandi Dabwali,
Sirsa, Haryana 125104, IN, [NAT: IN, RES: IN], for US
only
PATENT APPLICANT(S): VYOME BIOSCIENCES, Plot No. 459 F.I.E., 1st Floor,
Patparganj Industrial Area, Delhi 110092, IN, [NAT: IN,
RES: IN], for all designated states except US
BAPAT, Abhijit S., C-5/128, Milan Vihar, 72 I.P.
Extension, Patparganj, Delhi 110092, IN, [NAT: IN, RES:
IN], for US only
MAHESH, Gauthami, 5-C, Sanchar Lok, Near Max Hospital,
for US only
GOKHALE, Rajesh S., Director's Bunglow, Type VI-I, CRRI
Colony, C.V. Raman Marg, Maharani Bagh, New Delhi
110065, IN, [NAT: IN, RES: IN], for US only
SHAH, Sayali S., 5-C, Sanchar Lok, Near Max Hospital,
for US only
SENGUPTA, Shiladitya, 606 South Street, Apt. #C,
Waltham, Massachusetts 02453, US, [NAT: IN, RES: US],
for US only
PRASAD, Sudhanand, A/204, Eldeco Appartments, Sector 4,
Page 123 of 158

Vaishali, Ghaziabad, Uttar Pradesh 201010, IN, [NAT:
GHOSH, Sumana, Ashoka Enclave, Dwarka Sector-11, Plot
No-8A, Flat No. 2703, New Delhi 110065, IN, [NAT: IN,
RES: IN], for US only
CHAWRAI, Suresh R., 66, Vidhi Appartments, Plot No.
116, I.P. Extension, Patparganj, Delhi 110092, IN,
ARORA, Nidhi, G-1, Mansarover Garden (Ground Floor),
New Delhi 110015, IN, [NAT: CA, RES: IN], for US only
REDDY, D. Sreedhar, Ramachandrapuram, Nelakondapally
(MD), Khammam (Dt), Andhra Pradesh 507160, IN, [NAT:
MISHRA, Mallika, SF 66, Vardan Apartment, Abhaykhand 3,
Module 19 & 20, Indirapuram, Ghaziabad 201014, IN,
BAJAJ, Kirti, H. No. 1135, Ward No. 9, Mandi Dabwali,
Sirsa, Haryana 125104, IN, [NAT: IN, RES: IN], for US
only
PATENT INFORMATION: WO 2012177986 A2 20121227
APPLICATION INFO.: WO 2012-US43717 20120622
PRIORITY INFO.: IN 2011-DE1770 20110622
US 2011-61514305 20110802
ABEN
The invention provides conjugate-based antifungal or antibacterial prodrugs
formed by coupling at least one antifungal agent or antibacterial agent with at
least one linker and/or carrier. The prodrugs are of formula: (i) (AFA)m-X-(L)n;
(ii) [(AFA)m'-X]p-L; (iii) AFA-[X-(L)n']q; or (iv) (AFA)m"-X, wherein: AFA is an
antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m
ranges from 1 to 10; n ranges from 2 to 10; m' is 1 to 10; p is 1 to 10; n' is 1
to 10; and q is 1 to 10, provided that q' and n are not both 1; and m" is 1 to
10. The invention also provides nonaprticels comprising the conjugate-based
prodrugs. Additonoally, the invention also provides non-conjugated antifungal
and antibacterial agents in the form of nanoparticles.
ABFR
La presente invention concerne des promedicaments antifongiques ou
antibacteriens a base d'un conjugue obtenus par couplage d'au moins un agent
antifongique ou antibacterien avec au moins une sequence de liaison et/ou un
support. Lesdits promedicaments sont de formule (i) (AFA)m-X-(L)n ; (ii)
[(AFA)m'-X]p-L ; (iii) AFA-[X-(L)n']q ; ou (iv) (AFA)m -X. Dans
lesdites formules, AFA represente un agent antifongique ou antibacterien ; L
represente un support ; X represente une sequence de liaison ; m varie de 1 a
10 ; n varie de 2 a 10 ; m' est egal a 1 a 10 ; p est egal a 1 a 10 ; n' est
egal a 1 a 10 ; et q est egal a 1 a 10, sous reserve que q' et n ne soient
pas tous deux egaux a 1 ; et m est egal a 1 a 10. La presente
invention concerne egalement des nanoparticules contenant lesdits
promedicaments a base d'un conjugue. En outre, l'invention concerne egalement
des agents antifongiques et antibacteriens non-conjugues se presentant sous
la forme de nanoparticules.
DETDEN
[0016] In yet another aspect, the invention provides a method for treating or
preventing acne comprising applying a personal care compositions described
herein to the skin of a subject in need thereof.
DETDEN . . .
to treat or prevent dandruff. Compositions described herein can also be used
in skin care compositions to treat or prevent acne. In some embodiments,
Page 124 of 158

the composition described herein can be used to treat a fugal or bacterial
infection. For example, the. . .
DETDEN
[0074] In some embodiments, the antibacterial agent is an antiacne agent.
As used herein, the term "antiacne agent" refers to any chemical that is
effective in the treatment of acne and/or the symptoms associated
therewith. Antiacne agents are well known in the art such as U.S. Pat. App.
Pub. No. 2006/ 0008538 and U.S. Pat. No. 5,607,980, content of both of which
is incorporated herein by reference. Examples of useful antiacne agents
include, but are not limited to keratolyses, such as salicylic acid,
derivatives of salicylic acid, and resorcinol; retinoids, such. . .
tretinoin, adapalene, tazarotene; sulfur-containing D- and L-amino acids and
their derivatives and salts; lipoic acid; antibiotics and antimicrobials,
such as benzoyl peroxide, triclosan, chlorhexidine gluconate, octopirox,
tetracycline, 2,4,4'-trichloro-2'-hydroxy diphenyl ether,
3,4,4'-trichlorobanilide, nicotinamide, tea tree oil, rofecoxib, azelaic
acid and its derivatives, phenoxyethanol,
DETDEN
[0075] Additionally, the antiacne agent may be an antimicrobial peptide
having activity against P. acnes. Antimicrobial peptides are ubiquitous in
nature and play an. . .
DETDEN
[00122] Beta hydroxyl acid (BHA) is oil-soluble. Accordingly, BHA works very
well in clearing up whiteheads and blackheads by penetrating inside pores
that are clogged with sebum and a buildup of dead cells. BHA is a powerful
exfoliant. . .
DETDEN . . .
new ones. It keeps the pores of the skin clear, hence minimizes clogging and
actively breaks down all forms of acne. Salicylic acid loosens dry and
damaged skin patches by softening epidermal protein- keratin. It remains on
the skin surface long. . .
DETDEN . . .
peel and shed, revealing new and smoother skin underneath. It is effective in
clearing skin problems such as eczema, psoriasis, acne, and age spots; and
helps stimulate collagen growth in the cells. One major side effect of AHA is
increase in. . .
DETDEN . . .
be incorporated into the compositions include those that improve or eradicate
age spots, keratoses and wrinkles; local analgesics and anesthetics;
antiacne agents; antibacterials; antiyeast agents; antifungal agents;
antiviral agents; antidandruff agents; antidermatitis agents; antihistamine
agents; antipruritic agents; antiemetics;
DETDEN . . .
or salicylic acid. Triclosan can act as a protective agent that increases the
longetivity and effectiveness of other treatments of acne.
DETDEN . . .
peel and shed, revealing new and smoother skin underneath. It is effective in
clearing skin problems such as eczema, psoriasis, acne, and age spots; and
helps stimulate collagen growth in the cells. One major side effect of AHA is
increase in. . .
DETDEN
Page 125 of 158

[00148] Beta hydroxyl acid (BHA) is oil-soluble. Accordingly, BHA works very
well in clearing up whiteheads and blackheads by penetrating inside pores
that are clogged with sebum and a buildup of dead cells. BHA is a powerful
exfoliant. . .
DETDEN . . .
new ones. It keeps the pores of the skin clear, hence minimizes clogging and
actively breaks down all forms of acne. Salicylic acid loosens dry and
damaged skin patches by softening epidermal protein- keratin. It remains on
the skin surface long. . .
DETDEN . . .
It has both exfoliating and anti-inflammatory effects. It is possibly more
effective than tretinoin 0.025% gel in the treatment of acne.
DETDEN . . .
embodiments, the personal care composition is a skin care composition. A skin
care composition can be used to or prevent acne. Skin care compositions are
herein defined as compositions for the treatment of skin including, but not
limited to, skin conditioners,. . .
DETDEN . . .
as alpha-hydroxy acids and beta-hydroxy acids), and sunless tanning agents.
Examples of common raw materials and suitable adjuvants for an acne
treatment composition are described by Beumer et al. supra and Robinson et
al., supra.
DETDEN
[00228] In another aspect, a method is provided for treating or preventing
acne, the method comprising applying a skin care composition described
herein to the skin of subject in need thereof. After application,. . .
DETDEN
[00234] In some embodiments, the subject needs treatment for dandruff and/or
acne.
DETDEN
[00236] A subject can be one who is currently being treated for dandruff ,
acne, oral or vaginal candidiasis, ringworm (tinea infections of the body,
scalp, beard, jock itch, athlete's foot), nail infection, or ear. . .
DETDEN
[00238] In some embodiments of the aspects described herein, the method
further comprising diagnosing a subject for dandruff, acne, oral or vaginal
candidiasis, ringworm (tinea infections of the body, scalp, beard, jock itch,
athlete's foot), nail infection, or ear. . .
DETDEN
The conjugate-based prodrug of any of paragraphs 1-17, wherein the
antibacterial agent is effective against P. acne.
DETDEN . . .
selected from the group consisting of those that improve or eradicate age
spots, keratoses and wrinkles; local analgesics and anesthetics; antiacne
agents; antibacterials; antiyeast agents; antifungal agents; antiviral
agents; antidandruff agents; antidermatitis agents; antihistamine agents;
antipruritic agents; antiemetics; antimotionsickness agents;
antiinflammatory. . .
DETDEN
Page 126 of 158

49. A method for treating or preventing acne in a subject, the method
comprising the step of applying a composition of any of paragraph 41-46 or 48
to. . .
DETDEN
[00386] Minimum Inhibitory Concentration (MIC): MIC is an index which
measures the anti-acne efficacy. Generally, lower the MIC values of the
composition higher its antibacterial efficacy, because of its inherent
ability to inhibit. . .
CLMEN
The conjugate-based prodrug of any of claims 1 -17, wherein the antibacterial
agent is effective against P. acne.
CLMEN. . .
selected from the group consisting of those that improve or eradicate age
spots, keratoses and wrinkles; local analgesics and anesthetics; antiacne
agents; antibacterials; antiyeast agents; antifungal agents; antiviral
agents; antidandruff agents; antidermatitis agents; antihistamine agents;
antipruritic agents; antiemetics; antimotionsickness agents;
antiinflammatory. . .
CLMEN
49. A method for treating or preventing acne in a subject, the method
comprising the step of applying a composition of any of claim 41-46 or 48 to.
. .
Page 127 of 158

TITLE (ENGLISH): TOPICAL COMPOSITIONS FOR THE TREATMENT OF
DERMATOLOGICAL DISORDERS
TITLE (FRENCH): COMPOSITIONS TOPIQUES DESTINEES AU TRAITEMENT DE
TROUBLES DERMATOLOGIQUES
INVENTOR(S): WEINBERGER, Gary, I., 1975 Dodge Road, East Amherst, NY
14051, US, [NAT: US, RES: US], for US only
NAGEL, H., Robert, 21 Park Avenue, Newton, MA 02458,
US, [NAT: US, RES: US], for US only
BROWN, Richard, A., 2547 Lower Lando Lane, Park City,
UT 84098, US, [NAT: US, RES: US], for US only
PATENT APPLICANT(S): EVOLOGIE LLC, 21 Park Avenue, Newton, MA 02458, US,
[NAT: US, RES: US], for all designated states except US
WEINBERGER, Gary, I., 1975 Dodge Road, East Amherst, NY
14051, US, [NAT: US, RES: US], for US only
NAGEL, H., Robert, 21 Park Avenue, Newton, MA 02458,
US, [NAT: US, RES: US], for US only
BROWN, Richard, A., 2547 Lower Lando Lane, Park City,
UT 84098, US, [NAT: US, RES: US], for US only
PRIORITY INFO.: US 2011-61499523 20110621
ABEN
The present invention relates to pharmaceutical compositions and methods useful
for the treatment of dermatological disorders, and in particular acne vulgaris
and skin pigmentation disorders. Pharmaceutical compositions comprising one or
more arginine, salicylic acid and/or azelaic acid that are useful for the
treatment of dermatological diseases and the symptoms and underlying causes of
such dermatological diseases are also disclosed.
ABFR
La presente invention concerne des compositions pharmaceutiques et des
procedes utiles dans le traitement de troubles dermatologiques, et en
particulier de l'acne simple et des troubles de pigmentation de la peau. La
presente invention concerne des compositions pharmaceutiques comprenant de
l'arginine et/ou de l'acide salicylique et/ou de l'acide azelaique, utiles
dans le traitement de maladies dermatologiques et des symptomes et causes
sous-jacentes de ces maladies dermatologiques.
ABEN
The present invention relates to pharmaceutical compositions and methods useful
for the treatment of dermatological disorders, and in particular acne vulgaris
and skin pigmentation disorders. Pharmaceutical compositions comprising one or
more arginine, salicylic acid and/or azelaic acid that are useful. . .
ABFR. . .
presente invention concerne des compositions pharmaceutiques et des procedes
utiles dans le traitement de troubles dermatologiques, et en particulier de
l'acne simple et des troubles de pigmentation de la peau. La presente
invention concerne des compositions pharmaceutiques comprenant de l'arginine
et/ou. . .
DETDEN . . .
or more of arginine, salicylic acid and/or azelaic acid and are useful for
the treatment of dermatological disorders, such as acne vulgaris and skin
pigmentation disorders.
Page 128 of 158

DETDEN . . .
dermatological disorders often associated with the production or over
production of sebum are well known. One such dermatological disorder includes
acne vulgaris (acne), which is the most common dermatological disorder
treated by physicians. It is estimated that as many as 32 million Americans
exhibit some form of unwanted acne. Acne affects more than eighty-five
percent of teenagers, and although acne most commonly occurs during
adolescence, the condition may commonly continue into adulthood. (William,
J., N Engl J Med, (2005) 352:. . .
DETDEN
Acne is an inflammatory dermatological disorder affecting the pilosebaceous
units of affected subjects. Acne is cause by bacteria that infects the hair
follicles, which in turn leads to the formation of comedones composed of
sebum, keratin and further proliferation of microorganisms, which include for
example, Propionibacierium acnes (P. acnes or P. acneis).. . . is further
believed that P, acnes plays a role in the digestion of the sebum and keratin
present in the comedones into inflammatory by-products which are
responsible for further irritating the affected hair follicle, thereby
resulting in further inflammation, the formation. . .
DETDEN
In many affected subjects, acne scarring and/or post-inflammatory
hyperpigmentation (PIH) occurs as a result of inflammation of the
pilo-sebaceous unit (PSU), and in some cases. . . by PIH generally present
with irregular, darkly-pigmented spots occurring after inflammation due to a
skin insult such as, for example acne. In some individuals PIH may resolve
slowly but may persist for months. (Kenney, J., et al, Clinics in Dermatology
(1989). . .
DETDEN
The complications of acne are not limited to the skin of affected subjects.
The physical symptoms of acne may contribute to the development of
emotional and psychological distress, depression, anxiety and increased risks
of suicide. {See, e.g., Kilkenny. . . Paediat Child Health, (2006)
42:793-796.) The emotional distress which is caused by, or is otherwise
aggravated by, the symptoms of acne may be particularly troublesome for
adolescent subjects.
DETDEN
Various topical agents are utilized in the treatment of acne and these
include sulfur, resorcinol, salicylic acid, benzoyl peroxide, retinoids and
topical antibiotics. For example, commercially available topical
treatments include. . .
DETDEN
Systemically available treatments have also been used to treat acne,
including, for example tetracycline antibiotics such as minocycline.
Generally, subjects are prescribed an extended course of antibiotic therapy
and despite. . .
DETDEN
Oral retinoids, such as isotretinoin, may also be effective; however their
use is generally reserved for severe cases of acne due to the association
of serious side effects, which may include teratogenicity, depression and
suicidal ideation. Many of the available acne treatments are expensive and
may cause considerable adverse effects. Furthermore, some medications may
require continuous therapy and/or subjects may not. . .
DETDEN
Page 129 of 158

Novel and effective therapies are needed for the treatment of acne, and in
particular novel topical therapies that improve symptoms in a safe, rapid and
effective manner are needed. There is. . .
DETDEN . . .
compositions, as well as methods for treating subjects afflicted with or
otherwise affected by one or more dermatological disorders (e.g., acne
vulgaris and/or post-inflammatory hyperpigmentation (1E)). The
pharmaceutical compositions disclosed herein may be topically administered to
a subject and are generally. . .
DETDEN . . .
more dermatological disorders. Dermatological disorders for which the
pharmaceutical compositions disclosed herein may be used to treat include,
for example, acne, PIH, rosacea, dyspigmentation, uneven skin tones and
melasma. The pharmaceutical composition may be administered to the subject at
least once. . .
DETDEN . . .
upon application to a subject the pharmaceutical compositions disclosed
herein are preferably capable of improving the signs and symptoms of acne
(e.g., reduce excessive sebum production and/or reduce hyperpigmentation
caused by acne scarring). Accordingly, one aspect of the present inventions
relates to methods of treating one or more dermatological disorders,
including, but not limited to acne and PIH. For example, in one embodiment
the present invention relates to a method of treating a subject with a. . .
of azelaic acid, salicylic acid and arginine to a subject. The dermatological
disorders to be treated may include, for example, acne and/or PIH. In one
embodiment of the present invention, the treated subject is an adolescent or
an adult. In one. . .
DETDEN . . .
one embodiment of the present invention the signs and symptoms of the
dermatological disorders (e.g., sebum production, the presence of acne
lesions, inflammation, and/or scarring) improve or are otherwise resolved
following the administration of the pharmaceutical compositions of the
present invention. . .
DETDEN . . .
relates to novel pharmaceutical compositions and related methods of use for
the treatment of dermatological disorders, which include, for example, acne
vulgaris, acne rosacea and dermatological pigmentation disorders such as
post-inflammatory hyperpigmentation (P1H) and melasma. Such pharmaceutical
compositions are generally stable and comprise. . .
DETDEN . . .
other components of the pharmaceutical composition (e.g.,
therapeutically-active agents) into the skin of an affected subject (e.g., a
subject with acne). In some embodiments, the inclusion of one or more
arginine compounds in the pharmaceutical compositions of the present
invention may. . .
DETDEN . . .
in the amount of one or more therapeutically-active agents necessary to
achieve one or more clinical endpoints (e.g., resolution of acne symptoms
or reduced pigmentation). In one embodiment, the synergy demonstrated by the
pharmaceutical compositions of the present invention enable a. . .
DETDEN . . .
relates to the ability of one or more therapeutic compounds or agents to
Page 130 of 158

improve the objective signs and symptoms of acne (e.g., a statistically
significant reduction in mean inflammatory lesion count, erythema severity,
pigmentation, acne scarring and/or sebum production). In other embodiments
of the present invention, therapeutic activity relates to a subject's
subjective perception regarding. . .
DETDEN . . .
acids. Azelaic acid is known for its anti-bacterial and comedolytic
properties and has been used clinically for the treatment of acne and
hyperpigmentation disorders. (Fitton, A., et al, Drugs (1991 ) 41 (5):
180-798.) Generally, azelaic acid is an effective and well-tolerated
monotherapy in mild and moderate forms of acne and is comparable in its
efficacy to other topical acne treatments, such as benzoyl peroxide. (Liu,
R., et al, Arch. Dermatol. (2006) 142(8): 1047-1052.) Azelaic acid also
inhibits the growth. . .
DETDEN . . .
disorder" refers to any disease or condition of the skin, dermis, or any
substructure therein. Dermatological disorders include, for example, acne
vulgaris, pigmentation disorders such as post-inflammatory hyperpigmentation,
dyspigmentation, melasma, uneven skin tone, or hyperpigmentation or dark
spots resulting from aging or exposure to sunlight or ultraviolet radiation,
acne rosacea, xeroderma, psoriasis, ectopic dermatitis, skin cancers, and
any other disease or condition affecting the skin, dermis or structures
therein.. . . by topically administering such compositions to a subject
affected by such dermatological disorder. In certain embodiments, the
dermatological disorder is acne vulgaris. Acne vulgaris is a
dermatological disorder resulting from the action of hormones and other
substances on a subject's sebaceous glands and hair follicles, which result
in plugged pores and outbreaks of lesions commonly referred to as pimples.
Acne is frequently referred to as a disease of the pilosebaceous units
(PSU), which are found over most of the body.. . . each PSU consists of a
sebaceous gland connected to a canal, called a follicle that contains a fine
hair. Although acne is generally not viewed as a serious health threat, it
can be a source of significant emotional distress and in. . .
DETDEN
Subjects affected by acne frequently present with a variety of topical
lesions. The basic acne lesion, called the comedone, is simply an
enlarged and plugged hair follicle. If the plugged follicle, or comedone,
stays beneath the skin, it is referred to as a closed comedone and produces
a white bump referred to as a whitehead. A comedone that reaches the
surface of the skin and opens up is referred to as an open comedone or
blackhead because it looks black on the skin's surface.
DETDEN
hyperpigmentation caused by acne scarring). In another embodiment, the
present invention relates to the treatment of a subject with, for example,
acne by topically administering on a regular basis (e.g., once daily) a
topical pharmaceutical composition to the affected area of the. . .
DETDEN
Preferably, a therapeutically effective amount is sufficient to significantly
and positively modify the condition to be treated (e.g., acne) while
minimizing or avoiding serious adverse effects.
DETDEN . . .
lycopene). In some embodiments, the pharmaceutical compositions disclosed
herein may also comprise one or more antibacterial agents (e.g., azelaic
acid, benzoyl peroxide and/or tea tree oil).
Page 131 of 158

DETDEN . . .
of a pharmaceutical composition in the form of a serum and that is useful for
the treatment of, for example, acne.
DETDEN
Approximately l OOg of acne serum was produced comprising a tripartite
complex of azelaic acid, salicylic acid and arginine. Following exposure to
freeze/thaw cycling at. . .
DETDEN
A total of 60 subjects with acne vulgaris participated in a clinical trial
designed to demonstrate the safety and efficacy of the pharmaceutical
compositions of the present. . .
DETDEN
In addition to a reduction in the presence of acne lesions,
hyperpigmentation and acne scarring was also observed. No serious adverse
reactions were observed or otherwise reported to the investigators during the
investigation. The foregoing therefore provides that the compositions of
the present invention provide an effective therapy for the treatment of
acne and PIH, and in particular novel topical therapies that improve
symptoms in a safe, rapid and effective manner.
CLMEN
43. The method of claim 42, wherein the dermatological disorder is acne
vulgaris.
CLMEN
86. The method of claim 85, wherein the dermatological disorder is acne
vulgaris.
CLMEN
91 . The method of claim 90, wherein the dermatological disorder is selected
from the group consisting of acne vulgaris and post-inflammatory
hyperpigmentation (PIH).
CLMEN. . .
125. The method of claims 90-124, wherein the symptoms of the dermatological
disorder comprise one or more of sebum overproduction, comedones and acne
scarring.
Page 132 of 158

TITLE (ENGLISH): PERSONAL CARE COMPOSITIONS COMPRISING A DI-AMIDO
GELLANT AND METHODS OF USING
TITLE (FRENCH): COMPOSITIONS DE SOINS PERSONNELS COMPRENANT UN AGENT
GELIFIANT DI-AMIDO ET PROCEDES D'UTILISATION
INVENTOR(S): FERNANDEZ PRIETO, Susana, C/Hernan Cortes 45, 3-H,
E-12578 Benicarlo-castellon, ES, [NAT: ES, RES: ES],
for US only
SMETS, Johan, Bollenberg 79, B-3210 Lubbeek, BE, [NAT:
BE, RES: BE], for US only
ESCUDER GIL, Beatriu, Monges, 26, E-12170 Sant
Mateu-Castello, ES, [NAT: ES, RES: ES], for US only
MIRAVET CELADES, Juan, Felipe, C/ Rio Cenia 8, 1-D,
E-12005 Castellon, ES, [NAT: ES, RES: ES], for US only
NEBOT CARDA, Vicent, Josep, C/ Pere Gil N2, 1-D,
E-12540 Vila-real-Castellon, ES, [NAT: ES, RES: ES],
for US only
TANNER, Paul, Robert, 3325 Golden Fox Trail, Lebanon,
OH 45036, US, [NAT: US, RES: US], for US only
PATENT APPLICANT(S): THE PROCTER & GAMBLE COMPANY, One Procter & Gamble
Plaza, Cincinnati, OH 45202, US, [NAT: US, RES: US],
for all designated states except US
FERNANDEZ PRIETO, Susana, C/Hernan Cortes 45, 3-H,
E-12578 Benicarlo-castellon, ES, [NAT: ES, RES: ES],
for US only
SMETS, Johan, Bollenberg 79, B-3210 Lubbeek, BE, [NAT:
BE, RES: BE], for US only
ESCUDER GIL, Beatriu, Monges, 26, E-12170 Sant
Mateu-Castello, ES, [NAT: ES, RES: ES], for US only
MIRAVET CELADES, Juan, Felipe, C/ Rio Cenia 8, 1-D,
E-12005 Castellon, ES, [NAT: ES, RES: ES], for US only
NEBOT CARDA, Vicent, Josep, C/ Pere Gil N2, 1-D,
E-12540 Vila-real-Castellon, ES, [NAT: ES, RES: ES],
for US only
TANNER, Paul, Robert, 3325 Golden Fox Trail, Lebanon,
OH 45036, US, [NAT: US, RES: US], for US only
PRIORITY INFO.: US 2011-61496303 20110613
201161496303
61/496,303
US201161496303P
ABEN
A personal care composition is disclosed comprising a di-amido gellant, wherein
the di- amido gellant has a formula (I) wherein R1 and R2 are aminofunctional
end-groups which may be the same or different, and L is a linking moiety of
molecular weight from 14 to 500 g/mol. The personal care composition may take a
variety of forms such as a leave-on composition or an emulsion and/or may
comprise one or more actives or agents.
ABFR
L'invention concerne une composition de soins personnels comprenant un agent
gelifiant di-amido, dans lequel l'agent gelifiant di-amido a une formule (I)
dans laquelle R1 et R2 sont des groupes terminaux aminofonctionnels qui
peuvent etre identiques ou differents, et L est une fraction de liaison de
masse moleculaire de 14 a 500 g/mole. La composition de soins personnels peut
revetir une diversite de formes, telles qu'une composition a application sans
Page 133 of 158

rincage ou une emulsion et/ou peut comprendre un ou plusieurs actifs ou
agents.
DETDEN . . .
anti-wrinkle actives, anti-atrophy actives, flavonoids, N-acyl amino acid
compounds, retinoids, peptides, particulate materials, UV actives,
photostabilizers, anti-cellulite agents, desquamation actives, anti-acne
actives, antioxidants, radical scavengers, conditioning agents,
anti-inflammatory agents, tanning actives, skin lightening agents, botanical
extracts, antimicrobial actives, antifungal actives, antibacterial. . .
DETDEN . . .
actives, antioxidants, radical scavengers, conditioning agents,
DETDEN
17. Anti-Acne Actives
DETDEN
The compositions of the present invention can comprise one or more
anti-acne actives.
DETDEN
Suitable anti-acne actives include, but are not limited to, resorcinol,
sulfur, salicylic acid, retinoids such as retinoic acid and its derivatives,
sulfur-containing amino acids and their derivatives and salts (e.g. ,
N-acetyl derivatives such as N-acetyl-L-cysteinc), and lipoic acid. Other
suitable anti-acne actives may be chosen from (i) antibiotics and
antimicrobials such as benzoyl peroxide, octopirox, tetracycline,
2,4,4'trichloro-2'-hydiOxy diphenyl ether, 3,4,4'- trichlorobanilide,. . .
as flavonoids; and (iii) bile salts such as scymnol sulfate and its
derivatives, deoxycholate, and cholate. Further examples of suitable
anti-acne actives are described in U. S. Patent No. 5,607,980.
DETDEN . . .
% to about 30%, 25%, 20%, 10%, 7%, 5%, or 3%, by weight of the composition,
of one or more anti-acne compounds.
DETDEN
Suitable actives useful herein include those selected from the group
consisting of benzoyl peroxide, 3-hydroxy benzoic acid, glycolic acid,
lactic acid, 4-hydroxy benzoic acid, 2- hydroxybutanoic acid,
2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, phytic acid, lipoic. . .
bitter orange, urea preparations, griseofulvin, 8- Hydroxyquinoline
ciloquinol, thiobendazole, thiocarbamates, haloprogin, polyenes,
hydroxypyridone, mo holine, benzylamine, allylamines (such as terbinafine),
tea tree oil, clove leaf oil, coriander, palmarosa, berberine, thyme red,
cinnamon oil, cinnamic aldehyde, citronellic acid, hinokitol, ichthyol pale,
ethylhexylglycerin, hexamidine. . .
DETDEN . . .
be added to the composition herein. Examples of these functional classes
include, but are not limited to: abrasives, absorbents, fragrances,
anti-acne agents, anti- caking agents, antifoaming agents, antimicrobial
agents (e.g. , iodopropyl butylcarbamate), antifungal agents, antioxidants,
binders, buffering agents, bulking agents,. . .
Page 134 of 158

DETDEN . . .
vessels and/or red blotchiness on mammalian skin, fine lines and wrinkles,
dryness (e.g. , roughness, scaling, flak ing), cellulite, and acne.
CLMEN. . .
actives, anti-oxidants, radical scavengers, conditioning agents,
Page 135 of 158

TITLE (ENGLISH): EYE TREATMENT
TITLE (FRENCH): TRAITEMENT OCULAIRE
INVENTOR(S): NICHAMIN, Louis, D., 103 Jefferson Street, Brookville,
PA 15825, US, [NAT: US, RES: US], for all designated
states
PATENT APPLICANT(S): NICHAMIN, Louis, D., 103 Jefferson Street, Brookville,
PA 15825, US, [NAT: US, RES: US], for all designated
states
PRIORITY INFO.: US 2010-428043P 20101229
ABEN
Methods and kits for treating or preventing an eye condition or for cleaning an
eye area tissue are provided. A method of the invention includes administering
an isoprenoidal essential oil to eye area tissue, chafing eye area tissue with
an abrasive, and removing the abrasive. A kit according to the invention
includes an isoprenoidal essential oil, an abrasive for chafing eye area tissue,
and in instruction for use for treating an eye condition or cleansing an eye
area tissue. The invention also includes a composition of matter comprising an
isoprenoidal essential oil and a plurality of abrasive particles in
ophthamologically acceptable base.
ABFR
Cette invention concerne des methodes et des trousses pour traiter ou
prevenir une affection oculaire ou pour nettoyer un tissu de la zone
oculaire. La methode selon l'invention comprend l'administration d'une huile
essentielle derivee d'isoprenoides au tissu de la zone oculaire, le
frictionnement du tissu de la zone oculaire avec un abrasif, et l'elimination
de l'abrasif. Une trousse selon l'invention comprend une huile essentielle
derivee d'isoprenoides, un abrasif pour frictionner le tissu de la zone
oculaire, et des instructions d'utilisation pour traiter une affection
oculaire ou nettoyer un tissu de la zone oculaire. Cette invention concerne
egalement une composition de matiere comprenant une huile essentielle derivee
d'isoprenoides et une pluralite de particules abrasives dans une base
acceptable sur le plan ophtalmologique.
DETDEN
[00011] Although sometimes referred to as "acne rosacea" and confused with
acne vulgaris (referred to commonly as "acne") because both cause
irritation to the face, facial rosacea and acne are different, and
therefore the treatments recommended to manage them are also different.
[00012] Acne is the most common skin condition in the United States. While
it can occur at any age, it most commonly affects teenagers and young adults.
Facial rosacea is distinguished from acne vulgaris by the presence of
non-inflammatory comedones (follicles filled with sebum and sloughed off
cells; commonly referred to as "whiteheads" and "blackheads") with acne
and their absence in facial rosacea.
DETDEN
[00013] Although acne and rosacea sometimes co-exist in skin, they often
occur do not overlap and dermatologists recommend different protocols for
treatment of rosacea and acne. The goals with acne treatments are to
reduce oil production, speed up skin turnover, control bacterial infection
and reduce inflammation. In addition to cleansing the skin, acne may be
treated with application of acetone, alcohol, antibiotics, astringents,
benzoyl peroxide, retinoids and salicylic acid, and/or ingestion of oral. .
Page 136 of 158

.
DETDEN
[00014] The effects of acne may be reduced but not eliminated by applying a
sufficient amount of tea tree oil. Enshaieh et al. (Indian J.. . .
DETDEN
73(1 ):22-25) describe the difficulties of obtaining an acne treatment
medicine that has an effect and is tolerated by patients. Enshaieh et al.
report use of 5% tea tree oil to treat mild to moderate acne vulgaris
and found that 5% tea tree oil was 3.55 times more effective in improving
total acne lesions and 5.75 times more effective in reducing acne
severity as measured by the Acne Severity Index (ASI). Bassett et al.
(MedJAus), 1990, Oct. 15, 153(8):455-8 examined the effectiveness of 5% tea
tree oil in reducing the number of inflamed and non-inflamed lesions in
patients with acne. Application of 5% tea tree oil for twenty minutes
two times a day for 45 minutes to patients suffering from acne reduced the
number of lesions. The tea tree oil acted more slowly than the acne
treatment (benzoyl peroxide) to which it was compared. Of note, even
using frequent (e.g. twice daily) and relatively long application times over
the course of many weeks, 5% tea tree oil treatment was of limited
efficacy in treating acne.
DETDEN
[00015] U.S. Patent Application Publication 2005/0037034 to Rhoades describes
a composition for treating comedonal acne associated with acne vulgaris
and inflammatory acne. The composition contains an acne treatment agent
together with abrasive particles in a base. A method of using the agent is
described. The face is buffed or otherwise treated with the agent using, for
example, a hand-held vibratory device. The acne treatment agent can be, for
example, benzoyl peroxide, salicylic acid, retinol, hydroxyl acid, or
tea tree oil.
DETDEN
[00016] Increasingly aggressive acne treatment modalities may be used, as
shown by the use of oral medications such as isotretinoin, which has
significant side effects on the entire body for individuals whose acne
cannot be managed by other methods. Simple, effective and safe acne
treatments are still lacking.
DETDEN
[00017] These acne treatments tend to be harsh, and harsh treatments have
traditionally been thought to worsen the symptoms of rosacea. In particular,.
. .
DETDEN . . .
the deeper layers of the skin. Epithelialization and collagen production are
stimulated. It is used to counteract the effects of acne and photoaging and
reduces acne scars, age spots, enlarged pores, fine lines, and the
appearance of blemishes, other scars, stretch marks, undesired skin
pigmentation, and. . .
DETDEN
[00064] Other constituents may be added, either singularly or in combination,
including but not limited to acne treatment agent, alcohol, animal extract,
anti-oxidant agent, anti-parasitic agent, antiseptic agent, anti-bacterial
agent, ash, astringent, balm, binder, bleaching agents, collagen. . .
Page 137 of 158

L56 ANSWER 199 OF 199 IFIPAT COPYRIGHT 2013 IFI on STN
AN 03035874 IFIPAT;IFIUDB;IFICDB Full-text
TITLE: TOPICAL PRODUCT FORMULATIONS CONTAINING STRONTIUM FOR
REDUCING SKIN IRRITATION; SIDE EFFECT REDUCTION
INVENTOR(S): Hahn, Gary S., Cardiff by the Sea, CA
Quick, Timothy W., San Diego, CA
Thueson, David O., Poway, CA
PATENT ASSIGNEE(S): Cosmederm Technologies, La Jolla, CA
NUMBER PK DATE
----------------- -- --------
PATENT INFORMATION: US 5804203 A 19980908
(CITED IN 057 LATER PATENTS)
APPLICATION INFORMATION: US 1996-666978 19960620 (8)
EXPIRATION DATE: 21 Dec 2014
GRANTED PATENT NO.

APPLN. NUMBER DATE OR STATUS
----------------- -------- ------------------
CONTINUATION-IN-PART OF: US 1994-362100 19941221 5716625
FAMILY INFORMATION: US 5804203 19980908
US 5716625
Reassigned
OTHER SOURCE: CA 129:221022
ENTRY DATE: Entered STN: 15 Oct 1998
MICROFILM REEL NO: 008187 FRAME NO: 0186

008729 0641
009075 0431
010299 0036
010499 0614
011064 0991
013699 0103
013699 0115
013705 0735
AB Topical formulations comprising an anti-irritant amount of aqueous-soluble
strontium (Sr2+) cation, and method for using the same to inhibit skin
irritation are disclosed.
ACLM . . . therapeutically active ingredient is selected from the group
consisting of anti-inflammatory, antibiotic, local anesthetic, sunscreen,
retinoid, antiperspirant, antihistamine, analgesic, contraceptive,
anti-acne and anti-dandruff ingredients.
. . . therapeutically active ingredient is selected from the group
. . . therapeutically active ingredient is selected from the group
. . . the group consisting of steroidal or non-steroidal anti-inflammatory
agents, aloe vera, chamomile, Alpha -bisabolol, Cola nitida extract,
green tea extract, tea tree oil, licorice extract, allantoin, urea,
caffeine or other xanthines and glycyrrhizic acid.
. . . the group consisting of steroidal or non-steroidal anti-inflammatory
agents, aloe vera, chamomile, Alpha -bisabolol, Cola nitida extract,
green tea extract, tea tree oil, licorice extract, allantoin, urea,
caffeine or other xanthines and glycyrrhizic acid.
Page 138 of 158

Non-Patent References
For this sample report, only the 2 references from HCAPLUS, the reference from Medline, the first 2
references from Embase are displayed below.
L53 ANSWER 1 OF 42 HCAPLUS COPYRIGHT 2013 ACS on STN DUPLICATE 1
TITLE: Effective over-the-counter acne treatments
AUTHOR(S): Bowe, Whitney P.; Shalita, Alan R.
CORPORATE SOURCE: Department of Dermatology, SUNY Downstate Medical
Center, Brooklyn, NY, USA
SOURCE: Seminars in Cutaneous Medicine and Surgery (2008),
27(3), 170-176
PUBLISHER: Elsevier Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Acne is the most common disease of the skin, yet only a fraction of
acne sufferers are treated with prescription products by physicians. There is,
however, a large and expanding market for over-the-counter (OTC) medications,
many of which are not only effective but also well tolerated and cosmetically
elegant. Given the presence of OTC acne medications on the television, the
Internet, and store shelves, patients will be acutely aware of these OTC
remedies and will have questions. Patients will expect dermatologists to advise
them regarding products to use either as a sole therapy or in combination with
prescription drugs. Recently, combinations of OTC acne medications in treatment
regimens or "kits" have gained popularity and appear to have increased patient
compliance. Quality-of-life outcomes from OTC medication use, in at least one
study, have demonstrated good benefit. The most common OTC ingredients include
benzoyl peroxide, a potent antibacterial agent, and salicylic acid, a mild
comedolytic and antiinflammatory medication. Other, less-common OTC ingredients
include sulfur, sodium sulfacetamide, and alpha hydroxy acids. Zinc, vitamin A,
tea tree oil, and ayurvedic therapies also are available OTC for acne. Addnl.
and better studies are needed to clarify the benefit of these latter
medications.
CC 1-0 (Pharmacology)
ST review acne antibacterial antiinflammatory cosmetic
IT Essential oils
(Melaleuca alternifolia; effective over-the-counter
acne treatments)
IT Acne
(comedo; effective over-the-counter acne
treatments)
IT Acne
Human
(effective over-the-counter acne treatments)
IT Carboxylic acids
(hydroxy, ; effective over-the-counter acne
treatments)
Benzoyl peroxide, biological studies 127-56-0, Sodium
Page 139 of 158

sulfacetamide 7440-66-6, Zinc, biological studies 7704-34-9, Sulfur,
biological studies 11103-57-4, Vitamin A
(effective over-the-counter acne treatments)
Page 140 of 158

TITLE: Anti-acne actives
AUTHOR(S): Abrutyn, Eric S.
CORPORATE SOURCE: TPC2 Advisors Ltd., Inc., USA
SOURCE: Cosmetics & Toiletries (2011), 126(10), 684, 686-690
PUBLISHER: Allured Business Media
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Acne vulgaris (acne) is a skin disease that can be caused by multiple chronic
issues including: hyperkeratinization, sebaceous gland hyperplasia with
seborrhea, Propionibacterium acnes proliferation and inflammation. The
management of acne can be complex, often requiring aggressive combination
therapy and a long-term therapeutic strategy. Tea tree oil is sometimes
considered a good substitute for benzoyl peroxide in fighting acne.
Isotretinoin (13-cis retinoic acid) is also incorporated as a potent pharmacol.
inhibitor of sebum secretion. The key components of anti-acne actives, their
formulations and recent patents, including nano-sized silver and modulating the
CIDEA protein, are discussed.
CC 62 (Essential Oils and Cosmetics)
ST Propionibacterium acne sebaceous gland
IT INDEXING IN PROGRESS
IT Propionibacterium acnes
(Propionibacterium acnes caused development of acne in human)
(anti-acne agents; benzoyl peroxide,
salicylic acid and tea tree oil showed
effective antiacne activities in human)
IT Acne
Antibiotics
Human
Sebaceous gland
(benzoyl peroxide, salicylic acid and tea
tree oil showed effective antiacne
activities in human)
Page 141 of 158

L53 ANSWER 3 OF 42 MEDLINE on STN
ACCESSION NUMBER: 1991014851 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 2145499
TITLE: A comparative study of tea-tree oil versus
Benzoylperoxide in the treatment of acne.
AUTHOR: Bassett I B; Pannowitz D L; Barnetson R S
CORPORATE SOURCE: Department of Dermatology, Royal Prince Alfred Hospital,
Camperdown, NSW.
SOURCE: The Medical journal of Australia, (1990 Oct 15) Vol. 153,
No. 8, pp. 455-8.
Journal code: 0400714. ISSN: 0025-729X. L-ISSN: 0025-729X.
PUB. COUNTRY: Australia
DOCUMENT TYPE: (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
ENTRY MONTH: 199011
ENTRY DATE: Entered STN: 17 Jan 1991
Entered Medline: 16 Nov 1990
ABSTRACT:
Tea-tree oil (an essential oil of the Australian native tree Melaleuca
alternifolia) has long been regarded as a useful topical antiseptic agent in
Australia and has been shown to have a variety of antimicrobial activities;
however, only anecdotal evidence exists for its efficacy in the treatment of
various skin conditions. We have performed a single-blind, randomised clinical
trial on 124 patients to evaluate the efficacy and skin tolerance of 5%
tea-tree oil gel in the treatment of mild to moderate acne when compared
with 5% benzoyl peroxide lotion. The results of this study showed that
both 5% tea-tree oil and 5% benzoyl peroxide had a significant effect
in ameliorating the patients' acne by reducing the number of inflamed and
non-inflamed lesions (open and closed comedones), although the onset of
action in the case of tea-tree oil was slower. Encouragingly, fewer side
effects were experienced by patients treated with tea-tree oil.
CONTROLLED TERM: Check Tags: Female; Male
*Acne Vulgaris: DT, drug therapy
Acne Vulgaris: PA, pathology
Adolescent
Adult
Benzoyl Peroxide: AD, administration & dosage
Benzoyl Peroxide: AE, adverse effects
*Benzoyl Peroxide: TU, therapeutic use
Child
Gels
Humans
Oils, Volatile: AD, administration & dosage
Oils, Volatile: AE, adverse effects
*Oils, Volatile: TU, therapeutic use
Plant Oils: AD, administration & dosage
Plant Oils: AE, adverse effects
*Plant Oils: TU, therapeutic use
Prospective Studies
Single-Blind Method
Skin: PA, pathology
Time Factors
*Trees
CAS REGISTRY NO.: 94-36-0 (Benzoyl Peroxide)
CHEMICAL NAME: Gels; Oils, Volatile; Plant Oils
Page 142 of 158

L53 ANSWER 9 OF 42 EMBASE COPYRIGHT (c) 2013 Elsevier B.V. All rights
reserved on STN
ACCESSION NUMBER: 2012618102 EMBASE Full-text
TITLE: A review on anti-acne potential of medicinal plant
extracts against propionibacterium acnes.
AUTHOR: Amrita, G.; Greeshma, N.; Deepa, M.; Poornima, E.H.
(correspondence)
CORPORATE SOURCE: Department of Botany, Mount Carmel College (Autonomous),
Bangalore, India.
SOURCE: International Journal of Pharma and Bio Sciences,
(July/September 2012) Vol. 3, No. 3, pp. B987-B997.
Refs: 56
E-ISSN: 0975-6299
PUBLISHER: International Journal of Pharma and Bio Sciences, 103,
Bhagwan Towers, 7th Line, Muthyal Reddy Nagar,, Amaravathi
Road, Guntur,, 522002, India.
COUNTRY: India
DOCUMENT TYPE: Journal; General Review; (Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Nov 2012
ABSTRACT: Acne vulgaris (Acne) is the most common skin disorder characterized by
noninflammatory comedones or inflammatory papules, pustules
and nodules. Although acne does not pose serious threat to general health,
it is one of the most socially distressing conditions especially for
adolescents. The acne inflammation is triggered by pus forming bacteria
recognized as Propionibacterium acnes and Staphylococcus epidermidis. Acne
therapy includes prolonged use of comedolytic agents, antibiotics and
anti-inflammatory agents that are known to cause many side effects. Moreover,
the widespread and long-term use of antibiotics over the years has
unfortunately led to emergence of resistant strains. To avoid side effects,
traditional or herbal formulations are preferred. Herbs are safe, efficacious
and multifunctional. Medicinal plant extracts are known to have enormous
therapeutic potential. Plant-based preparations with little or no side effects
are cyclically returning to complement dermatological therapy. They serve as
safer choice or in some cases is the only effective treatment.
CONTROLLED TERM: Medical Descriptors:

*acne: DT, drug therapy
*acne: ET, etiology
*acne: SI, side effect
Amphiroa
antibacterial activity
antifungal activity
antimicrobial activity
autoimmune hepatitis: SI, side effect
Ayurveda
dizziness: SI, side effect
DRESS syndrome: SI, side effect
*drug identification
dry skin: SI, side effect
erythema: SI, side effect
Halimeda macroloba
human
injection site stinging: SI, side effect
liver toxicity: SI, side effect
lung toxicity: SI, side effect
*medicinal plant
nephrotoxicity: SI, side effect
nonhuman
*Propionibacterium acnes
Page 143 of 158

pruritus: SI, side effect
review
Sargassum
Sargassum binderi
skin burning sensation: SI, side effect
skin infection: DT, drug therapy
systemic lupus erythematosus: SI, side effect
Turbinaria conoides
unspecified side effect: SI, side effect
CONTROLLED TERM: Drug Descriptors:
acetylsalicylic acid: CM, drug comparison
algal extract: AN, drug analysis
Aloe vera extract: DT, drug therapy
Aloe vera extract: PD, pharmacology
Amphiroa extract: AN, drug analysis
antibiotic agent: AE, adverse drug reaction
antibiotic agent: CB, drug combination
antibiotic agent: DT, drug therapy
antibiotic agent: PO, oral drug administration
antibiotic agent: TP, topical drug administration
Azadirachta indica extract: DT, drug therapy
Azadirachta indica extract: PD, pharmacology
benzoyl peroxide: AE, adverse drug reaction
benzoyl peroxide: CB, drug combination
benzoyl peroxide: DT, drug therapy
benzoyl peroxide: TP, topical drug administration
Calendula extract: DT, drug therapy
Calendula extract: PD, pharmacology
clindamycin: DT, drug therapy
clindamycin: PO, oral drug administration
clindamycin: TP, topical drug administration
Cymbopogon citratus extract: AN, drug analysis
erythromycin: DT, drug therapy
erythromycin: PO, oral drug administration
erythromycin: TP, topical drug administration
guava extract: AN, drug analysis
Halimeda macroloba extract: AN, drug analysis
lupeol: AN, drug analysis
metronidazole: AE, adverse drug reaction
metronidazole: PO, oral drug administration
metronidazole: TP, topical drug administration
minocycline: AE, adverse drug reaction
minocycline: CM, drug comparison
minocycline: DT, drug therapy
minocycline: PO, oral drug administration
minocycline: TP, topical drug administration
Momordica charantia extract: DT, drug therapy
Momordica charantia extract: PD, pharmacology
phenylbutazone: CM, drug comparison
pinene: AN, drug analysis
red clover extract: DT, drug therapy
red clover extract: PD, pharmacology
retinoid derivative: AE, adverse drug reaction
retinoid derivative: CB, drug combination
retinoid derivative: DT, drug therapy
retinoid derivative: TP, topical drug administration
salicylic acid: DT, drug therapy
Sargassum binderi extract: AN, drug analysis
tea tree oil: DT, drug therapy
tea tree oil: PD, pharmacology
Page 144 of 158

tetracycline: DT, drug therapy
tetracycline: PO, oral drug administration
tetracycline: TP, topical drug administration
tetracycline derivative: AE, adverse drug reaction
tetracycline derivative: CM, drug comparison
tetracycline derivative: PO, oral drug administration
tetracycline derivative: TP, topical drug administration
triclosan: DT, drug therapy
triclosan: PO, oral drug administration
triclosan: TP, topical drug administration
Turbinaria conoides extract: AN, drug analysis
Turbinaria conoides extract: CM, drug comparison
turpentine: AN, drug analysis
unclassified drug
unindexed drug
SUPPLEMENTARY TERM: Acne vulgaris; Comedones; Propionibacterium acnes and
staphylococcus epidermidis
CAS REGISTRY NO.: (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4,
53664-49-6, 63781-77-1; (benzoyl peroxide) 94-36-0;
(clindamycin) 18323-44-9; (erythromycin) 114-07-8,
70536-18-4; (lupeol) 545-47-1; (metronidazole) 39322-38-8,
443-48-1; (minocycline) 10118-90-8, 11006-27-2, 13614-98-7;
(phenylbutazone) 129-18-0, 50-33-9, 8054-70-4; (pinene)
80-56-8; (salicylic acid) 63-36-5, 69-72-7; (tetracycline)
23843-90-5, 60-54-8, 64-75-5, 8021-86-1; (triclosan)
3380-34-5; (turpentine) 9005-90-7
Page 145 of 158

L53 ANSWER 10 OF 42 EMBASE COPYRIGHT (c) 2013 Elsevier B.V. All rights
reserved on STN
ACCESSION NUMBER: 2012601594 EMBASE Full-text
TITLE: Harnessing the power of crowds: Crowdsourcing as a novel
research method for evaluation of acne treatments.
AUTHOR: Armstrong, April W., Dr. Prof. (correspondence); Wu, Julie;
Harskamp, Caitlin T.; Schupp, Clayton W.
CORPORATE SOURCE: Department of Dermatology, University of California Davis
Health System, 3301 C Street, Sacramento, CA 95816, United
States. aprilarmstrong@post.harvard.edu
AUTHOR: Cheeney, Safia
CORPORATE SOURCE: University of Arizona, Tucson, AZ, United States.
SOURCE: American Journal of Clinical Dermatology, (2012) Vol. 13,
No. 6, pp. 405-416.
Refs: 50
PUBLISHER: Adis International Ltd, 41 Centorian Drive, Private Bag
65901, Mairangi Bay, Auckland 10, 1311, New Zealand.
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; Article
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Oct 2012
ABSTRACT: Background: Crowdsourcing is a novel process of data collection that can
provide insight into the effectiveness of acne treatments in real-world
settings. Little is known regarding the feasibility of crowdsourcing as a
means of collecting dermatology research data, the quality of collected data,
and how the data compare to the published literature. Objective: The objective
of this analysis is to compare acne data collected from a medical
crowdsourcing site with high-quality controlled studies from peer-reviewed
medical literature. Methods: Crowdsourced data was collected from 662 online
acne patients. Online patients reported data in a Likert-type format to
characterize their symptom severity (740 total responses) and their treatment
outcomes (958 total responses). The crowdsourced data were compared with
meta-analyses and reviews on acne treatment from August 20, 2010 to August
20, 2011. Results: We compared topical, oral systemic, alternative,
phototherapy, and physical acne treatments of crowdsourced data to published
literature. We focused on topical tretinoin due to the large number of online
patient responses. While approximately 80% of tretinoin users observed
clinical improvement after a 12-week treatment period in clinical trials, 46%of
online users reported improvement in an unspecified time period. For most
topical treatments, medication with high efficacy in clinical trials did not
produce high effectiveness ratings based on the crowdsourced online data.
Conclusion: While limitations exist with the current methods of crowdsourced
data collection, with standardization of data collection and use of validated
instruments, crowdsourcing will provide an important and valuable platform for
collecting high-volume patient data in real-world settings. Adis .COPYRGT.
2012 Springer International Publishing AG. All rights reserved.
CONTROLLED TERM: Medical Descriptors:

*acne: DT, drug therapy
*acne: TH, therapy
alternative medicine
article
comparative study
crowding
*data collection method
drug efficacy
drug response
human
information processing
Internet
Page 146 of 158

major clinical study
online analysis
*online system
peer review
phototherapy
priority journal
quality control
standardization
treatment outcome
treatment response
CONTROLLED TERM: Drug Descriptors:
benzoyl peroxide: DT, drug therapy
benzoyl peroxide: TP, topical drug administration
benzoyl peroxide plus clindamycin: DT, drug therapy
benzoyl peroxide plus clindamycin: TP, topical drug
administration
clindamycin: TP, topical drug administration
cosmetic
cotrimoxazole: DT, drug therapy
cotrimoxazole: PO, oral drug administration
doxycycline: DT, drug therapy
doxycycline: PO, oral drug administration
isotretinoin: DT, drug therapy
isotretinoin: PO, oral drug administration
oral contraceptive agent: PO, oral drug administration
retinoic acid: DT, drug therapy
retinoic acid: TP, topical drug administration
salicylic acid: TP, topical drug administration
tea tree oil
tetracycline: DT, drug therapy
tetracycline: PO, oral drug administration
SUPPLEMENTARY TERM: Acne; Data collection
CAS REGISTRY NO.: (benzoyl peroxide) 94-36-0; (clindamycin) 18323-44-9;
(cotrimoxazole) 8064-90-2; (doxycycline) 10592-13-9,
17086-28-1, 564-25-0; (isotretinoin) 4759-48-2; (retinoic
acid) 302-79-4; (salicylic acid) 63-36-5, 69-72-7;
(tetracycline) 23843-90-5, 60-54-8, 64-75-5, 8021-86-1
CHEMICAL NAME: acnetrex; bactrim; benzaclin; doryx; retin a; roaccutane;
stieva a
Page 147 of 158

L53 ANSWER 34 OF 42 IPA COPYRIGHT (c) 2013 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:10666 IPA Full-text

DOCUMENT NUMBER: 41-10667
TITLE: ACNE - diet doesn't count
AUTHOR: Anonymous
SOURCE: Pharmacy Today (New Zealand), (2004) p. 18.
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
A review of pharmaceutical therapies available for the treatment of acne, including
manifestations of disease, OTC drugs, role of keratolytic,
antiseptic, antibiotic agents and available formulations in controling the
disease.
Hormonal products are also discussed.
SECTION: 11 Pharmacology; 6 Drug Evaluations
CLASSIFICATION: 84:28 Keratolytic agents; 28:08.04 Anti inflammatory
agents; 84:28 Keratolytic agents; 84:00 Skin and mucous
membrane preparations; 68:00 Hormones; 8:12 Antibiotics
INDEX TERM: Benzoyl peroxide; Acne vulgaris
INDEX TERM: Tea tree oil; Acne vulgaris
INDEX TERM: Isotretinoin; Acne vulgaris
INDEX TERM: Azelaic acid; Acne vulgaris
INDEX TERM: Acne vulgaris; benzoyl peroxide
INDEX TERM: Keratolytic agents; benzoyl peroxide
INDEX TERM: Acne vulgaris; tea tree oil
INDEX TERM: Anti inflammatory agents; tea tree oil
INDEX TERM: Acne vulgaris; isotretinoin
INDEX TERM: Keratolytic agents; isotretinoin
INDEX TERM: Acne vulgaris; azelaic acid
INDEX TERM: Skin and mucous membrane preparations; azelaic acid
INDEX TERM: Drugs, over the counter; Acne vulgaris
INDEX TERM: Hormones; Acne vulgaris
INDEX TERM: Nutrition; diet
INDEX TERM: Antibiotics; Acne vulgaris
INDEX TERM: Plants; medicinal
CAS REGISTRY NO.: 94-36-0 (Benzoyl peroxide)
CAS REGISTRY NO.: 68647-73-4 (Tea tree oil)
CAS REGISTRY NO.: 4759-48-2 (Isotretinoin)
CAS REGISTRY NO.: 123-99-9 (Azelaic acid)
CHEMICAL NAME: Benzoyl peroxide (Benzac W 5); Isotretinoin (Roaccutane)
Page 148 of 158

Science IP Search Documentation

Search Strategy
FILE 'REGISTRY' ENTERED AT 08:55:25 ON 09 JAN 2013

L1 2 SEA ABB=ON "TEA TREE OIL"/CN
FILE 'HCAPLUS' ENTERED AT 08:55:34 ON 09 JAN 2013

L2 0 SEA ABB=ON L1
L3 1676 SEA ABB=ON "ESSENTIAL OILS (L) MELALEUCA"/CT
L4 866 SEA ABB=ON TEA TREE OIL#
L5 1096 SEA ABB=ON TEA TREE(S)OIL#
L6 1951 SEA ABB=ON L3 OR L4 OR L5

E BENZOYL PEROXIDE/CN
L7 1 SEA ABB=ON "BENZOYL PEROXIDE"/CN
FILE 'STNGUIDE' ENTERED AT 08:59:35 ON 09 JAN 2013

L8 QUE ABB=ON ACNE OR ANTIACNE# OR PIMPLE# OR BLACKHEAD# OR
BLACK HEAD# OR WHITEHEAD# OR WHITE HEAD# OR COMEDONE# OR
COMEDO OR COMEDOS OR ZIT OR ZITS
L9 QUE ABB=ON TEATREE OR TEA TREE
L10 QUE ABB=ON MELAELUCA
L11 QUE ABB=ON BENZOYL PEROXIDE#

SEL L7 1- NAME
FILE 'STNGUIDE' ENTERED AT 09:26:00 ON 09 JAN 2013

D SEL
L12 QUE ABB=ON "BENZOYL PEROXIDE"/BI OR "BENZOYL SUPEROXIDE"/BI
OR BENOXYL/BI OR BENZAGEL/BI OR LUCIDOL/BI OR BREVOXYL/BI OR
"DIBENZOYL PEROXIDE"/BI OR "DIPHENYLGLYOXAL PEROXIDE"/BI OR
PEROXYDERM/BI OR SOLUGEL/BI OR PANOXYL/BI OR LOROXIDE/BI OR
BENZASHAVE/BI OR BENZOPEROXIDE/BI OR ACETOXYL/BI OR ACNEZOYL/BI
EDIT QUE L12

L13 QUE ABB=ON "BENZOYL PEROXIDE" OR "BENZOYL SUPEROXIDE" OR
BENOXYL OR BENZAGEL OR LUCIDOL OR BREVOXYL OR "DIBENZOYL
PEROXIDE" OR "DIPHENYLGLYOXAL PEROXIDE" OR PEROXYDERM OR
SOLUGEL OR PANOXYL OR LOROXIDE OR BENZASHAVE OR BENZOPEROXI
DE OR ACETOXYL OR ACNEZOYL

L14 28 SEA ABB=ON (L13 OR L7 OR L11) AND (L9 OR L10 OR L6) AND L8
FILE 'WPINDEX' ENTERED AT 09:30:07 ON 09 JAN 2013

L16 12616 SEA ABB=ON L15/DCR
L17 17006 SEA ABB=ON L16 OR L13
L18 1 SEA ABB=ON "TEA TREE OIL"/CN
L19 606 SEA ABB=ON L18/DCR
L21 33 SEA ABB=ON (L17 OR L11) AND L20 AND L8
Page 149 of 158

FILE 'FRANCEPAT, JAPIO, KOREAPAT, RUSSIAPAT' ENTERED AT 09:31:38 ON 09
JAN 2013
L22 1 SEA ABB=ON (L9 OR L10) AND (L13 OR L11) AND L8
INDEX '2MOBILITY, ADISCTI, AGRICOLA, ANABSTR, APOLLIT, BIBLIODATA,

BIOSIS, BIOTECHABS, BIOTECHDS, CABA, CEABA-VTB, CHEMINFORMRX, CHEMSAFE,
COMPENDEX, COMPUSCIENCE, CROPB, CSNB, DDFB, DDFU, DETHERM, DKF, DRUGB,
DRUGU, EMBAL, EMBASE, ENCOMPLIT, ENCOMPLIT2, ...' ENTERED AT 09:32:18 ON
09 JAN 2013
SEA L22
---------
1 FILE ADISCTI
2 FILE BIOSIS
1 FILE CABA
4 FILE DDFU
30 FILE EMBASE
1 FILE IPA
6 FILE KOSMET
2 FILE MEDLINE
6 FILE SCISEARCH
L23 QUE ABB=ON L22
---------
FILE 'MEDLINE, ADISCTI, BIOSIS, DDFU, EMBASE, IPA, KOSMET, SCISEARCH,

CABA' ENTERED AT 09:34:40 ON 09 JAN 2013
L24 53 SEA ABB=ON L23
L25 41 DUPLICATE REMOV L24 (12 DUPLICATES REMOVED)
ANSWERS '1-2' FROM FILE MEDLINE
ANSWER '3' FROM FILE ADISCTI
ANSWER '4' FROM FILE BIOSIS
ANSWERS '5-7' FROM FILE DDFU
ANSWERS '8-32' FROM FILE EMBASE
ANSWER '33' FROM FILE IPA
ANSWERS '34-39' FROM FILE KOSMET
ANSWER '40' FROM FILE SCISEARCH
ANSWER '41' FROM FILE CABA
FILE 'USPATFULL, USPAT2' ENTERED AT 09:35:39 ON 09 JAN 2013

L26 70 SEA ABB=ON (L13 OR L11)(250A)(L9 OR L10)(250A) L8
L27 101 SEA ABB=ON (L13 OR L11)(250A)(L9 OR L10) AND L8
L28 41 SEA ABB=ON (L13/TI,AB,CLM OR L11/TI,AB,CLM) AND (L9/TI,AB,CLM
OR L10/TI,AB,CLM) AND L8/TI,AB,CLM
FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, AUPATFULL, CANPATFULL,

CNFULL, JPFULL' ENTERED AT 09:37:32 ON 09 JAN 2013
FILE 'IFIREF' ENTERED AT 09:41:15 ON 09 JAN 2013

SEL L34 1- UN
FILE 'IFIUDB' ENTERED AT 09:41:30 ON 09 JAN 2013

L35 9780 SEA ABB=ON 50118/UN
Page 150 of 158

FILE 'IFIPAT' ENTERED AT 09:41:33 ON 09 JAN 2013

L37 46 SEA ABB=ON (L36 OR L13 OR L11) AND (L9 OR L10) AND L8
Removing Duplicates
SEL L14 1- PN
L38 2 SEA ABB=ON L14 NOT P/DT
L39 26 SEA ABB=ON L14 AND P/DT
FILE 'WPINDEX' ENTERED AT 09:42:58 ON 09 JAN 2013

L40 12 SEA ABB=ON L21 NOT (GB2474930/PN OR CA2776482/PN OR US20110281
827/PN OR WO2011138678/PN OR AU2006339311/PN OR CA2208078/PN
OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR US20120064135
/PN OR WO2004037225/PN OR WO2004103321/PN OR WO2004103353/PN
OR WO2007099396/PN OR WO2008152444/PN OR WO2010087964/PN OR
WO2011039637/PN OR WO2011039638/PN OR WO2012037000/PN OR
WO2012047733/PN OR AT237298/PN OR AU2001023937/PN OR AU20042406
15/PN OR AU2004313285/PN OR AU2006201878/PN OR AU2007355106/PN
OR AU2009261995/PN OR AU2010302350/PN OR AU782515/PN OR
AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR BR2004010358/PN
OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN OR CA2397068/P
N OR CA2524868/PN OR CA2534306/PN OR CA2611577/PN OR CA2726836/
PN OR CA2750233/PN OR CA2776366/PN OR CA2776471/PN OR CA2776474
/PN OR CA2776692/PN OR CN102076333/PN OR CN102686205/PN OR
CN1787806/PN OR EP1250116/PN OR EP1626779/PN OR EP1685824/PN
OR EP1919449/PN OR EP2097065/PN OR EP2310000/PN OR EP2391342/PN
OR EP2482788/PN OR EP796078/PN OR EP799018/PN OR ES2192586/PN
OR IL198688/PN OR IL209697/PN OR IN2002CN01062/PN OR IN2002CN01
082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN OR IN221380/PN
OR JP11502504/PN OR JP2003528821/PN OR JP2005314437/PN OR
JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN OR
KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR MX2012003
985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/PN OR
US20030157138/PN OR US20040228822/PN OR US20040228885/PN OR
US201
SEL L40 1- PN
FILE 'FRANCEPAT, JAPIO, KOREAPAT, RUSSIAPAT' ENTERED AT 09:43:30 ON 09

JAN 2013
L41 0 SEA ABB=ON L22 NOT ((GB2474930/PN OR CA2776482/PN OR US2011028
Page 151 of 158

US201
FILE 'USPATFULL, USPAT2' ENTERED AT 09:44:41 ON 09 JAN 2013

US201
L43 ANALYZE L42 1- PN : 91 TERMS
FILE 'IFIPAT' ENTERED AT 09:45:48 ON 09 JAN 2013

L45 39 SEA ABB=ON L37 NOT L44
L46 1 SEA ABB=ON L45 NOT (50118/UN OR GB2474930/PN OR CA2776482/PN
OR US20110281827/PN OR WO2011138678/PN OR AU2006339311/PN OR
Page 152 of 158

CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR
US20120064135/PN OR WO2004037225/PN OR WO2004103321/PN OR
WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU20010239
AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR
BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN
OR CA2397068/PN OR CA2524868/PN OR CA2534306/PN OR CA2611577/P
PN OR CA2776474/PN OR CA2776692/PN OR CN102076333/PN OR
CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN
OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/
PN OR IN2002CN01082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN
OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314
437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN
OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR
MX2012003985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/
PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN
OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR
US201
SEL L46 1- PN

L48 70 SEA ABB=ON US5804203/PN OR L47
L49 ANALYZE L48 1- PN : 361 TERMS
FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, AUPATFULL, CANPATFULL,

CNFULL, JPFULL' ENTERED AT 09:46:48 ON 09 JAN 2013
L52 73 SEA ABB=ON L33 NOT ((50118/UN OR GB2474930/PN OR CA2776482/PN
OR US20110281827/PN OR WO2011138678/PN OR AU2006339311/PN OR
CA2208078/PN OR EP1136065/PN OR EP2422768/PN OR EP801554/PN OR
US20120064135/PN OR WO2004037225/PN OR WO2004103321/PN OR
WO2012037000/PN OR WO2012047733/PN OR AT237298/PN OR AU20010239
AU782515/PN OR AU9645285/PN OR AU9646060/PN OR AU9646064/PN OR
BR2004010358/PN OR BR9510478/PN OR CA2208079/PN OR CA2208500/PN
OR CA2397068/PN OR CA2524868/PN OR CA2534306/PN OR CA2611577/P
PN OR CA2776474/PN OR CA2776692/PN OR CN102076333/PN OR
CN102686205/PN OR CN1787806/PN OR EP1250116/PN OR EP1626779/PN
OR ES2192586/PN OR IL198688/PN OR IL209697/PN OR IN2002CN01062/
PN OR IN2002CN01082/PN OR IN2007KN04925/PN OR IN2011CN00566/PN
OR IN221380/PN OR JP11502504/PN OR JP2003528821/PN OR JP2005314
Page 153 of 158

437/PN OR JP2007502326/PN OR JP2011526302/PN OR KR2011033243/PN
OR KR9607395/PN OR MX2005012381/PN OR MX2010013562/PN OR
MX2012003985/PN OR NZ520014/PN OR PT801554/PN OR US20030124202/
PN OR US20030157138/PN OR US20040228822/PN OR US20040228885/PN
OR US20040253275/PN OR US20050031547/PN OR US20050031571/PN OR
US201
Non-Patent Literature References

FILE 'HCAPLUS, MEDLINE, ADISCTI, BIOSIS, DDFU, EMBASE, IPA, KOSMET,
SCISEARCH, CABA' ENTERED AT 09:50:12 ON 09 JAN 2013
L53 42 DUPLICATE REMOV L38 L25 (1 DUPLICATE REMOVED)
ANSWERS '1-2' FROM FILE HCAPLUS
ANSWER '3' FROM FILE MEDLINE
ANSWER '4' FROM FILE ADISCTI
ANSWER '5' FROM FILE BIOSIS
ANSWERS '6-8' FROM FILE DDFU
ANSWERS '9-33' FROM FILE EMBASE
ANSWER '34' FROM FILE IPA
ANSWERS '35-40' FROM FILE KOSMET
ANSWER '41' FROM FILE SCISEARCH
ANSWER '42' FROM FILE CABA
D L53 1-2 IBIB AB HITIND
D L53 3 IALL
D L53 9-10 IALL
D L53 34 IALL
FILE 'INPAFAMDB' ENTERED AT 09:51:05 ON 09 JAN 2013

L54 2 SEA ABB=ON (L9 OR L10) AND (L13 OR L11) AND L8
Page 154 of 158

US201
FILE 'HCAPLUS, WPINDEX, USPATFULL, USPAT2, EPFULL, GBFULL, PCTFULL,

AUPATFULL, CANPATFULL, CNFULL, JPFULL, IFIPAT' ENTERED AT 09:52:27 ON 09
JAN 2013
L56 199 DUPLICATE REMOV L39 L40 L42 L52 L46 (0 DUPLICATES REMOVED)
ANSWERS '1-26' FROM FILE HCAPLUS
ANSWERS '27-38' FROM FILE WPINDEX
ANSWERS '39-105' FROM FILE USPATFULL
ANSWERS '106-125' FROM FILE USPAT2
ANSWERS '126-130' FROM FILE EPFULL
ANSWER '131' FROM FILE GBFULL
ANSWERS '132-168' FROM FILE PCTFULL
ANSWERS '169-177' FROM FILE AUPATFULL
ANSWERS '178-191' FROM FILE CANPATFULL
ANSWERS '192-197' FROM FILE CNFULL
ANSWER '198' FROM FILE JPFULL
ANSWER '199' FROM FILE IFIPAT
D 1-26 IBIB AB HITIND
D 39-45 IBIB AB KWIC
D 132-135 IBIB AB KWIC
D 199 IBIB AB KWIC
Page 155 of 158

Sources Used
For more information about individual databases, please see the STN Database Summary Sheets at
http://stnguide.cas.org/
FILE REGISTRY (CAS Registry)

STRUCTURE FILE UPDATES: 8 JAN 2013 HIGHEST RN 1416207-43-6
DICTIONARY FILE UPDATES: 8 JAN 2013 HIGHEST RN 1416207-43-6
FILE HCAPLUS (Chemical Abstracts Plus)

FILE COVERS 1907 - 9 Jan 2013 VOL 158 ISS 3
FILE LAST UPDATED: 8 Jan 2013 (20130108/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: November 2012
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: November 2012
FILE WPINDEX (Derwent World Patents Index)

FILE LAST UPDATED: 7 JAN 2013 <20130107/UP>
MOST RECENT UPDATE: 201302 <201302/DW>
DERWENT WORLD PATENTS INDEX, COVERS 1963 TO DATE
FILE FRANCEPAT (French Patent Abstracts)

FILE LAST UPDATED: 6 NOV 2009 <20091106/UP>
FILE COVERS 1961 TO NOVEMBER 6, 2009 - FILE CLOSED
FILE JAPIO (Japan Patent Information Organization)

FILE KOREAPAT (Korean Patent Abstracts)

FILE LAST UPDATED: 18 DEC 2012 <20121218/UP>
FILE RUSSIAPAT (Russian Patent Abstracts)

FILE COVERS 1924 TO DATE
FILE STNINDEX
FILE MEDLINE (MEDLINE)

FILE LAST UPDATED: 8 Jan 2013 (20130108/UP). FILE COVERS 1946 TO DATE.
FILE ADISCTI (Adis Clinical Trials Insight)

FILE COVERS 1998 TO 4 Jan 2013 (20130104/ED)
FILE LAST UPDATED: 4 JAN 2013 (20130104/ED)
FILE BIOSIS (BIOSIS Previews)

FILE COVERS 1926 TO DATE.
RECORDS LAST ADDED: 2 January 2013 (20130102/ED)
FILE DDFU (Derwent Drug File for nonsubscribers)

>>> FILE COVERS 1983 TO DATE <<<
FILE EMBASE (Excerpta Medica)

FILE COVERAGE: Embase-originated material 1947 to 7 Jan 2013 (20130107/ED
Unique MEDLINE content 1948 to present
Emtree thesaurus updated on October 8, 2012. See NEWS for details.
FILE IPA (International Pharmaceutical Abstracts)

FILE COVERS 1970 TO 4 DEC 2012 (20121204/ED)
Page 156 of 158

FILE KOSMET (Cosmetic & Perfume Science and Technology)

FILE SCISEARCH (Science Citation Index Expanded)

FILE COVERS 1974 TO 7 Jan 2013 (20130107/ED)
FILE CABA (CAB Abstracts)

FILE USPATFULL (U.S. Patents Full Text)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 Jan 2013 (20130108/PD)
HIGHEST GRANTED PATENT NUMBER: US8353061
HIGHEST APPLICATION PUBLICATION NUMBER: US20120265827
FILE USPAT2 (U.S. Patents Full Text Latest Publications)

FILE COVERS 2001 TO PUBLICATION DATE: 8 Jan 2013 (20130108/PD)
FILE EPFULL (European Patents Full text)

FILE FRFULL (French Patents Full Text)

FILE GBFULL (British Patents Full Text)

FILE PATDPAFULL (German Patents Full Text)

MOST RECENT UPDATE WEEK: 201301 <201301/EW>
FILE PCTFULL (PCT Published Patent Applications Full Text)

FILE AUPATFULL (Australia Patents Full Text)

FILE CANPATFULL
FILE CNFULL
FILE JPFULL
Page 157 of 158

FILE COVERS APPLICATION YEARS FROM 2004 ONWARDS
FILE IFIREF (IFI Uniterm and U.S. Class Reference File)

FILE COVERS CURRENT DATA. LAST UPDATE: NOVEMBER 2009
FILE IFIUDB (IFI Uniterm Database)

FILE IFIPAT (IFI Patent Database)

FILE INPAFAMDB
Page 158 of 158

ScienceIP SampleTextSearchReport

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ScienceIP SampleTextSearchReport

Uploaded by

Copyright:

Available Formats

Science IP Order: 3550000

Client Reference: 3456-789

Benzoyl Peroxide and Tea Tree Oil in Acne

Prepared for Dr. Jane Doe

Click (or Ctrl-click) page number to jump to a section

Primary Searcher: Sharilyn Woods

Original Search Request

Science IPs Understanding of the Request

Science IP Search Results

Please let me know if you have any questions.

Discussion of Search Strategy

Return to Table of Contents

L56 ANSWER 1 OF 199 HCAPLUS COPYRIGHT 2013 ACS on STN

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

PATENT NO. KIND DATE APPLICATION NO. DATE

Page 100 of 158

NUMBER KIND DATE

Page 101 of 158

Page 102 of 158

Page 103 of 158

Page 104 of 158

NUMBER KIND DATE

Page 105 of 158

Page 106 of 158

Page 107 of 158

Page 108 of 158

NUMBER KIND DATE

Page 109 of 158

Page 110 of 158

Page 111 of 158

CLM What is claimed is:

Page 112 of 158

CLM What is claimed is:

CLM What is claimed is:

Page 113 of 158

NUMBER KIND DATE

Page 114 of 158

Page 115 of 158

Page 116 of 158